type	clinical_trial_id	title	last_update_posted	recruitment_status	project.project_id
clinical_trial	NCT03278340	Using Technology to Scale-Up an Occupational Sun Protection Policy Program (SSW-T)	July 9, 2021	Enrolling by invitation	1R01CA210259-01A1
clinical_trial	NCT03278340	Using Technology to Scale-Up an Occupational Sun Protection Policy Program (SSW-T)	July 9, 2021	Enrolling by invitation	1R01CA210259-01A1
clinical_trial	NCT04131062	Trial to Compare eConsent With Standard Consent Among Prospective Biobank Participants	January 22, 2021	Enrolling by invitation	1R01CA211723-01A1
clinical_trial	NCT00106015	Diamond Blackfan Anemia Registry (DBAR) (DBAR)	March 4, 2021	Recruiting	1R01CA211723-01A1
clinical_trial	NCT03478397	Evaluation of a mHealth Intervention to Increase Adherence to Triage of Self-collected HPV+ Women (ATICA Project) (ATICA)	April 6, 2021	Completed	1R01CA218306-01
clinical_trial	NCT03478397	Evaluation of a mHealth Intervention to Increase Adherence to Triage of Self-collected HPV+ Women (ATICA Project) (ATICA)	April 6, 2021	Completed	1R01CA218306-01
clinical_trial	NCT03478397	Evaluation of a mHealth Intervention to Increase Adherence to Triage of Self-collected HPV+ Women (ATICA Project) (ATICA)	April 6, 2021	Completed	1R01CA218306-01
clinical_trial	NCT01714739	A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors	December 14, 2020	Completed	1R33CA225291-01
clinical_trial	NCT01714739	A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors	December 14, 2020	Completed	1U54CA224070-01
clinical_trial	NCT01714739	A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors	December 14, 2020	Completed	1U54CA232561-01A1
clinical_trial	NCT02083484	Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030)	January 26, 2018	No longer available	1R33CA225291-01
clinical_trial	NCT02083484	Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030)	January 26, 2018	No longer available	1U54CA224070-01
clinical_trial	NCT01543698	A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors	October 6, 2021	Active, not recruiting	1R33CA225291-01
clinical_trial	NCT01543698	A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors	October 6, 2021	Active, not recruiting	1U54CA224070-01
clinical_trial	NCT01543698	A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors	October 6, 2021	Active, not recruiting	1U54CA224070-01
clinical_trial	NCT01072175	Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 &amp; GSK1120212	July 5, 2019	Completed	1R33CA225291-01
clinical_trial	NCT01072175	Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 &amp; GSK1120212	July 5, 2019	Completed	1U54CA224070-01
clinical_trial	NCT00949702	A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma	July 25, 2017	Completed	1R33CA225291-01
clinical_trial	NCT00949702	A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma	July 25, 2017	Completed	1U54CA224070-01
clinical_trial	NCT01783938	Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)	August 13, 2021	Completed	1R33CA225291-01
clinical_trial	NCT01783938	Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)	August 13, 2021	Completed	1U54CA224070-01
clinical_trial	NCT01006980	A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)	September 28, 2016	Completed	1R33CA225291-01
clinical_trial	NCT01006980	A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)	September 28, 2016	Completed	1U54CA224070-01
clinical_trial	NCT01195922	Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma	December 6, 2017	Completed	1R33CA225291-01
clinical_trial	NCT01195922	Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma	December 6, 2017	Completed	1R33CA225291-01
clinical_trial	NCT02358031	A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)	October 23, 2020	Active, not recruiting	1R33CA225291-01
clinical_trial	NCT02358031	A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)	October 23, 2020	Active, not recruiting	1U01DE028227-01
clinical_trial	NCT02741570	Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (CheckMate 651)	April 19, 2021	Active, not recruiting	1R33CA225291-01
clinical_trial	NCT02741570	Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (CheckMate 651)	April 19, 2021	Active, not recruiting	1U01DE028227-01
clinical_trial	NCT00771641	Fractionated Radiation Therapy in Treating Advanced Squamous Cell Carcinoma of the Head and Neck	January 24, 2014	Completed	1R33CA225291-01
clinical_trial	NCT00771641	Fractionated Radiation Therapy in Treating Advanced Squamous Cell Carcinoma of the Head and Neck	January 24, 2014	Completed	1U01DE028227-01
clinical_trial	NCT03383094	Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer	October 8, 2021	Recruiting	1R33CA225291-01
clinical_trial	NCT03383094	Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer	October 8, 2021	Recruiting	1U01DE028227-01
clinical_trial	NCT03317327	REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors (REPORT)	September 30, 2019	Recruiting	1R33CA225291-01
clinical_trial	NCT03317327	REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors (REPORT)	September 30, 2019	Recruiting	1U01DE028227-01
clinical_trial	NCT03546582	SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma (KEYSTROKE)	August 3, 2021	Recruiting	1R33CA225291-01
clinical_trial	NCT03546582	SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma (KEYSTROKE)	August 3, 2021	Recruiting	1U01DE028227-01
clinical_trial	NCT02296684	Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma	August 30, 2021	Active, not recruiting	1R33CA225291-01
clinical_trial	NCT02296684	Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma	August 30, 2021	Active, not recruiting	1U01DE028227-01
clinical_trial	NCT02296684	Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma	August 30, 2021	Active, not recruiting	3U24CA237719-02S1
clinical_trial	NCT03051906	Durvalumab, Cetuximab and Radiotherapy in Head Neck Cancer (DUCRO-HN)	November 22, 2017	Not yet recruiting	1R33CA225291-01
clinical_trial	NCT03051906	Durvalumab, Cetuximab and Radiotherapy in Head Neck Cancer (DUCRO-HN)	November 22, 2017	Not yet recruiting	1U01DE028227-01
clinical_trial	NCT02999087	Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH) (REACH)	November 4, 2020	Active, not recruiting	1R33CA225291-01
clinical_trial	NCT02999087	Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH) (REACH)	November 4, 2020	Active, not recruiting	1U01DE028227-01
clinical_trial	NCT02764593	Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer	August 3, 2021	Active, not recruiting	1R33CA225291-01
clinical_trial	NCT02764593	Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer	August 3, 2021	Active, not recruiting	1U01DE028227-01
clinical_trial	NCT03247712	Neoadjuvant Immunoradiotherapy in Head &amp; Neck Cancer	May 20, 2021	Active, not recruiting	1R33CA225291-01
clinical_trial	NCT03247712	Neoadjuvant Immunoradiotherapy in Head &amp; Neck Cancer	May 20, 2021	Active, not recruiting	1U01DE028227-01
clinical_trial	NCT03673735	Maintenance Immune Check-point Inhibitor Following Post-operative Chemo-radiation in Subjects With HPV-negative HNSCC (ADHERE)	May 10, 2021	Withdrawn	1R33CA225291-01
clinical_trial	NCT03673735	Maintenance Immune Check-point Inhibitor Following Post-operative Chemo-radiation in Subjects With HPV-negative HNSCC (ADHERE)	May 10, 2021	Withdrawn	1U01DE028227-01
clinical_trial	NCT03529422	Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN	May 11, 2021	Recruiting	1R33CA225291-01
clinical_trial	NCT03529422	Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN	May 11, 2021	Recruiting	1U01DE028227-01
clinical_trial	NCT03426657	Radiotherapy With Double Checkpoint Blockade of Locally Advanced HNSCC	September 28, 2021	Active, not recruiting	1R33CA225291-01
clinical_trial	NCT03426657	Radiotherapy With Double Checkpoint Blockade of Locally Advanced HNSCC	September 28, 2021	Active, not recruiting	1U01DE028227-01
clinical_trial	NCT03509012	Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors (CLOVER)	October 11, 2021	Active, not recruiting	1R33CA225291-01
clinical_trial	NCT03509012	Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors (CLOVER)	October 11, 2021	Active, not recruiting	1U01DE028227-01
clinical_trial	NCT03539198	Study of Proton SBRT and Immunotherapy for Recurrent/Progressive Locoregional or Metastatic Head and Neck Cancer	September 27, 2021	Active, not recruiting	1R33CA225291-01
clinical_trial	NCT03539198	Study of Proton SBRT and Immunotherapy for Recurrent/Progressive Locoregional or Metastatic Head and Neck Cancer	September 27, 2021	Active, not recruiting	1U01DE028227-01
clinical_trial	NCT03085719	Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN	November 13, 2020	Recruiting	1R33CA225291-01
clinical_trial	NCT03085719	Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN	November 13, 2020	Recruiting	1U01DE028227-01
clinical_trial	NCT03283605	Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas	May 27, 2021	Recruiting	1R33CA225291-01
clinical_trial	NCT03283605	Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas	May 27, 2021	Recruiting	1U01DE028227-01
clinical_trial	NCT03313804	Priming Immunotherapy in Advanced Disease With Radiation	June 14, 2021	Recruiting	1R33CA225291-01
clinical_trial	NCT03313804	Priming Immunotherapy in Advanced Disease With Radiation	June 14, 2021	Recruiting	1U01DE028227-01
clinical_trial	NCT02777385	Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer	April 6, 2021	Recruiting	1R33CA225291-01
clinical_trial	NCT02777385	Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer	April 6, 2021	Recruiting	1U01DE028227-01
clinical_trial	NCT03349710	Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer	August 9, 2021	Completed	1R33CA225291-01
clinical_trial	NCT03349710	Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer	August 9, 2021	Completed	1U01DE028227-01
clinical_trial	NCT02892201	Pembrolizumab in HNSCC With Residual Disease After Radiation	July 15, 2021	Active, not recruiting	1R33CA225291-01
clinical_trial	NCT02892201	Pembrolizumab in HNSCC With Residual Disease After Radiation	July 15, 2021	Active, not recruiting	1U01DE028227-01
clinical_trial	NCT02841748	A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study	January 7, 2021	Recruiting	1R33CA225291-01
clinical_trial	NCT02841748	A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study	January 7, 2021	Recruiting	1U01DE028227-01
clinical_trial	NCT03040999	Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)	April 19, 2021	Active, not recruiting	1R33CA225291-01
clinical_trial	NCT03040999	Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)	April 19, 2021	Active, not recruiting	1U01DE028227-01
clinical_trial	NCT02952586	Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)	September 22, 2021	Terminated	1R33CA225291-01
clinical_trial	NCT02952586	Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)	September 22, 2021	Terminated	1U01DE028227-01
clinical_trial	NCT02952586	Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)	September 22, 2021	Terminated	1U01DE029188-01
clinical_trial	NCT03452137	A Study of Atezolizumab (Anti-Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck	September 29, 2021	Recruiting	1R33CA225291-01
clinical_trial	NCT03452137	A Study of Atezolizumab (Anti-Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck	September 29, 2021	Recruiting	1U01DE028227-01
clinical_trial	NCT01302834	Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer	February 23, 2021	Active, not recruiting	1R33CA225291-01
clinical_trial	NCT01302834	Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer	February 23, 2021	Active, not recruiting	1U01DE028227-01
clinical_trial	NCT01040832	EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Na&#239;ve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck	January 30, 2017	Completed	1R33CA225291-01
clinical_trial	NCT01040832	EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Na&#239;ve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck	January 30, 2017	Completed	1U01DE028227-01
clinical_trial	NCT01334177	TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck	March 5, 2015	Completed	1R33CA225291-01
clinical_trial	NCT01334177	TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck	March 5, 2015	Completed	1U01DE028227-01
clinical_trial	NCT01360827	EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck	June 17, 2014	Terminated	1R33CA225291-01
clinical_trial	NCT01360827	EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck	June 17, 2014	Terminated	1U01DE028227-01
clinical_trial	NCT01468896	Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery	September 24, 2021	Active, not recruiting	1R33CA225291-01
clinical_trial	NCT01468896	Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery	September 24, 2021	Active, not recruiting	1U01DE028227-01
clinical_trial	NCT01836029	Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck	October 29, 2019	Completed	1R33CA225291-01
clinical_trial	NCT01836029	Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck	October 29, 2019	Completed	1U01DE028227-01
clinical_trial	NCT01935921	Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer	June 15, 2021	Active, not recruiting	1R33CA225291-01
clinical_trial	NCT01935921	Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer	June 15, 2021	Active, not recruiting	1U01DE028227-01
clinical_trial	NCT02110082	Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer	April 19, 2017	Completed	1R33CA225291-01
clinical_trial	NCT02110082	Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer	April 19, 2017	Completed	1U01DE028227-01
clinical_trial	NCT02124850	A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab	October 25, 2019	Terminated	1R33CA225291-01
clinical_trial	NCT02124850	A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab	October 25, 2019	Terminated	1U01DE028227-01
clinical_trial	NCT02633800	Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )	January 7, 2019	Terminated	1R33CA225291-01
clinical_trial	NCT02633800	Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )	January 7, 2019	Terminated	1U01DE028227-01
clinical_trial	NCT02643550	Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck	February 9, 2021	Active, not recruiting	1R33CA225291-01
clinical_trial	NCT02643550	Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck	February 9, 2021	Active, not recruiting	1U01DE028227-01
clinical_trial	NCT02938273	Bioimmunoradiotherapy (Cetuximab/RT/Avelumab)	December 11, 2019	Completed	1R33CA225291-01
clinical_trial	NCT02938273	Bioimmunoradiotherapy (Cetuximab/RT/Avelumab)	December 11, 2019	Completed	1U01DE028227-01
clinical_trial	NCT03082534	Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head &amp; Neck Squamous Cell Carcinoma	March 11, 2021	Recruiting	1R33CA225291-01
clinical_trial	NCT03082534	Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head &amp; Neck Squamous Cell Carcinoma	March 11, 2021	Recruiting	1U01DE028227-01
clinical_trial	NCT03370276	Cetuximab &amp; Nivolumab in Patients With Recurrent/Metastatic Head &amp; Neck Squamous Cell Carcinoma	September 20, 2021	Active, not recruiting	1R33CA225291-01
clinical_trial	NCT03370276	Cetuximab &amp; Nivolumab in Patients With Recurrent/Metastatic Head &amp; Neck Squamous Cell Carcinoma	September 20, 2021	Active, not recruiting	1U01DE028227-01
clinical_trial	NCT03494322	EACH: Evaluating Avelumab in Combination With Cetuximab in Head and Neck Cancer (EACH)	November 5, 2020	Active, not recruiting	1R33CA225291-01
clinical_trial	NCT03494322	EACH: Evaluating Avelumab in Combination With Cetuximab in Head and Neck Cancer (EACH)	November 5, 2020	Active, not recruiting	1U01DE028227-01
clinical_trial	NCT03498378	Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	October 7, 2021	Active, not recruiting	1R33CA225291-01
clinical_trial	NCT03498378	Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	October 7, 2021	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT03498378	Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	October 7, 2021	Active, not recruiting	1U01DE028227-01
clinical_trial	NCT01860430	Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer	June 15, 2021	Active, not recruiting	1R33CA225291-01
clinical_trial	NCT01860430	Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer	June 15, 2021	Active, not recruiting	1U01DE028227-01
clinical_trial	NCT02581137	Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion	September 16, 2021	Active, not recruiting	1R33CA225291-01
clinical_trial	NCT02581137	Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion	September 16, 2021	Active, not recruiting	1U01DE028227-01
clinical_trial	NCT03074513	Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors	February 24, 2021	Active, not recruiting	1R33CA225291-01
clinical_trial	NCT03074513	Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors	February 24, 2021	Active, not recruiting	1U01DE028227-01
clinical_trial	NCT02233595	Evaluation of Rectal Cancer Treatment Response Using PET/MRI (Rectal PET/MRI)	August 13, 2019	Terminated	1R33CA225310-01
clinical_trial	NCT02902757	FDG PET/CT in Monitoring Very Early Therapy Response in Patients With Glioblastoma	February 4, 2021	Recruiting	1R33CA225310-01
clinical_trial	NCT02773238	FLARE RT for Patients With Stage IIB-IIIB Non-small Cell Lung Cancer: Personalizing Radiation Therapy Using PET/CT and SPECT/CT Imaging	July 9, 2021	Active, not recruiting	1R33CA225310-01
clinical_trial	NCT02492867	A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer	February 10, 2021	Active, not recruiting	1R33CA225310-01
clinical_trial	NCT02492867	A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer	February 10, 2021	Active, not recruiting	3P30CA046592-31S8
clinical_trial	NCT02492867	A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer	February 10, 2021	Active, not recruiting	3P30CA046592-31S4
clinical_trial	NCT00574353	Study Using Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission Tomography to Detect Hypoxia in Locally Advanced (T3-T4 and./or N1)Primary Rectal Cancer Patients	April 8, 2020	Withdrawn	1R33CA225310-01
clinical_trial	NCT02016872	Prognostic Value of Tumor Hypoxia, as Measured by 18F-FMISO Breath Hold PET/CT, in Non-Small-Cell-Lung Cancer (NSCLC) Patients	January 5, 2021	Active, not recruiting	1R33CA225310-01
clinical_trial	NCT01212354	Impact of Selective Radiation Dose Escalation and Tumour Hypoxia Status on Locoregional Tumour Control After Radiochemotherapy of HNT (Escalox)	February 9, 2016	Recruiting	1R33CA225310-01
clinical_trial	NCT01507428	Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients With Stage III Non-small Cell Lung Cancer	April 29, 2021	Active, not recruiting	1R33CA225310-01
clinical_trial	NCT01542177	A Study Using 18F-FAZA and PET Scans to Study Hypoxia in Pancreatic Cancer	December 16, 2019	Active, not recruiting	1R33CA225310-01
clinical_trial	NCT01549730	Cervix Hypoxia FAZA	October 6, 2021	Active, not recruiting	1R33CA225310-01
clinical_trial	NCT02328300	FLT PET/MR for Evaluation of Pseudoprogression in Patients With Brain Lesions	November 14, 2018	Withdrawn	1R33CA225310-01
clinical_trial	NCT02456246	Piloting the Feasibility of FLT-PET/CT Non-Small Cell Lung Cancer Managed With SBRT (SBRT FLT-PET)	October 5, 2021	Active, not recruiting	1R33CA225310-01
clinical_trial	NCT01666808	FACBC Outcomes for Post Prostatectomy	February 2, 2021	Active, not recruiting	1R33CA225310-01
clinical_trial	NCT03115333	DSC-MRI in Measuring Relative Cerebral Blood Volume for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma	May 21, 2020	Recruiting	1R33CA225310-01
clinical_trial	NCT02031250	Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer	January 28, 2021	Active, not recruiting	1R33CA225310-01
clinical_trial	NCT03151642	A PILOT STUDY OF DIFFUSION WEIGHTED MRI TO ASSESS ESOPHAGEAL TUMOR RESONSE TO NEOADJUVANT CHEMORADIATION	April 26, 2021	Completed	1R33CA225310-01
clinical_trial	NCT02497573	Can DW MRI Predict Outcome During Radiotherapy for Head and Neck Cancer? (MeRInO)	November 2, 2016	Unknown	1R33CA225310-01
clinical_trial	NCT00581906	Dynamic Contrast Enhanced MRI (DCE-MRI) Diffusion Weighted MRI (DW-MRI) and Magnetic Resonance Spectroscopy (MRS) of Head and Neck Tumors	March 2, 2021	Active, not recruiting	1R33CA225310-01
clinical_trial	NCT02319239	Prostate Cancer Stereotactic Radiotherapy (ESKO)	October 28, 2020	Completed	1R33CA225310-01
clinical_trial	NCT02233374	Predicting RadIotherapy ReSponse of Rectal Cancer With MRI and PET (PRISM)	September 18, 2019	Completed	1R33CA225310-01
clinical_trial	NCT02415816	Diffusion Weighted Magnetic Resonance in Imaging Younger Patients With Newly Diagnosed Bone or Soft Tissue Sarcomas	January 7, 2021	Recruiting	1R33CA225310-01
clinical_trial	NCT01992861	MRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA Cervical Cancer	September 22, 2021	Suspended	1R33CA225310-01
clinical_trial	NCT02137759	MRSI to Predict Response to RT/TMZ &#177; Belinostat in GBM	September 5, 2021	Active, not recruiting	1R33CA225310-01
clinical_trial	NCT01507506	Phase III Study Comparing 2 Brain Conformational Radiotherapy in Combination With Chemotherapy in the Treatment of Glioblastoma (SPECTRO GLIO)	January 12, 2021	Terminated	1R33CA225310-01
clinical_trial	NCT03137888	Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma	March 1, 2021	Active, not recruiting	1R33CA225310-01
clinical_trial	NCT03698162	Precise DCE-MRI in Diagnosing Participants With Recurrent High Grade Glioma or Melanoma Brain Metastases	April 5, 2021	Not yet recruiting	1R33CA225400-01
clinical_trial	NCT02358161	Phase I/II Study of LDE225 With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer (MATRIX)	January 9, 2020	Completed	1U01CA224145-01
clinical_trial	NCT02358161	Phase I/II Study of LDE225 With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer (MATRIX)	January 9, 2020	Completed	1U54CA224083-01
clinical_trial	NCT02358161	Phase I/II Study of LDE225 With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer (MATRIX)	January 9, 2020	Completed	3P30CA046592-31S8
clinical_trial	NCT02358161	Phase I/II Study of LDE225 With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer (MATRIX)	January 9, 2020	Completed	3P30CA046592-31S4
clinical_trial	NCT02588443	Study of Neo-adjuvant RO7009789 Alone or Neo-adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine Followed by Adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma	April 16, 2019	Completed	1U01CA224145-01
clinical_trial	NCT02588443	Study of Neo-adjuvant RO7009789 Alone or Neo-adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine Followed by Adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma	April 16, 2019	Completed	1U01CA224193-01
clinical_trial	NCT02588443	Study of Neo-adjuvant RO7009789 Alone or Neo-adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine Followed by Adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma	April 16, 2019	Completed	1U24CA224285-01
clinical_trial	NCT02184195	Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy (POLO)	September 28, 2021	Active, not recruiting	1U01CA224146-01
clinical_trial	NCT02639026	Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers	October 14, 2021	Active, not recruiting	1U01CA224146-01
clinical_trial	NCT02639026	Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers	October 14, 2021	Active, not recruiting	1U01CA224175-01
clinical_trial	NCT02639026	Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers	October 14, 2021	Active, not recruiting	1U01CA224193-01
clinical_trial	NCT02648282	Study With CY, Pembrolizumab, GVAX, and SBRT in Patients With Locally Advanced Pancreatic Cancer	August 9, 2021	Active, not recruiting	1U01CA224146-01
clinical_trial	NCT02648282	Study With CY, Pembrolizumab, GVAX, and SBRT in Patients With Locally Advanced Pancreatic Cancer	August 9, 2021	Active, not recruiting	1U01CA224175-01
clinical_trial	NCT02648282	Study With CY, Pembrolizumab, GVAX, and SBRT in Patients With Locally Advanced Pancreatic Cancer	August 9, 2021	Active, not recruiting	1U01CA224193-01
clinical_trial	NCT02648282	Study With CY, Pembrolizumab, GVAX, and SBRT in Patients With Locally Advanced Pancreatic Cancer	August 9, 2021	Active, not recruiting	3P30CA125123-14S6
clinical_trial	NCT03245541	Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer	October 5, 2021	Recruiting	1U01CA224146-01
clinical_trial	NCT03245541	Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer	October 5, 2021	Recruiting	1U01CA224175-01
clinical_trial	NCT03245541	Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer	October 5, 2021	Recruiting	1U01CA224193-01
clinical_trial	NCT03190265	Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer	August 20, 2021	Recruiting	1U01CA224146-01
clinical_trial	NCT03190265	Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer	August 20, 2021	Recruiting	1U01CA224175-01
clinical_trial	NCT03190265	Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer	August 20, 2021	Recruiting	1U01CA224193-01
clinical_trial	NCT02451982	Neoadjuvant/Adjuvant GVAX Pancreas Vaccine (With CY) With or Without Nivolumab and Urelumab Trial for Surgically Resectable Pancreatic Cancer	March 22, 2021	Recruiting	1U01CA224146-01
clinical_trial	NCT02451982	Neoadjuvant/Adjuvant GVAX Pancreas Vaccine (With CY) With or Without Nivolumab and Urelumab Trial for Surgically Resectable Pancreatic Cancer	March 22, 2021	Recruiting	1U01CA224175-01
clinical_trial	NCT02451982	Neoadjuvant/Adjuvant GVAX Pancreas Vaccine (With CY) With or Without Nivolumab and Urelumab Trial for Surgically Resectable Pancreatic Cancer	March 22, 2021	Recruiting	1U01CA224193-01
clinical_trial	NCT03153410	Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas	August 19, 2021	Active, not recruiting	1U01CA224146-01
clinical_trial	NCT03153410	Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas	August 19, 2021	Active, not recruiting	1U01CA224175-01
clinical_trial	NCT03153410	Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas	August 19, 2021	Active, not recruiting	1U01CA224193-01
clinical_trial	NCT03006302	Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer	August 20, 2021	Recruiting	1U01CA224146-01
clinical_trial	NCT03006302	Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer	August 20, 2021	Recruiting	1U01CA224175-01
clinical_trial	NCT03006302	Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer	August 20, 2021	Recruiting	1U01CA224193-01
clinical_trial	NCT03214250	Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma	October 14, 2021	Active, not recruiting	1U01CA224146-01
clinical_trial	NCT03214250	Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma	October 14, 2021	Active, not recruiting	1U01CA224175-01
clinical_trial	NCT03214250	Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma	October 14, 2021	Active, not recruiting	1U01CA224193-01
clinical_trial	NCT03214250	Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma	October 14, 2021	Active, not recruiting	1U01CA224193-01
clinical_trial	NCT03214250	Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma	October 14, 2021	Active, not recruiting	1U24CA224285-01
clinical_trial	NCT03214250	Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma	October 14, 2021	Active, not recruiting	1U54CA232568-01
clinical_trial	NCT03214250	Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma	October 14, 2021	Active, not recruiting	3P30CA016520-44S5
clinical_trial	NCT03214250	Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma	October 14, 2021	Active, not recruiting	3P30CA016520-44S5
clinical_trial	NCT03214250	Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma	October 14, 2021	Active, not recruiting	3P30CA016520-44S6
clinical_trial	NCT03214250	Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma	October 14, 2021	Active, not recruiting	3P30CA016520-44S6
clinical_trial	NCT02758587	Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)	March 19, 2018	Recruiting	1U01CA224146-01
clinical_trial	NCT02758587	Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)	March 19, 2018	Recruiting	1U01CA224175-01
clinical_trial	NCT02758587	Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)	March 19, 2018	Recruiting	1U01CA224193-01
clinical_trial	NCT02546531	Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer	July 20, 2021	Completed	1U01CA224146-01
clinical_trial	NCT02546531	Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer	July 20, 2021	Completed	1U01CA224175-01
clinical_trial	NCT02546531	Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer	July 20, 2021	Completed	1U01CA224193-01
clinical_trial	NCT02546531	Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer	July 20, 2021	Completed	1U54CA224083-01
clinical_trial	NCT03481920	A Trial of PEGPH20 in Combination With Avelumab in Chemotherapy Resistant Pancreatic Cancer	August 22, 2019	Terminated	1U01CA224146-01
clinical_trial	NCT03481920	A Trial of PEGPH20 in Combination With Avelumab in Chemotherapy Resistant Pancreatic Cancer	August 22, 2019	Terminated	1U01CA224175-01
clinical_trial	NCT03481920	A Trial of PEGPH20 in Combination With Avelumab in Chemotherapy Resistant Pancreatic Cancer	August 22, 2019	Terminated	1U01CA224193-01
clinical_trial	NCT03193190	A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)	August 5, 2021	Active, not recruiting	1U01CA224146-01
clinical_trial	NCT03193190	A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)	August 5, 2021	Active, not recruiting	1U01CA224175-01
clinical_trial	NCT03193190	A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)	August 5, 2021	Active, not recruiting	1U01CA224193-01
clinical_trial	NCT03193190	A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)	August 5, 2021	Active, not recruiting	1U01CA224193-01
clinical_trial	NCT03634332	Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC	May 7, 2019	Unknown	1U01CA224146-01
clinical_trial	NCT03634332	Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC	May 7, 2019	Unknown	1U01CA224175-01
clinical_trial	NCT03634332	Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC	May 7, 2019	Unknown	1U01CA224193-01
clinical_trial	NCT02777710	Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers (MEDIPLEX)	September 5, 2021	Completed	1U01CA224146-01
clinical_trial	NCT02777710	Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers (MEDIPLEX)	September 5, 2021	Completed	1U01CA224175-01
clinical_trial	NCT02777710	Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers (MEDIPLEX)	September 5, 2021	Completed	1U01CA224193-01
clinical_trial	NCT02777710	Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers (MEDIPLEX)	September 5, 2021	Completed	1U01CA224193-01
clinical_trial	NCT02777710	Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers (MEDIPLEX)	September 5, 2021	Completed	1U01CA224348-01
clinical_trial	NCT02526017	Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers (FPA008-003)	July 31, 2020	Completed	1U01CA224146-01
clinical_trial	NCT02526017	Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers (FPA008-003)	July 31, 2020	Completed	1U01CA224160-01
clinical_trial	NCT02526017	Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers (FPA008-003)	July 31, 2020	Completed	1U01CA224175-01
clinical_trial	NCT02526017	Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers (FPA008-003)	July 31, 2020	Completed	1U01CA224193-01
clinical_trial	NCT02526017	Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers (FPA008-003)	July 31, 2020	Completed	1U01CA224193-01
clinical_trial	NCT02526017	Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers (FPA008-003)	July 31, 2020	Completed	1U01CA224348-01
clinical_trial	NCT02436668	Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)	December 30, 2020	Completed	1U01CA224146-01
clinical_trial	NCT02436668	Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)	December 30, 2020	Completed	1U01CA224175-01
clinical_trial	NCT02436668	Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)	December 30, 2020	Completed	1U01CA224193-01
clinical_trial	NCT03496662	BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)	July 23, 2021	Recruiting	1U01CA224146-01
clinical_trial	NCT03496662	BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)	July 23, 2021	Recruiting	1U01CA224175-01
clinical_trial	NCT03496662	BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)	July 23, 2021	Recruiting	1U01CA224193-01
clinical_trial	NCT03404960	Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy (Parpvax)	June 10, 2021	Recruiting	1U01CA224146-01
clinical_trial	NCT03404960	Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy (Parpvax)	June 10, 2021	Recruiting	1U01CA224175-01
clinical_trial	NCT03404960	Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy (Parpvax)	June 10, 2021	Recruiting	1U01CA224193-01
clinical_trial	NCT03404960	Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy (Parpvax)	June 10, 2021	Recruiting	1U01CA224193-01
clinical_trial	NCT03212274	Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations	September 9, 2021	Recruiting	1U01CA224146-01
clinical_trial	NCT02588105	Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer (AToM)	August 18, 2021	Active, not recruiting	1U01CA224146-01
clinical_trial	NCT02588105	Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer (AToM)	August 18, 2021	Active, not recruiting	1U54CA244719-01
clinical_trial	NCT03462342	Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer (CAPRI)	September 27, 2021	Recruiting	1U01CA224146-01
clinical_trial	NCT04149145	Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian Cancer (PARP)	July 6, 2021	Not yet recruiting	1U01CA224146-01
clinical_trial	NCT03669601	AZD6738 &amp; Gemcitabine as Combination Therapy (ATRiUM)	June 4, 2021	Recruiting	1U01CA224146-01
clinical_trial	NCT04095273	Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the ATR Inhibitor BAY1895344 in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug	September 5, 2021	Recruiting	1U01CA224146-01
clinical_trial	NCT03057145	Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors	September 2, 2021	Completed	1U01CA224146-01
clinical_trial	NCT02632448	A Study of LY2880070 in Participants With Advanced or Metastatic Cancer	September 16, 2020	Recruiting	1U01CA224146-01
clinical_trial	NCT03495323	A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors	April 15, 2021	Completed	1U01CA224146-01
clinical_trial	NCT03724890	Study of Avelumab-M3814 Combinations	August 17, 2021	Recruiting	1U01CA224146-01
clinical_trial	NCT03770689	Study of Peposertib in Combination With Capecitabine and RT in Rectal Cancer	August 31, 2021	Active, not recruiting	1U01CA224146-01
clinical_trial	NCT04197713	Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study	June 18, 2021	Recruiting	1U01CA224146-01
clinical_trial	NCT03012477	CISPLATIN + AZD-1775 In Breast Cancer	June 28, 2021	Completed	1U01CA224146-01
clinical_trial	NCT02617277	Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours	September 5, 2021	Active, not recruiting	1U01CA224146-01
clinical_trial	NCT01560923	Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer	April 3, 2020	Completed	1U01CA224151-01
clinical_trial	NCT02073123	Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma	June 5, 2020	Completed	1U01CA224151-01
clinical_trial	NCT02835729	A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia	June 4, 2020	Completed	1U01CA224151-01
clinical_trial	NCT02052648	Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors	May 28, 2020	Completed	1U01CA224151-01
clinical_trial	NCT03301636	A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma (NLG2107)	June 5, 2020	Terminated	1U01CA224151-01
clinical_trial	NCT02502708	Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors	June 4, 2020	Completed	1U01CA224151-01
clinical_trial	NCT02502708	Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors	June 4, 2020	Completed	1U54CA232561-01A1
clinical_trial	NCT02502648	N/A	N/A	N/A	1U01CA224151-01
clinical_trial	NCT01920191	Phase I/II Trial of IMA950 Multi-peptide Vaccine Plus Poly-ICLC in Glioblastoma	April 20, 2016	Completed	1U01CA224160-01
clinical_trial	NCT02454634	Phase I Trial of IDH1 Peptide Vaccine in IDH1R132H-mutated Grade III-IV Gliomas (NOA-16)	November 7, 2018	Completed	1U01CA224160-01
clinical_trial	NCT02794883	Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma	April 5, 2019	Unknown	1U01CA224160-01
clinical_trial	NCT02017717	A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients (CheckMate 143)	April 19, 2021	Active, not recruiting	1U01CA224160-01
clinical_trial	NCT02017717	A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients (CheckMate 143)	April 19, 2021	Active, not recruiting	1U01CA224160-01
clinical_trial	NCT02337491	Pembrolizumab +/- Bevacizumab for Recurrent GBM	December 22, 2020	Completed	1U01CA224160-01
clinical_trial	NCT02337491	Pembrolizumab +/- Bevacizumab for Recurrent GBM	December 22, 2020	Completed	1U01CA224348-01
clinical_trial	NCT02311582	MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas	September 5, 2021	Active, not recruiting	1U01CA224160-01
clinical_trial	NCT01952769	Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma	September 13, 2016	Unknown	1U01CA224160-01
clinical_trial	NCT02336165	Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma	July 15, 2021	Completed	1U01CA224160-01
clinical_trial	NCT02336165	Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma	July 15, 2021	Completed	1U01CA224348-01
clinical_trial	NCT02327078	A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)	August 28, 2020	Completed	1U01CA224160-01
clinical_trial	NCT02313272	Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas	August 10, 2021	Completed	1U01CA224160-01
clinical_trial	NCT02335918	A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors	December 9, 2019	Completed	1U01CA224160-01
clinical_trial	NCT02337686	Pembrolizumab in Treating Patients With Recurrent Glioblastoma	January 29, 2020	Active, not recruiting	1U01CA224160-01
clinical_trial	NCT02550249	Neoadjuvant Nivolumab in Glioblastoma (Neo-nivo)	April 11, 2017	Completed	1U01CA224160-01
clinical_trial	NCT02529072	Nivolumab With DC Vaccines for Recurrent Brain Tumors (AVERT)	March 26, 2020	Completed	1U01CA224160-01
clinical_trial	NCT02529072	Nivolumab With DC Vaccines for Recurrent Brain Tumors (AVERT)	March 26, 2020	Completed	1U24CA224285-01
clinical_trial	NCT02617589	An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) (CheckMate 498)	February 3, 2021	Active, not recruiting	1U01CA224160-01
clinical_trial	NCT02617589	An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) (CheckMate 498)	February 3, 2021	Active, not recruiting	1U01CA224348-01
clinical_trial	NCT02617589	An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) (CheckMate 498)	February 3, 2021	Active, not recruiting	1U2CCA233262-01
clinical_trial	NCT02617589	An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) (CheckMate 498)	February 3, 2021	Active, not recruiting	3P30CA006516-55S9
clinical_trial	NCT02648633	Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma	May 31, 2017	Terminated	1U01CA224160-01
clinical_trial	NCT02658279	Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype	September 22, 2021	Recruiting	1U01CA224160-01
clinical_trial	NCT02658981	Anti-LAG-3 Alone &amp; in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)	September 10, 2021	Active, not recruiting	1U01CA224160-01
clinical_trial	NCT02667587	An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) (CheckMate548)	September 11, 2020	Active, not recruiting	1U01CA224160-01
clinical_trial	NCT02798406	Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects (CAPTIVE)	July 15, 2021	Completed	1U01CA224160-01
clinical_trial	NCT02829723	A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors	September 30, 2021	Active, not recruiting	1U01CA224160-01
clinical_trial	NCT02829723	A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors	September 30, 2021	Active, not recruiting	1U01CA224193-01
clinical_trial	NCT02852655	A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma	October 12, 2021	Completed	1U01CA224160-01
clinical_trial	NCT02937844	Pilot Study of Autologous Chimeric Switch Receptor Modified T Cells in Recurrent Glioblastoma Multiforme	October 19, 2016	Unknown	1U01CA224160-01
clinical_trial	NCT02866747	A Study Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and Durvalumab for Patients With Recurrent Glioblastoma (STERIMGLI)	July 28, 2021	Recruiting	1U01CA224160-01
clinical_trial	NCT02968940	Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma	June 18, 2021	Completed	1U01CA224160-01
clinical_trial	NCT00643097	Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (ACTIVATe)	February 1, 2017	Completed	1U01CA224160-01
clinical_trial	NCT00458601	Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme (ACT III)	January 16, 2018	Completed	1U01CA224160-01
clinical_trial	NCT00458601	Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme (ACT III)	January 16, 2018	Completed	1U01CA224160-01
clinical_trial	NCT01480479	Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma (ACT IV)	January 16, 2018	Completed	1U01CA224160-01
clinical_trial	NCT01498328	A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma (ReACT)	February 17, 2020	Completed	1U01CA224160-01
clinical_trial	NCT01130077	A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction With Poly-ICLC in Pediatric Gliomas	August 10, 2021	Active, not recruiting	1U01CA224160-01
clinical_trial	NCT02078648	Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme	January 26, 2018	Completed	1U01CA224160-01
clinical_trial	NCT02149225	GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients	August 7, 2018	Completed	1U01CA224160-01
clinical_trial	NCT02287428	Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM	May 21, 2021	Recruiting	1U01CA224160-01
clinical_trial	NCT02193347	IDH1 Peptide Vaccine for Recurrent Grade II Glioma (RESIST)	March 15, 2021	Active, not recruiting	1U01CA224160-01
clinical_trial	NCT00293423	GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive Glioma	May 13, 2021	Completed	1U01CA224160-01
clinical_trial	NCT01814813	Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery	August 18, 2021	Active, not recruiting	1U01CA224160-01
clinical_trial	NCT02546102	Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma	August 13, 2018	Suspended	1U01CA224160-01
clinical_trial	NCT00045968	Study of a Drug [DCVax&#174;-L] to Treat Newly Diagnosed GBM Brain Cancer (GBM)	October 14, 2016	Unknown	1U01CA224160-01
clinical_trial	NCT00846456	Safe Study of Dendritic Cell (DC) Based Therapy Targeting Tumor Stem Cells in Glioblastoma	October 20, 2015	Completed	1U01CA224160-01
clinical_trial	NCT02049489	A Study of ICT-121 Dendritic Cell Vaccine in Recurrent Glioblastoma	August 13, 2018	Completed	1U01CA224160-01
clinical_trial	NCT00626483	Basiliximab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia (REGULATe)	March 9, 2021	Completed	1U01CA224160-01
clinical_trial	NCT00639639	Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (ATTAC)	January 26, 2021	Active, not recruiting	1U01CA224160-01
clinical_trial	NCT02366728	DC Migration Study for Newly-Diagnosed GBM (ELEVATE)	November 7, 2019	Active, not recruiting	1U01CA224160-01
clinical_trial	NCT00345163	A Study to Evaluate Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme (BRAIN) (BRAIN)	May 16, 2017	Completed	1U01CA224160-01
clinical_trial	NCT00612430	Ph II Bevacizumab + Etoposide for Pts w Recurrent MG	August 12, 2013	Completed	1U01CA224160-01
clinical_trial	NCT00595322	Bevacizumab in the Radiation Treatment of Recurrent Malignant Glioma	May 23, 2017	Completed	1U01CA224160-01
clinical_trial	NCT01238237	Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA	February 1, 2017	Completed	1U01CA224160-01
clinical_trial	NCT01884740	Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22	April 20, 2021	Recruiting	1U01CA224160-01
clinical_trial	NCT00753246	Nimotuzumab in Adults With Glioblastoma Multiforma	December 3, 2012	Completed	1U01CA224160-01
clinical_trial	NCT02573324	A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)	May 24, 2021	Active, not recruiting	1U01CA224160-01
clinical_trial	NCT02573324	A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)	May 24, 2021	Active, not recruiting	1U01CA224160-01
clinical_trial	NCT00730613	Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma	October 9, 2017	Completed	1U01CA224160-01
clinical_trial	NCT00730613	Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma	October 9, 2017	Completed	1U54CA244438-01
clinical_trial	NCT02209376	Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma	March 5, 2019	Terminated	1U01CA224160-01
clinical_trial	NCT01109095	CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM (HERT-GBM)	April 25, 2019	Completed	1U01CA224160-01
clinical_trial	NCT01491893	PVSRIPO for Recurrent Glioblastoma (GBM) (PVSRIPO)	January 12, 2021	Active, not recruiting	1U01CA224160-01
clinical_trial	NCT01491893	PVSRIPO for Recurrent Glioblastoma (GBM) (PVSRIPO)	January 12, 2021	Active, not recruiting	1U01CA224160-01
clinical_trial	NCT01301430	Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme. (ParvOryx01)	December 4, 2015	Completed	1U01CA224160-01
clinical_trial	NCT00390299	Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme	January 2, 2020	Completed	1U01CA224160-01
clinical_trial	NCT01174537	New Castle Disease Virus (NDV) in Glioblastoma Multiforme (GBM), Sarcoma and Neuroblastoma	June 11, 2015	Withdrawn	1U01CA224160-01
clinical_trial	NCT01811992	Combined Cytotoxic and Immune-Stimulatory Therapy for Glioma	August 31, 2021	Completed	1U01CA224160-01
clinical_trial	NCT01811992	Combined Cytotoxic and Immune-Stimulatory Therapy for Glioma	August 31, 2021	Completed	1U01CA224160-01
clinical_trial	NCT01811992	Combined Cytotoxic and Immune-Stimulatory Therapy for Glioma	August 31, 2021	Completed	1U01CA224160-01
clinical_trial	NCT00002824	Gene Therapy in Treating Patients With Primary Brain Tumors	March 13, 2019	Completed	1U01CA224160-01
clinical_trial	NCT02311920	Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma	July 6, 2021	Active, not recruiting	1U01CA224160-01
clinical_trial	NCT02414165	The Toca 5 Trial: Toca 511 &amp; Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma (Toca5)	February 7, 2020	Terminated	1U01CA224160-01
clinical_trial	NCT00805376	DNX-2401 (Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas	July 16, 2018	Completed	1U01CA224160-01
clinical_trial	NCT01472003	An Evaluation of the Biodistribution and Imaging Characteristics of ABT-806i (111In-ABT-806) in Subjects With Advanced Solid Tumor Types	January 14, 2013	Completed	1U01CA224160-01
clinical_trial	NCT01255657	A Study of ABT-806 in Subjects With Advanced Solid Tumor Types	November 21, 2017	Completed	1U01CA224160-01
clinical_trial	NCT01406119	An Extension Study of ABT-806 in Subjects With Advanced Solid Tumors	January 27, 2017	Completed	1U01CA224160-01
clinical_trial	NCT02381886	A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations	July 26, 2021	Active, not recruiting	1U01CA224160-01
clinical_trial	NCT02381886	A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations	July 26, 2021	Active, not recruiting	3P30CA082103-21S9
clinical_trial	NCT02381886	A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations	July 26, 2021	Active, not recruiting	3P30CA082103-21S6
clinical_trial	NCT02977689	Trial of IDH305 in IDH1 Mutant Grade II or III Glioma	December 20, 2017	Withdrawn	1U01CA224160-01
clinical_trial	NCT02253212	Safety of BBB Opening With the SonoCloud (SONOCLOUD)	October 12, 2018	Completed	1U01CA224160-01
clinical_trial	NCT02343406	Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas (INTELLANCE-2)	May 22, 2020	Completed	1U01CA224160-01
clinical_trial	NCT03899857	Pembrolizumab for Newly Diagnosed Glioblastoma (PERGOLA)	December 16, 2020	Recruiting	1U01CA224160-01
clinical_trial	NCT03726515	CART-EGFRvIII + Pembrolizumab in GBM	March 3, 2021	Completed	1U01CA224160-01
clinical_trial	NCT03726515	CART-EGFRvIII + Pembrolizumab in GBM	March 3, 2021	Completed	1U01CA239258-01
clinical_trial	NCT02661282	Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma	October 8, 2021	Active, not recruiting	1U01CA224160-01
clinical_trial	NCT02255461	Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors	March 2, 2021	Terminated	1U01CA224160-01
clinical_trial	NCT02255461	Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors	March 2, 2021	Terminated	2UM1CA081457-21
clinical_trial	NCT03387020	Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors	August 27, 2021	Completed	1U01CA224160-01
clinical_trial	NCT03355794	A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)	August 27, 2021	Active, not recruiting	1U01CA224160-01
clinical_trial	NCT02644460	Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors (AflacST1501)	March 4, 2021	Recruiting	1U01CA224160-01
clinical_trial	NCT02717455	Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma (PBTC-047)	September 22, 2021	Recruiting	1U01CA224160-01
clinical_trial	NCT03632317	A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas	August 19, 2019	Withdrawn	1U01CA224160-01
clinical_trial	NCT03566199	MTX110 by Convection-Enhanced Delivery in Treating Participants With Newly-Diagnosed Diffuse Intrinsic Pontine Glioma (PNOC015)	April 13, 2021	Completed	1U01CA224160-01
clinical_trial	NCT03178032	Oncolytic Adenovirus, DNX-2401, for Naive Diffuse Intrinsic Pontine Gliomas	July 16, 2020	Active, not recruiting	1U01CA224160-01
clinical_trial	NCT03178032	Oncolytic Adenovirus, DNX-2401, for Naive Diffuse Intrinsic Pontine Gliomas	July 16, 2020	Active, not recruiting	1U54CA232561-01A1
clinical_trial	NCT03927105	Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma	September 10, 2021	Active, not recruiting	1U01CA224193-01
clinical_trial	NCT03697564	Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer Achieving Disease Control in Response to First-line Chemotherapy (GemCaN Trial).	May 7, 2020	Suspended	1U01CA224193-01
clinical_trial	NCT02880371	A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors	March 22, 2021	Completed	1U01CA224193-01
clinical_trial	NCT03502330	APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma	December 22, 2020	Recruiting	1U01CA224193-01
clinical_trial	NCT03502330	APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma	December 22, 2020	Recruiting	1U24CA224285-01
clinical_trial	NCT03238027	A Phase 1 Study to Investigate SNDX-6352 Alone or in Combination With Durvalumab in Patients With Solid Tumors	May 6, 2021	Active, not recruiting	1U01CA224193-01
clinical_trial	NCT03161431	SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab	September 23, 2021	Recruiting	1U01CA224193-01
clinical_trial	NCT03161431	SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab	September 23, 2021	Recruiting	3P30CA046592-31S8
clinical_trial	NCT03161431	SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab	September 23, 2021	Recruiting	3P30CA046592-31S4
clinical_trial	NCT03999749	A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma	June 1, 2021	Recruiting	1U01CA224193-01
clinical_trial	NCT01130142	A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer	March 6, 2017	Completed	1U01CA224193-01
clinical_trial	NCT01130142	A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer	March 6, 2017	Completed	1U01CA224348-01
clinical_trial	NCT01130142	A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer	March 6, 2017	Completed	1U54CA224083-01
clinical_trial	NCT00633724	Multiple-Vaccine Therapy in Treating Patients With Non-small Cell Lung Cancer	August 15, 2013	Completed	1U01CA224348-01
clinical_trial	NCT00874588	Peptide Vaccine Targeting to Cancer Specific Antigen Combined With Anti-angiogenic Peptide Antigen in Treating Patients With Non-small Cell Lung Cancer	August 15, 2013	Completed	1U01CA224348-01
clinical_trial	NCT02562755	Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone (PHOCUS)	December 16, 2020	Completed	1U01CA224348-01
clinical_trial	NCT02616185	A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)	March 9, 2021	Completed	1U01CA224348-01
clinical_trial	NCT01218867	CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer	December 10, 2019	Terminated	1U01CA224348-01
clinical_trial	NCT01218867	CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer	December 10, 2019	Terminated	1U24CA224331-01
clinical_trial	NCT01218867	CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer	December 10, 2019	Terminated	1U01CA233100-01
clinical_trial	NCT01218867	CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer	December 10, 2019	Terminated	1U01CA239258-01
clinical_trial	NCT01218867	CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer	December 10, 2019	Terminated	1U54CA244438-01
clinical_trial	NCT01218867	CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer	December 10, 2019	Terminated	3P30CA021765-41S3
clinical_trial	NCT01218867	CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer	December 10, 2019	Terminated	3P30CA006516-55S9
clinical_trial	NCT02857920	Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors	September 14, 2020	Completed	1U01CA224348-01
clinical_trial	NCT02857920	Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors	September 14, 2020	Completed	1U24CA224285-01
clinical_trial	NCT00678119	Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment	July 15, 2013	Completed	1U01CA224348-01
clinical_trial	NCT01582672	Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)	June 14, 2018	Terminated	1U01CA224348-01
clinical_trial	NCT01454102	Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)	October 12, 2021	Completed	1U01CA224348-01
clinical_trial	NCT02410512	A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors	March 1, 2021	Completed	1U01CA224348-01
clinical_trial	NCT02754856	Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery	January 22, 2021	Active, not recruiting	1U01CA224348-01
clinical_trial	NCT02496208	Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors	October 4, 2021	Active, not recruiting	1U01CA224348-01
clinical_trial	NCT01688206	A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors	October 5, 2018	Completed	1U01CA224348-01
clinical_trial	NCT02665416	Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors	April 7, 2020	Completed	1U01CA224348-01
clinical_trial	NCT02665416	Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors	April 7, 2020	Completed	1U24CA224285-01
clinical_trial	NCT02715531	A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors	July 9, 2021	Completed	1U01CA224348-01
clinical_trial	NCT02942329	Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer	February 26, 2018	Unknown	1U01CA224348-01
clinical_trial	NCT02856425	Trial Of Pembrolizumab And Nintedanib (PEMBIB)	April 7, 2020	Recruiting	1U01CA224348-01
clinical_trial	NCT03081494	Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer	December 11, 2020	Completed	1U01CA224348-01
clinical_trial	NCT01472081	Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)	April 22, 2020	Active, not recruiting	1U01CA224348-01
clinical_trial	NCT02959554	Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease Control (NIVOSWITCH)	September 8, 2021	Terminated	1U01CA224348-01
clinical_trial	NCT02471716	Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor (FPA008-002)	August 31, 2021	Completed	1U01CA224348-01
clinical_trial	NCT02141295	A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer (McCAVE)	March 25, 2020	Terminated	1U01CA224348-01
clinical_trial	NCT01831505	Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents	February 27, 2017	Completed	1U01CA224348-01
clinical_trial	NCT03056599	Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma	September 24, 2021	Completed	1U01CA224348-01
clinical_trial	NCT03127631	A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients (RADICALPC)	August 28, 2018	Unknown	1U01CA224348-01
clinical_trial	NCT02907021	Safety of Continuing CHemotherapy in Overt Left Ventricular Dysfunction Using Antibodies to HER-2 (SCHOLAR)	October 9, 2020	Completed	1U01CA224348-01
clinical_trial	NCT02236806	Cardiotoxicity Prevention in Breast Cancer Patients Treated With Anthracyclines and/or Trastuzumab (SAFE)	January 7, 2021	Active, not recruiting	1U01CA224348-01
clinical_trial	NCT01904903	Cardiac Safety Study in Patients With HER2 + Breast Cancer (SAFE-HEaRt)	February 2, 2021	Completed	1U01CA224348-01
clinical_trial	NCT03265574	PROACT: Can we Prevent Chemotherapy-related Heart Damage in Patients With Breast Cancer and Lymphoma? (PROACT)	July 17, 2020	Recruiting	1U01CA224348-01
clinical_trial	NCT01968200	Prevention of Anthracycline-induced Cardiotoxicity (ICOS-ONE)	August 13, 2021	Active, not recruiting	1U01CA224348-01
clinical_trial	NCT01009918	Lisinopril or Coreg CR&#174; in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab	March 30, 2021	Completed	1U01CA224348-01
clinical_trial	NCT01805453	Angiotensin II Receptor Blockers, Steroids and Radiotherapy in Glioblastoma (ASTER)	May 8, 2020	Completed	1U01CA224348-01
clinical_trial	NCT01754909	Mitigation of Radiation Pneumonitis and Fibrosis	October 8, 2019	Completed	1U01CA224348-01
clinical_trial	NCT01880528	Lisinopril in Reducing Shortness of Breath Caused by Radiation Therapy in Patients With Lung Cancer	January 2, 2020	Completed	1U01CA224348-01
clinical_trial	NCT00004230	Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation	June 6, 2012	Completed	1U01CA224348-01
clinical_trial	NCT02651415	Phase II Study of Perindopril and Regorafenib in mCRC (PARICCA)	September 12, 2019	Completed	1U01CA224348-01
clinical_trial	NCT01705392	Bevacizumab vs Dacarbazine in Metastatic Melanoma	February 24, 2017	Terminated	1U01CA224348-01
clinical_trial	NCT02259621	Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC (NA_00092076)	July 27, 2021	Recruiting	1U01CA224348-01
clinical_trial	NCT02259621	Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC (NA_00092076)	July 27, 2021	Recruiting	3P30CA008748-54S3
clinical_trial	NCT03123783	CD40 Agonistic Antibody APX005M in Combination With Nivolumab	May 4, 2021	Completed	1U01CA224348-01
clinical_trial	NCT03123783	CD40 Agonistic Antibody APX005M in Combination With Nivolumab	May 4, 2021	Completed	1U24CA224285-01
clinical_trial	NCT02376699	Safety Study of SEA-CD40 in Cancer Patients	September 21, 2021	Active, not recruiting	1U01CA224348-01
clinical_trial	NCT02376699	Safety Study of SEA-CD40 in Cancer Patients	September 21, 2021	Active, not recruiting	1U24CA224285-01
clinical_trial	NCT03270176	A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy	September 23, 2021	Active, not recruiting	1U01CA224348-01
clinical_trial	NCT01502293	Trial of pIL-12 Electroporation Malignant Melanoma (IL-12MEL)	October 9, 2019	Completed	1U01CA224348-01
clinical_trial	NCT01747551	FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer	February 10, 2020	Completed	1U01CA224348-01
clinical_trial	NCT00756106	MRI Scans in Evaluating the Effects of Radiation Therapy and Chemotherapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Glioma	May 13, 2020	Terminated	1U01CA224348-01
clinical_trial	NCT01004172	Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases	December 14, 2018	Completed	1U01CA224348-01
clinical_trial	NCT01821729	Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer	September 25, 2020	Active, not recruiting	1U01CA224348-01
clinical_trial	NCT01821729	Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer	September 25, 2020	Active, not recruiting	1U01CA224348-01
clinical_trial	NCT01821729	Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer	September 25, 2020	Active, not recruiting	1U54CA224083-01
clinical_trial	NCT03563248	Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer	January 20, 2021	Recruiting	1U01CA224348-01
clinical_trial	NCT03563248	Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer	January 20, 2021	Recruiting	1U01CA224348-01
clinical_trial	NCT03563248	Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer	January 20, 2021	Recruiting	1U54CA224083-01
clinical_trial	NCT03744247	Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC	May 2, 2019	Withdrawn	1U01CA224348-01
clinical_trial	NCT03434379	A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma [IMbrave150] (IMbrave150)	July 22, 2021	Active, not recruiting	1U01CA224348-01
clinical_trial	NCT01140347	A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib (REACH)	December 28, 2015	Completed	1U01CA224348-01
clinical_trial	NCT02435433	A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (REACH-2)	July 30, 2021	Active, not recruiting	1U01CA224348-01
clinical_trial	NCT02410733	Evaluation of the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced Melanoma (Lipo-MERIT)	October 13, 2021	Active, not recruiting	1U01CA224348-01
clinical_trial	NCT03729245	A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)	October 7, 2021	Active, not recruiting	1U01CA224348-01
clinical_trial	NCT03729245	A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)	October 7, 2021	Active, not recruiting	1U24CA224331-01
clinical_trial	NCT03729245	A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)	October 7, 2021	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT03729245	A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)	October 7, 2021	Active, not recruiting	3P30CA006516-55S9
clinical_trial	NCT01753089	Dendritic Cell Activating Scaffold in Melanoma	July 20, 2021	Active, not recruiting	1U01CA224348-01
clinical_trial	NCT03472833	High-dose Vitamin D3 in Pancreas Cancer (VITdCUT)	September 14, 2020	Recruiting	1U01CA224348-01
clinical_trial	NCT04320238	Experimental Trial of rhIFN&#945; Nasal Drops to Prevent 2019-nCOV in Medical Staff	March 31, 2020	Recruiting	1U01CA224348-01
clinical_trial	NCT01239134	Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors (TRX518-001)	August 14, 2019	Completed	1U01CA224348-01
clinical_trial	NCT01239134	Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors (TRX518-001)	August 14, 2019	Completed	1U2CCA233262-01
clinical_trial	NCT01239134	Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors (TRX518-001)	August 14, 2019	Completed	3P30CA006516-55S9
clinical_trial	NCT04021043	BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers	October 6, 2021	Recruiting	1U01CA224348-01
clinical_trial	NCT04021043	BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers	October 6, 2021	Recruiting	1U2CCA233262-01
clinical_trial	NCT04021043	BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers	October 6, 2021	Recruiting	3P30CA006516-55S9
clinical_trial	NCT02740270	Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas	February 21, 2021	Completed	1U01CA224348-01
clinical_trial	NCT02740270	Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas	February 21, 2021	Completed	1U2CCA233262-01
clinical_trial	NCT02740270	Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas	February 21, 2021	Completed	3P30CA006516-55S9
clinical_trial	NCT02628574	Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab	October 26, 2020	Completed	1U01CA224348-01
clinical_trial	NCT02628574	Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab	October 26, 2020	Completed	1U2CCA233262-01
clinical_trial	NCT02628574	Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab	October 26, 2020	Completed	3P30CA006516-55S9
clinical_trial	NCT02598960	An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread.	December 21, 2020	Completed	1U01CA224348-01
clinical_trial	NCT02598960	An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread.	December 21, 2020	Completed	1U2CCA233262-01
clinical_trial	NCT02598960	An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread.	December 21, 2020	Completed	3P30CA006516-55S9
clinical_trial	NCT04225039	Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma	February 5, 2021	Recruiting	1U01CA224348-01
clinical_trial	NCT04225039	Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma	February 5, 2021	Recruiting	1U2CCA233262-01
clinical_trial	NCT04225039	Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma	February 5, 2021	Recruiting	3P30CA006516-55S9
clinical_trial	NCT00546156	Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer	May 18, 2021	Completed	1U01CA224348-01
clinical_trial	NCT00798213	SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED)	February 4, 2015	Terminated	1U24CA224067-01
clinical_trial	NCT00937937	Dinaciclib in Treating Patients With Stage IV Melanoma	August 5, 2021	Active, not recruiting	1U24CA224067-01
clinical_trial	NCT00937937	Dinaciclib in Treating Patients With Stage IV Melanoma	August 5, 2021	Active, not recruiting	1U54CA224070-01
clinical_trial	NCT03253679	AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification	October 4, 2021	Suspended	1U24CA224067-01
clinical_trial	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	October 14, 2021	Recruiting	1U24CA224067-01
clinical_trial	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	October 14, 2021	Recruiting	1U54CA224070-01
clinical_trial	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	October 14, 2021	Recruiting	1U54CA224083-01
clinical_trial	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	October 14, 2021	Recruiting	1U54CA233223-01
clinical_trial	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	October 14, 2021	Recruiting	1U54CA233306-01
clinical_trial	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	October 14, 2021	Recruiting	3U54CA224065-01S1
clinical_trial	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	October 14, 2021	Recruiting	3U54CA224076-01S2
clinical_trial	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	October 14, 2021	Recruiting	3P30CA125123-14S6
clinical_trial	NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	October 14, 2021	Recruiting	3P30CA042014-31S5
clinical_trial	NCT02675439	Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas	July 9, 2020	Active, not recruiting	1U24CA224285-01
clinical_trial	NCT02675439	Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas	July 9, 2020	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT02675439	Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas	July 9, 2020	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT02675439	Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas	July 9, 2020	Active, not recruiting	1U01DE029255-01
clinical_trial	NCT03172936	Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas	October 12, 2021	Terminated	1U24CA224285-01
clinical_trial	NCT03172936	Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas	October 12, 2021	Terminated	2P01CA155258-06
clinical_trial	NCT03172936	Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas	October 12, 2021	Terminated	1U01CA233100-01
clinical_trial	NCT03172936	Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas	October 12, 2021	Terminated	1U01DE029255-01
clinical_trial	NCT03172936	Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas	October 12, 2021	Terminated	1U54CA244719-01
clinical_trial	NCT03010176	Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)	October 13, 2021	Active, not recruiting	1U24CA224285-01
clinical_trial	NCT03010176	Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)	October 13, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03010176	Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)	October 13, 2021	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT03010176	Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)	October 13, 2021	Active, not recruiting	1U01DE028227-01
clinical_trial	NCT03010176	Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)	October 13, 2021	Active, not recruiting	1U01DE029255-01
clinical_trial	NCT03010176	Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)	October 13, 2021	Active, not recruiting	1U54CA244719-01
clinical_trial	NCT02953509	Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma	September 24, 2021	Recruiting	1U24CA224285-01
clinical_trial	NCT04313881	Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) (ENHANCE)	October 4, 2021	Recruiting	1U24CA224285-01
clinical_trial	NCT03248479	Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies	July 19, 2021	Recruiting	1U24CA224285-01
clinical_trial	NCT03056339	Umbilical &amp; Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies	July 19, 2021	Recruiting	1U24CA224285-01
clinical_trial	NCT03056339	Umbilical &amp; Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies	July 19, 2021	Recruiting	1U01CA239258-01
clinical_trial	NCT03056339	Umbilical &amp; Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies	July 19, 2021	Recruiting	1U01CA239258-01
clinical_trial	NCT03056339	Umbilical &amp; Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies	July 19, 2021	Recruiting	3P30CA021765-41S3
clinical_trial	NCT04004637	CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia	September 28, 2020	Recruiting	1U24CA224285-01
clinical_trial	NCT04052061	QUILT 3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma	May 18, 2021	Withdrawn	1U24CA224285-01
clinical_trial	NCT04050709	QUILT 3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers	March 18, 2021	Active, not recruiting	1U24CA224285-01
clinical_trial	NCT03532451	Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer (PrE0807)	September 1, 2021	Active, not recruiting	1U24CA224285-01
clinical_trial	NCT03341936	Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN	July 23, 2021	Active, not recruiting	1U24CA224285-01
clinical_trial	NCT03489343	Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas	October 12, 2021	Completed	1U24CA224285-01
clinical_trial	NCT03005782	Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers	July 26, 2021	Recruiting	1U24CA224285-01
clinical_trial	NCT04354246	COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies	October 5, 2021	Recruiting	1U24CA224285-01
clinical_trial	NCT04370704	Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies	August 11, 2021	Recruiting	1U24CA224285-01
clinical_trial	NCT04150965	Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT	September 10, 2021	Recruiting	1U24CA224285-01
clinical_trial	NCT03214666	GTB-3550 Tri-Specific Killer Engager (TriKE&#174;) for High Risk Hematological Malignancies	September 21, 2021	Active, not recruiting	1U24CA224285-01
clinical_trial	NCT02304393	A Study of Selicrelumab (RO7009789) in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors	December 13, 2019	Completed	1U24CA224285-01
clinical_trial	NCT02482168	Study of the CD40 Agonistic Monoclonal Antibody APX005M	April 28, 2020	Completed	1U24CA224285-01
clinical_trial	NCT03719430	APX005M and Doxorubicin in Advanced Sarcoma	April 19, 2021	Recruiting	1U24CA224285-01
clinical_trial	NCT03165994	APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers	June 30, 2021	Recruiting	1U24CA224285-01
clinical_trial	NCT02706353	APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma	December 14, 2020	Recruiting	1U24CA224285-01
clinical_trial	NCT03597282	A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma	September 3, 2020	Terminated	1U24CA224285-01
clinical_trial	NCT03389802	Phase I Study of APX005M in Pediatric CNS Tumors	September 22, 2021	Recruiting	1U24CA224285-01
clinical_trial	NCT02379741	ADC-1013 First-in-Human Study	March 27, 2017	Completed	1U24CA224285-01
clinical_trial	NCT02829099	A Study of Safety, Pharmacokinetics and Pharmacodynamics of JNJ-64457107 in Participants With Advanced Stage Tumors	August 31, 2021	Completed	1U24CA224285-01
clinical_trial	NCT02955251	A Study of ABBV-428, an Immunotherapy, in Subjects With Advanced Solid Tumors	July 20, 2020	Completed	1U24CA224285-01
clinical_trial	NCT02001974	Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)	September 27, 2021	Completed	1U24CA224285-01
clinical_trial	NCT02001974	Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)	September 27, 2021	Completed	3P30CA046592-31S8
clinical_trial	NCT02001974	Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)	September 27, 2021	Completed	3P30CA046592-31S4
clinical_trial	NCT02370238	A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer (FRIDA)	June 2, 2021	Completed	1U24CA224285-01
clinical_trial	NCT01736813	CCR5-blockade in Metastatic Colorectal Cancer (MARACON)	March 22, 2017	Completed	1U24CA224285-01
clinical_trial	NCT03274804	Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC (PICCASSO)	April 22, 2021	Completed	1U24CA224285-01
clinical_trial	NCT02216409	Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody	February 5, 2019	Completed	1U24CA224285-01
clinical_trial	NCT03717103	A Phase 1 Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignancies	July 21, 2021	Active, not recruiting	1U24CA224285-01
clinical_trial	NCT02367196	A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers	August 12, 2021	Completed	1U24CA224285-01
clinical_trial	NCT02076451	Open-label Study of DS-8273a to Assess Its Safety and Tolerability, and Assess Its Pharmacokinetic and Pharmacodynamic Properties in Subjects With Advanced Solid Tumors or Lymphomas	February 12, 2019	Completed	1U24CA224285-01
clinical_trial	NCT03371979	Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer	May 12, 2021	Completed	1U24CA224285-01
clinical_trial	NCT02903914	Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors	September 30, 2021	Active, not recruiting	1U24CA224285-01
clinical_trial	NCT03361228	A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors	May 21, 2020	Terminated	1U24CA224285-01
clinical_trial	NCT03314935	A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors	July 20, 2020	Active, not recruiting	1U24CA224285-01
clinical_trial	NCT03665129	IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors (STELLAR-001)	January 22, 2021	Active, not recruiting	1U24CA224285-01
clinical_trial	NCT00356460	Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma	March 19, 2014	Completed	1U24CA224285-01
clinical_trial	NCT01582269	A Study in Recurrent Glioblastoma (GB)	August 23, 2021	Active, not recruiting	1U24CA224285-01
clinical_trial	NCT01682187	A Dose-Escalation Study in Participants With Recurrent Malignant Glioma	August 18, 2021	Active, not recruiting	1U24CA224285-01
clinical_trial	NCT01220271	A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma	February 16, 2017	Completed	1U24CA224285-01
clinical_trial	NCT01373164	A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer	May 16, 2018	Completed	1U24CA224285-01
clinical_trial	NCT01373164	A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer	May 16, 2018	Completed	1U54CA224083-01
clinical_trial	NCT01246986	A Study of LY2157299 in Participants With Hepatocellular Carcinoma	January 12, 2021	Completed	1U24CA224285-01
clinical_trial	NCT02423343	A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma	September 9, 2021	Completed	1U24CA224285-01
clinical_trial	NCT02423343	A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma	September 9, 2021	Completed	1U01CA233100-01
clinical_trial	NCT02423343	A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma	September 9, 2021	Completed	3P30CA016520-44S5
clinical_trial	NCT02423343	A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma	September 9, 2021	Completed	3P30CA016520-44S6
clinical_trial	NCT03059485	DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission	October 22, 2020	Recruiting	1U24CA224285-01
clinical_trial	NCT03059485	DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission	October 22, 2020	Recruiting	1U54CA224019-01
clinical_trial	NCT03059485	DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission	October 22, 2020	Recruiting	1U01CA233084-01
clinical_trial	NCT03152565	Avelumab Plus Autologous Dendritic Cell Vaccine in Pre-treated Metastatic Colorectal Cancer Patients (AVEVAC)	October 6, 2020	Completed	1U24CA224285-01
clinical_trial	NCT01973322	Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumor Lysate or Homogenate Combined With Immunomodulating Radiotherapy and/or Preleukapheresis IFN-alfa in Patients With Metastatic Melanoma: a Randomized &quot;Proof-of-principle&quot; Phase II Study (ABSIDE)	February 26, 2021	Recruiting	1U24CA224285-01
clinical_trial	NCT03035331	Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma	September 13, 2021	Recruiting	1U24CA224285-01
clinical_trial	NCT03360630	Anti-PD-1 Alone or Combined With Autologous Cell Therapy in Advanced NSCLC	November 6, 2019	Recruiting	1U24CA224285-01
clinical_trial	NCT01302496	Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma (TriMix-Ipi)	March 29, 2021	Completed	1U24CA224285-01
clinical_trial	NCT04203901	Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma	September 25, 2020	Recruiting	1U24CA224285-01
clinical_trial	NCT04203901	Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma	September 25, 2020	Recruiting	1U24CA224331-01
clinical_trial	NCT04203901	Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma	September 25, 2020	Recruiting	1U01CA233100-01
clinical_trial	NCT04203901	Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma	September 25, 2020	Recruiting	3P30CA006516-55S9
clinical_trial	NCT01876212	Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma	August 22, 2019	Completed	1U24CA224285-01
clinical_trial	NCT02030561	NK Cell Infusions With Trastuzumab for Patients With HER2+ Breast and Gastric Cancer	June 22, 2016	Unknown	1U24CA224285-01
clinical_trial	NCT02843126	Combination of Trastuzumab and NK Immunotherapy for Recurrent Breast Cancer	September 12, 2019	Completed	1U24CA224285-01
clinical_trial	NCT02805829	Combination Trastuzumab With Expanded Natural Killer Cells for Treating HER2-positive Gastric Cancer	June 22, 2016	Unknown	1U24CA224285-01
clinical_trial	NCT02843061	Combination of Rituximab and NK Immunotherapy for B Lymphoma	September 12, 2019	Completed	1U24CA224285-01
clinical_trial	NCT02507154	Reactivating NK Cells in Treating Refractory Head and Neck Cancer (NKEXPHNC)	August 21, 2018	Unknown	1U24CA224285-01
clinical_trial	NCT02507154	Reactivating NK Cells in Treating Refractory Head and Neck Cancer (NKEXPHNC)	August 21, 2018	Unknown	1U01CA239258-01
clinical_trial	NCT02845856	Combination of Cetuximab and NK Immunotherapy for Recurrent Non-small Cell Lung Cancer	September 12, 2019	Completed	1U24CA224285-01
clinical_trial	NCT03003728	2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)	July 10, 2020	Withdrawn	1U24CA224285-01
clinical_trial	NCT03003728	2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)	July 10, 2020	Withdrawn	1U01CA239258-01
clinical_trial	NCT03319459	FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors	January 9, 2020	Active, not recruiting	1U24CA224285-01
clinical_trial	NCT03242603	Immunotherapy of Neuroblastoma Patients Using a Combination of Anti-GD2 and NK Cells (NKEXPGD2)	March 30, 2018	Unknown	1U24CA224285-01
clinical_trial	NCT03242603	Immunotherapy of Neuroblastoma Patients Using a Combination of Anti-GD2 and NK Cells (NKEXPGD2)	March 30, 2018	Unknown	1U01CA239258-01
clinical_trial	NCT02843204	Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors	May 28, 2020	Completed	1U24CA224285-01
clinical_trial	NCT02890758	Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803	July 27, 2021	Active, not recruiting	1U24CA224285-01
clinical_trial	NCT04134325	Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma	July 15, 2021	Recruiting	1U24CA224285-01
clinical_trial	NCT02650999	Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas	July 22, 2021	Completed	1U24CA224285-01
clinical_trial	NCT00586391	CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL &amp; CLL (CRETI-NH)	March 10, 2021	Active, not recruiting	1U24CA224285-01
clinical_trial	NCT02706405	JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma	July 16, 2021	Active, not recruiting	1U24CA224285-01
clinical_trial	NCT02706405	JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma	July 16, 2021	Active, not recruiting	1U01CA247548-01
clinical_trial	NCT01881867	CYT107 After Vaccine Treatment (Provenge&#174;) in Patients With Metastatic Castration-Resistant Prostate Cancer	July 9, 2019	Completed	1U24CA224309-01
clinical_trial	NCT01881867	CYT107 After Vaccine Treatment (Provenge&#174;) in Patients With Metastatic Castration-Resistant Prostate Cancer	July 9, 2019	Completed	2UM1CA154967-07
clinical_trial	NCT00065442	Provenge&#174; (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy	September 6, 2010	Completed	1U24CA224309-01
clinical_trial	NCT00065442	Provenge&#174; (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy	September 6, 2010	Completed	2UM1CA154967-07
clinical_trial	NCT03184571	Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC	October 14, 2021	Recruiting	1U24CA224316-01
clinical_trial	NCT02054104	Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum	May 20, 2021	Terminated	1U24CA224319-01
clinical_trial	NCT02054104	Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum	May 20, 2021	Terminated	1U01DK124165-01
clinical_trial	NCT01358721	Phase I Biomarker Study (BMS-936558)	October 29, 2020	Completed	1U24CA224331-01
clinical_trial	NCT01354431	BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)	September 9, 2020	Active, not recruiting	1U24CA224331-01
clinical_trial	NCT01668784	Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)	August 24, 2020	Active, not recruiting	1U24CA224331-01
clinical_trial	NCT03734198	Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction (IDA53)	June 29, 2021	Recruiting	1U24CA224331-01
clinical_trial	NCT03915379	A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)	October 8, 2021	Recruiting	1U24CA224331-01
clinical_trial	NCT03915379	A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)	October 8, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT03915379	A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)	October 8, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT04181827	A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (CARTITUDE-4)	September 17, 2021	Recruiting	1U24CA224331-01
clinical_trial	NCT04181827	A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (CARTITUDE-4)	September 17, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT02989714	Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer	July 13, 2021	Completed	1U24CA224331-01
clinical_trial	NCT02989714	Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer	July 13, 2021	Completed	1U01CA233100-01
clinical_trial	NCT02989714	Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer	July 13, 2021	Completed	3P30CA006516-55S9
clinical_trial	NCT02306954	Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer	March 3, 2020	Recruiting	1U24CA224331-01
clinical_trial	NCT02306954	Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer	March 3, 2020	Recruiting	1U01CA233100-01
clinical_trial	NCT02306954	Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer	March 3, 2020	Recruiting	1U01CA233102-01
clinical_trial	NCT02306954	Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer	March 3, 2020	Recruiting	1U54CA232568-01
clinical_trial	NCT02306954	Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer	March 3, 2020	Recruiting	3P30CA006516-55S9
clinical_trial	NCT02983045	A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors (PIVOT-02)	October 7, 2021	Active, not recruiting	1U24CA224331-01
clinical_trial	NCT02983045	A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors (PIVOT-02)	October 7, 2021	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT02983045	A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors (PIVOT-02)	October 7, 2021	Active, not recruiting	3P30CA006516-55S9
clinical_trial	NCT02667886	Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma	September 22, 2021	Active, not recruiting	1U24CA224331-01
clinical_trial	NCT02667886	Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma	September 22, 2021	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT02667886	Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma	September 22, 2021	Active, not recruiting	3P30CA006516-55S9
clinical_trial	NCT02830724	Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers	January 29, 2021	Suspended	1U24CA224331-01
clinical_trial	NCT02830724	Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers	January 29, 2021	Suspended	1U01CA233100-01
clinical_trial	NCT02830724	Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers	January 29, 2021	Suspended	1U54CA244438-01
clinical_trial	NCT02830724	Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers	January 29, 2021	Suspended	3P30CA006516-55S9
clinical_trial	NCT02926053	TIL Therapy for Metastatic Renal Cell Carcinoma	December 23, 2019	Recruiting	1U24CA224331-01
clinical_trial	NCT02926053	TIL Therapy for Metastatic Renal Cell Carcinoma	December 23, 2019	Recruiting	1U01CA233100-01
clinical_trial	NCT02926053	TIL Therapy for Metastatic Renal Cell Carcinoma	December 23, 2019	Recruiting	3P30CA168524-09S3
clinical_trial	NCT02926053	TIL Therapy for Metastatic Renal Cell Carcinoma	December 23, 2019	Recruiting	3P30CA006516-55S9
clinical_trial	NCT03354390	HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma	September 27, 2021	Recruiting	1U24CA224331-01
clinical_trial	NCT03354390	HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma	September 27, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT03354390	HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma	September 27, 2021	Recruiting	3P30CA006516-55S9
clinical_trial	NCT03354390	HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma	September 27, 2021	Recruiting	3P30CA006516-55S9
clinical_trial	NCT02950766	NeoVax Plus Ipilimumab in Renal Cell Carcinoma	March 3, 2021	Recruiting	1U24CA224331-01
clinical_trial	NCT02950766	NeoVax Plus Ipilimumab in Renal Cell Carcinoma	March 3, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT02950766	NeoVax Plus Ipilimumab in Renal Cell Carcinoma	March 3, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT02950766	NeoVax Plus Ipilimumab in Renal Cell Carcinoma	March 3, 2021	Recruiting	3P30CA006516-55S9
clinical_trial	NCT03289962	A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors	October 12, 2021	Recruiting	1U24CA224331-01
clinical_trial	NCT03289962	A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors	October 12, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT03289962	A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors	October 12, 2021	Recruiting	3P30CA006516-55S9
clinical_trial	NCT02964013	Study of Vibostolimab Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001)	August 30, 2021	Recruiting	1U24CA224331-01
clinical_trial	NCT02964013	Study of Vibostolimab Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001)	August 30, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT02964013	Study of Vibostolimab Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001)	August 30, 2021	Recruiting	3P30CA006516-55S9
clinical_trial	NCT02179918	A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036)	February 8, 2019	Completed	1U24CA224331-01
clinical_trial	NCT02179918	A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036)	February 8, 2019	Completed	1U01CA233100-01
clinical_trial	NCT02179918	A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036)	February 8, 2019	Completed	3P30CA006516-55S9
clinical_trial	NCT03192943	A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced Tumors	April 1, 2019	Completed	1U24CA224331-01
clinical_trial	NCT03192943	A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced Tumors	April 1, 2019	Completed	1U01CA233100-01
clinical_trial	NCT03192943	A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced Tumors	April 1, 2019	Completed	3P30CA006516-55S9
clinical_trial	NCT02655822	Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers	August 30, 2021	Completed	1U24CA224331-01
clinical_trial	NCT02655822	Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers	August 30, 2021	Completed	1U01CA233100-01
clinical_trial	NCT02655822	Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers	August 30, 2021	Completed	1U01CA233100-01
clinical_trial	NCT02655822	Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers	August 30, 2021	Completed	1U01CA244452-01
clinical_trial	NCT02655822	Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers	August 30, 2021	Completed	3P30CA006516-55S9
clinical_trial	NCT02754141	An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab	February 16, 2021	Active, not recruiting	1U24CA224331-01
clinical_trial	NCT02754141	An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab	February 16, 2021	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT02754141	An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab	February 16, 2021	Active, not recruiting	3P30CA006516-55S9
clinical_trial	NCT03260894	Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)	September 1, 2021	Active, not recruiting	1U24CA224331-01
clinical_trial	NCT03260894	Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)	September 1, 2021	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT03260894	Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)	September 1, 2021	Active, not recruiting	3P30CA006516-55S9
clinical_trial	NCT03638206	Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies	December 11, 2019	Recruiting	1U24CA224331-01
clinical_trial	NCT03638206	Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies	December 11, 2019	Recruiting	1U01CA233100-01
clinical_trial	NCT03638206	Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies	December 11, 2019	Recruiting	3P30CA006516-55S9
clinical_trial	NCT03393936	Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma	April 7, 2020	Active, not recruiting	1U24CA224331-01
clinical_trial	NCT03393936	Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma	April 7, 2020	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT03393936	Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma	April 7, 2020	Active, not recruiting	1U54CA244438-01
clinical_trial	NCT03393936	Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma	April 7, 2020	Active, not recruiting	3P30CA006516-55S9
clinical_trial	NCT01970358	A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma	December 9, 2020	Completed	1U24CA224331-01
clinical_trial	NCT01970358	A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma	December 9, 2020	Completed	3P30CA006516-55S9
clinical_trial	NCT01415882	Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib	September 24, 2021	Recruiting	1U54CA224018-01
clinical_trial	NCT03066648	Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS	July 30, 2021	Active, not recruiting	1U54CA224019-01
clinical_trial	NCT03381118	Haploidentical Lymphocytes With Nivolumab/Ara-C as Consolidation in Elderly AML Patients	April 5, 2019	Terminated	1U54CA224019-01
clinical_trial	NCT01096602	Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission	August 3, 2021	Active, not recruiting	1U54CA224019-01
clinical_trial	NCT01822509	Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant	June 24, 2021	Completed	1U54CA224019-01
clinical_trial	NCT01919619	Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies	August 13, 2021	Active, not recruiting	1U54CA224019-01
clinical_trial	NCT01953692	A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013)	August 4, 2021	Completed	1U54CA224019-01
clinical_trial	NCT02117219	Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome	May 10, 2019	Completed	1U54CA224019-01
clinical_trial	NCT02275533	Nivolumab in Eliminating Minimal Residual Disease and Preventing Relapse in Patients With Acute Myeloid Leukemia in Remission After Chemotherapy	September 2, 2021	Active, not recruiting	1U54CA224019-01
clinical_trial	NCT02397720	Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia	January 15, 2021	Recruiting	1U54CA224019-01
clinical_trial	NCT02464657	Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)	October 7, 2021	Completed	1U54CA224019-01
clinical_trial	NCT02530463	Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome	January 15, 2021	Recruiting	1U54CA224019-01
clinical_trial	NCT02532231	Nivolumab in AML in Remission at High Risk for Relapse	February 13, 2020	Recruiting	1U54CA224019-01
clinical_trial	NCT02599649	Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)	January 14, 2020	Terminated	1U54CA224019-01
clinical_trial	NCT02708641	A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients &#8805; 60 With AML	August 10, 2021	Completed	1U54CA224019-01
clinical_trial	NCT02768792	High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML	September 5, 2021	Active, not recruiting	1U54CA224019-01
clinical_trial	NCT02771197	Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant	September 5, 2021	Active, not recruiting	1U54CA224019-01
clinical_trial	NCT02775903	An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)	August 23, 2021	Active, not recruiting	1U54CA224019-01
clinical_trial	NCT02845297	Study of Azacitidine in Combination With Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients and in Newly Diagnosed Older (&#8805;65 Years) AML Patients	May 19, 2021	Active, not recruiting	1U54CA224019-01
clinical_trial	NCT02846376	Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant (CPIT-002)	October 5, 2021	Active, not recruiting	1U54CA224019-01
clinical_trial	NCT02890329	Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia	September 8, 2021	Recruiting	1U54CA224019-01
clinical_trial	NCT02935361	Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed	April 6, 2021	Active, not recruiting	1U54CA224019-01
clinical_trial	NCT02936752	Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents	July 2, 2021	Active, not recruiting	1U54CA224019-01
clinical_trial	NCT02953561	Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia	October 22, 2020	Terminated	1U54CA224019-01
clinical_trial	NCT02981914	Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation	June 30, 2021	Recruiting	1U54CA224019-01
clinical_trial	NCT02985554	Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic Malignancies	June 25, 2020	Terminated	1U54CA224019-01
clinical_trial	NCT02996474	Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia	June 9, 2020	Completed	1U54CA224019-01
clinical_trial	NCT03092674	Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome	September 8, 2021	Active, not recruiting	1U54CA224019-01
clinical_trial	NCT03094637	Azacitidine and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome	October 1, 2021	Active, not recruiting	1U54CA224019-01
clinical_trial	NCT03146468	Nivolumab for Relapsed or Residual Haematological Malignancies After Allogeneic Stem Cell Transplantation (NIVALLO)	September 23, 2021	Active, not recruiting	1U54CA224019-01
clinical_trial	NCT03154827	A Phase Ib/II, Multicenter, Single Arm, Open-Label Study, To Evaluate the Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab Combination for Maintenance Treatment in Subjects With Acute Myeloid Leukemia Who Are 60 Years or Older - The BATTLE Study	May 18, 2020	Terminated	1U54CA224019-01
clinical_trial	NCT03259516	Nivolumab With Chemotherapy in Refractory MDS	April 5, 2019	Terminated	1U54CA224019-01
clinical_trial	NCT03286114	Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab	May 27, 2021	Recruiting	1U54CA224019-01
clinical_trial	NCT03291353	Phase 0- Pilot Study of Pembrolizumab on Immune Cells in Patient With Refractory Acute Myeloid Leukemia	April 19, 2019	Withdrawn	1U54CA224019-01
clinical_trial	NCT03358719	DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia	October 5, 2021	Completed	1U54CA224019-01
clinical_trial	NCT03390296	OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	February 12, 2021	Recruiting	1U54CA224019-01
clinical_trial	NCT03395873	Avelumab With Decitabine as First Line for AML Treatment of Patients With AML, Who Are Unfit for Intensive Chemotherapy	August 21, 2019	Terminated	1U54CA224019-01
clinical_trial	NCT02996500	Safety and Efficacy of Pf-06650833 In Subjects With Rheumatoid Arthritis, With An Inadequate Response To Methotrexate	February 27, 2020	Completed	1U54CA224019-01
clinical_trial	NCT03328078	A Study of CA-4948 in Patients With Relapsed or Refractory Hematologic Malignancies	May 5, 2021	Recruiting	1U54CA224019-01
clinical_trial	NCT03328078	A Study of CA-4948 in Patients With Relapsed or Refractory Hematologic Malignancies	May 5, 2021	Recruiting	1U54CA224083-01
clinical_trial	NCT03328078	A Study of CA-4948 in Patients With Relapsed or Refractory Hematologic Malignancies	May 5, 2021	Recruiting	1U54CA224083-01
clinical_trial	NCT02891603	A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression	October 12, 2021	Recruiting	1U54CA224019-01
clinical_trial	NCT01235871	A Single and Multiple-Dose Study of SB1578	April 20, 2012	Completed	1U54CA224019-01
clinical_trial	NCT01728402	Pathogenesis of Hematologic Malignancies	August 30, 2021	Enrolling by invitation	1U54CA224019-01
clinical_trial	NCT01728402	Pathogenesis of Hematologic Malignancies	August 30, 2021	Enrolling by invitation	1U54CA224019-01
clinical_trial	NCT01728402	Pathogenesis of Hematologic Malignancies	August 30, 2021	Enrolling by invitation	1U54CA224019-01
clinical_trial	NCT02158858	A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis	August 25, 2021	Recruiting	1U54CA224019-01
clinical_trial	NCT01713582	A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001)	January 26, 2021	Completed	1U54CA224019-01
clinical_trial	NCT01713582	A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001)	January 26, 2021	Completed	5R01CA176745-09
clinical_trial	NCT02698189	A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005)	July 13, 2021	Active, not recruiting	1U54CA224019-01
clinical_trial	NCT02698189	A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005)	July 13, 2021	Active, not recruiting	5R01CA176745-09
clinical_trial	NCT02308761	A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndrome	December 11, 2017	Completed	1U54CA224019-01
clinical_trial	NCT02308761	A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndrome	December 11, 2017	Completed	5R01CA176745-09
clinical_trial	NCT02431260	An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies	June 14, 2019	Terminated	1U54CA224019-01
clinical_trial	NCT02391480	A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer	November 29, 2019	Completed	1U54CA224019-01
clinical_trial	NCT01943851	A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies	May 19, 2021	Completed	1U54CA224019-01
clinical_trial	NCT02683395	A Study of PLX51107 in Advanced Malignancies	December 24, 2018	Terminated	1U54CA224019-01
clinical_trial	NCT01522469	Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations	June 28, 2018	Completed	1U54CA224019-01
clinical_trial	NCT01657682	A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations	July 20, 2020	Completed	1U54CA224019-01
clinical_trial	NCT01657682	A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations	July 20, 2020	Completed	3R01CA182543-05S2
clinical_trial	NCT02092324	Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia	November 16, 2020	Completed	1U54CA224019-01
clinical_trial	NCT03465540	Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies	October 11, 2021	Terminated	1U54CA224019-01
clinical_trial	NCT01750918	BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)	April 19, 2021	Completed	1U54CA224068-01
clinical_trial	NCT01719380	Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer	June 23, 2021	Completed	1U54CA224068-01
clinical_trial	NCT02974725	A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma	September 8, 2021	Recruiting	1U54CA224068-01
clinical_trial	NCT01032122	Rituximab in Metastatic Melanoma	April 25, 2013	Terminated	1U54CA224068-01
clinical_trial	NCT01376713	Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma	October 6, 2015	Completed	1U54CA224068-01
clinical_trial	NCT01376713	Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma	October 6, 2015	Completed	1U54CA224070-01
clinical_trial	NCT01307267	A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab	March 17, 2020	Completed	1U54CA224068-01
clinical_trial	NCT03600883	A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of AMG 510 in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)	September 2, 2021	Recruiting	1U54CA224068-01
clinical_trial	NCT03600883	A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of AMG 510 in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)	September 2, 2021	Recruiting	3P30CA125123-14S6
clinical_trial	NCT03785249	Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1	September 29, 2021	Recruiting	1U54CA224068-01
clinical_trial	NCT01659151	Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer &amp; High Dose IL-2 Metastatic Melanoma	June 15, 2021	Active, not recruiting	1U54CA224070-01
clinical_trial	NCT03454919	Efficacy of Palbociclib in Advanced Acral Melanoma With Cell Cycle Gene Aberrations	March 6, 2018	Unknown	1U54CA224070-01
clinical_trial	NCT01120275	Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma	June 14, 2016	Terminated	1U54CA224070-01
clinical_trial	NCT00005057	Gene Therapy and Ganciclovir in Treating Patients With Stage IV Melanoma	April 29, 2015	Completed	1U54CA224070-01
clinical_trial	NCT01720407	Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face (ImiReduc)	August 7, 2019	Active, not recruiting	1U54CA224070-01
clinical_trial	NCT02723721	Prospective Study of Ingenol Mebutate for Non-invasive Lentigo Melanoma of the Face (PICAMEL)	August 23, 2017	Unknown	1U54CA224070-01
clinical_trial	NCT02685592	Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing Cream (LM PDT)	May 30, 2018	Completed	1U54CA224070-01
clinical_trial	NCT03955354	PD-1 Antibody SHR-1210 Combined With Apatinib of First-line Treatment of Advanced Acral Melanoma	May 20, 2019	Unknown	1U54CA224070-01
clinical_trial	NCT00700882	Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery	March 16, 2021	Completed	1U54CA224070-01
clinical_trial	NCT02071940	PLX3397 KIT in Acral aNd mucOsal Melanoma (PIANO)	August 12, 2021	Completed	1U54CA224070-01
clinical_trial	NCT00788775	Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma	November 15, 2018	Completed	1U54CA224070-01
clinical_trial	NCT02978443	A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab	January 10, 2020	Active, not recruiting	1U54CA224070-01
clinical_trial	NCT00577382	SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma	December 8, 2016	Completed	1U54CA224070-01
clinical_trial	NCT00424515	Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma (BUS255)	December 8, 2016	Completed	1U54CA224070-01
clinical_trial	NCT03991975	Study of TQB2450 Combined With Anlotinib in Subjects With Advanced Acral Malignant Melanoma	October 30, 2019	Recruiting	1U54CA224070-01
clinical_trial	NCT03138642	Mucosal Melanoma of Head and Neck in Intensity-modulated Radiotherapy Era	January 30, 2018	Unknown	1U54CA224070-01
clinical_trial	NCT03178123	The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by Surgery	September 30, 2020	Active, not recruiting	1U54CA224070-01
clinical_trial	NCT03602547	Study of the Combination of CM082 With JS001 in Patients With Advanced Mucosal Melanoma.	July 5, 2019	Unknown	1U54CA224070-01
clinical_trial	NCT03241186	Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma	August 12, 2021	Recruiting	1U54CA224070-01
clinical_trial	NCT03986515	Apatinib Plus SHR1210 in Advanced Mucosal Melanoma	June 14, 2019	Recruiting	1U54CA224070-01
clinical_trial	NCT03022565	Vorinostat in Patients With Class 2 High Risk Uveal Melanoma	February 6, 2020	Withdrawn	1U54CA224070-01
clinical_trial	NCT02913417	Yttrium90, Ipilimumab, &amp; Nivolumab for Uveal Melanoma With Liver Metastases	April 19, 2021	Active, not recruiting	1U54CA224070-01
clinical_trial	NCT03417739	A Phase II Study of BVD-523 in Metastatic Uveal Melanoma	August 3, 2021	Active, not recruiting	1U54CA224070-01
clinical_trial	NCT01983748	Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma	April 28, 2021	Recruiting	1U54CA224070-01
clinical_trial	NCT02768766	Intermittent Selumetinib for Uveal Melanoma	March 19, 2021	Recruiting	1U54CA224070-01
clinical_trial	NCT02159066	LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma (LOGIC-2)	June 15, 2021	Active, not recruiting	1U54CA224070-01
clinical_trial	NCT01390818	Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors	March 7, 2017	Completed	1U54CA224070-01
clinical_trial	NCT00831792	TKI258 in Castrate Resistant Prostate Cancer	September 11, 2019	Completed	1U54CA224079-01
clinical_trial	NCT02122913	A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer	May 12, 2021	Completed	1U54CA224079-01
clinical_trial	NCT02637687	A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children (SCOUT)	October 12, 2021	Recruiting	1U54CA224079-01
clinical_trial	NCT02576431	A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors (NAVIGATE)	September 8, 2021	Recruiting	1U54CA224079-01
clinical_trial	NCT03213704	Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)	October 14, 2021	Recruiting	1U54CA224079-01
clinical_trial	NCT03215511	A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer	October 13, 2021	Active, not recruiting	1U54CA224079-01
clinical_trial	NCT02097810	Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations. (STARTRK-1)	June 9, 2021	Completed	1U54CA224079-01
clinical_trial	NCT02568267	Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)	August 30, 2021	Recruiting	1U54CA224079-01
clinical_trial	NCT02650401	Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options (STARTRK-NG)	September 30, 2021	Recruiting	1U54CA224079-01
clinical_trial	NCT03093116	A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)	February 1, 2021	Recruiting	1U54CA224079-01
clinical_trial	NCT02920996	Merestinib In Non-Small Cell Lung Cancer And Solid Tumors	August 31, 2021	Active, not recruiting	1U54CA224079-01
clinical_trial	NCT02675491	Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors	January 13, 2021	Active, not recruiting	1U54CA224079-01
clinical_trial	NCT02279433	A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b	September 22, 2020	Completed	1U54CA224079-01
clinical_trial	NCT01804530	Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors	August 2, 2018	Terminated	1U54CA224079-01
clinical_trial	NCT02219711	Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer	January 30, 2020	Active, not recruiting	1U54CA224079-01
clinical_trial	NCT01482962	Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma	July 31, 2018	Completed	1U54CA224079-01
clinical_trial	NCT02606123	Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer	March 1, 2018	Terminated	1U54CA224079-01
clinical_trial	NCT02952534	A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON2)	August 30, 2021	Completed	1U54CA224079-01
clinical_trial	NCT02952534	A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON2)	August 30, 2021	Completed	1U01CA233100-01
clinical_trial	NCT02987543	Study of Olaparib (Lynparza&#8482;) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)	August 4, 2021	Active, not recruiting	1U54CA224079-01
clinical_trial	NCT02854436	An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies (Galahad)	October 8, 2021	Active, not recruiting	1U54CA224079-01
clinical_trial	NCT02525068	A Study of Enzalutamide in Combination With AZD5363 in Patients With mCRPC (RE-AKT)	August 8, 2018	Unknown	1U54CA224079-01
clinical_trial	NCT03310541	AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations	July 6, 2021	Active, not recruiting	1U54CA224079-01
clinical_trial	NCT03567642	A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers	March 19, 2021	Recruiting	1U54CA224079-01
clinical_trial	NCT03263650	Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC	April 6, 2021	Active, not recruiting	1U54CA224079-01
clinical_trial	NCT03582475	Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate	July 14, 2021	Recruiting	1U54CA224079-01
clinical_trial	NCT03582475	Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate	July 14, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT03582475	Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate	July 14, 2021	Recruiting	1U01CA244452-01
clinical_trial	NCT03837353	A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1	March 23, 2021	Recruiting	1U54CA224079-01
clinical_trial	NCT01391143	Safety Study of MGA271 in Refractory Cancer	January 10, 2020	Completed	1U54CA224079-01
clinical_trial	NCT04129320	Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck	October 14, 2020	Withdrawn	1U54CA224079-01
clinical_trial	NCT00410059	BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLC	August 2, 2017	Completed	1U54CA224081-01
clinical_trial	NCT00411671	BATTLE Program: Sorafenib in Patients With NSCLC	February 11, 2016	Completed	1U54CA224081-01
clinical_trial	NCT03630120	Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer	July 14, 2021	Terminated	1U54CA224081-01
clinical_trial	NCT03543969	Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma	September 14, 2021	Recruiting	1U54CA224081-01
clinical_trial	NCT03511196	Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer	July 19, 2021	Active, not recruiting	1U54CA224081-01
clinical_trial	NCT02415621	Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer	October 12, 2021	Active, not recruiting	1U54CA224081-01
clinical_trial	NCT03227926	Rechallenge With Panitumumab Driven by RAS Dynamic of Resistance (CHRONOS)	August 31, 2021	Active, not recruiting	1U54CA224081-01
clinical_trial	NCT03259009	RAS Mutations in ctDNA and Anti-EGFR reINTROduction in mCRC (RASINTRO) (RASINTRO)	September 11, 2017	Unknown	1U54CA224081-01
clinical_trial	NCT02296203	Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET). (CRICKET)	February 15, 2018	Unknown	1U54CA224081-01
clinical_trial	NCT01158521	Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer	September 12, 2018	Completed	1U54CA224081-01
clinical_trial	NCT03088930	Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer	April 23, 2021	Completed	1U54CA224081-01
clinical_trial	NCT03088930	Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer	April 23, 2021	Completed	1U54CA224081-01
clinical_trial	NCT03433469	Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery	June 3, 2021	Recruiting	1U54CA224081-01
clinical_trial	NCT03433469	Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery	June 3, 2021	Recruiting	1U54CA224081-01
clinical_trial	NCT02443948	Circulating Cell-free Tumor DNA in the Plasma of Patients With Gastrointestinal Stromal Tumors (GIST)	February 14, 2017	Unknown	1U54CA224081-01
clinical_trial	NCT03691012	Circulating Tumour DNA as a Marker of Residual Disease &amp; Response to Adjuvant Chemotherapy in Stage I-IV Ovarian Cancer	November 3, 2020	Recruiting	1U54CA224081-01
clinical_trial	NCT02245100	Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung Cancer	September 1, 2021	Active, not recruiting	1U54CA224081-01
clinical_trial	NCT03637686	Circulating Tumor DNA Analysis to Optimize Treatment for Patients With Colorectal Cancer (IMPROVE)	January 14, 2021	Recruiting	1U54CA224081-01
clinical_trial	NCT02883517	Cell-free Circulating DNA in Primary Cutaneous Lymphomas (MATULILA)	February 23, 2017	Unknown	1U54CA224081-01
clinical_trial	NCT02424617	A Study of BGB324 in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer	July 6, 2017	Unknown	1U54CA224081-01
clinical_trial	NCT03839342	Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations (BEAVER)	September 30, 2021	Recruiting	1U54CA224081-01
clinical_trial	NCT04249843	Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors	December 17, 2020	Recruiting	1U54CA224081-01
clinical_trial	NCT02428712	A Study of PLX8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors	July 1, 2021	Recruiting	1U54CA224081-01
clinical_trial	NCT02607813	Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations	September 23, 2021	Active, not recruiting	1U54CA224081-01
clinical_trial	NCT03905148	Study of the Safety and Pharmacokinetics of BGB-283 (Lifirfenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors	June 18, 2021	Recruiting	1U54CA224081-01
clinical_trial	NCT01781429	Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies	March 20, 2020	Completed	1U54CA224083-01
clinical_trial	NCT02608229	BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer	April 21, 2021	Terminated	1U54CA224083-01
clinical_trial	NCT02124902	Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity	July 23, 2021	Active, not recruiting	1U54CA224083-01
clinical_trial	NCT02550327	Gemcitabine, Nab-Paclitaxel, Cisplatin and Anakinra Treatment on Patients With Pancreatic Cancer	June 22, 2021	Completed	1U54CA224083-01
clinical_trial	NCT02550327	Gemcitabine, Nab-Paclitaxel, Cisplatin and Anakinra Treatment on Patients With Pancreatic Cancer	June 22, 2021	Completed	1U54CA224083-01
clinical_trial	NCT02550327	Gemcitabine, Nab-Paclitaxel, Cisplatin and Anakinra Treatment on Patients With Pancreatic Cancer	June 22, 2021	Completed	1U54CA224083-01
clinical_trial	NCT01383538	FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma	August 8, 2017	Completed	1U54CA224083-01
clinical_trial	NCT01195415	Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer	August 7, 2017	Completed	1U54CA224083-01
clinical_trial	NCT01064622	Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer	August 14, 2015	Completed	1U54CA224083-01
clinical_trial	NCT01088815	Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas	April 26, 2019	Completed	1U54CA224083-01
clinical_trial	NCT01487785	Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients	December 19, 2020	Completed	1U54CA224083-01
clinical_trial	NCT02734160	A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer	August 5, 2019	Completed	1U54CA224083-01
clinical_trial	NCT02734160	A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer	August 5, 2019	Completed	1U01CA233100-01
clinical_trial	NCT03941093	Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Locally Advanced Pancreatic Cancer	September 17, 2021	Recruiting	1U54CA224083-01
clinical_trial	NCT04054362	Paricalcitol Addition to Chemotherapy in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PINBALL)	December 16, 2019	Unknown	1U54CA224083-01
clinical_trial	NCT04524702	Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced or Metastatic Pancreatic Cancer	February 21, 2021	Recruiting	1U54CA224083-01
clinical_trial	NCT03883919	Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy	October 7, 2021	Active, not recruiting	1U54CA224083-01
clinical_trial	NCT03331562	A SU2C Catalyst&#174; Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer	October 8, 2020	Completed	1U54CA224083-01
clinical_trial	NCT03307148	Stromal TARgeting for PAncreatic Cancer (STAR_PAC) (STAR_PAC)	January 22, 2020	Completed	1U54CA224083-01
clinical_trial	NCT02715804	A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma	July 14, 2020	Terminated	1U54CA224083-01
clinical_trial	NCT01959139	S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer	January 5, 2021	Active, not recruiting	1U54CA224083-01
clinical_trial	NCT01472198	A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma	March 10, 2015	Completed	1U54CA224083-01
clinical_trial	NCT02661022	SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma	April 7, 2020	Completed	2P01CA155258-06
clinical_trial	NCT01309334	Imaging Young Myeloma (IMAgerie JEune My&#233;lome) (IMAJEM)	August 25, 2014	Completed	2P01CA155258-06
clinical_trial	NCT01191060	Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years (IFM/DFCI2009)	April 18, 2019	Completed	2P01CA155258-06
clinical_trial	NCT01191060	Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years (IFM/DFCI2009)	April 18, 2019	Completed	2P01CA155258-06
clinical_trial	NCT01191060	Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years (IFM/DFCI2009)	April 18, 2019	Completed	2P01CA155258-06
clinical_trial	NCT01191060	Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years (IFM/DFCI2009)	April 18, 2019	Completed	2P01CA155258-06
clinical_trial	NCT01191060	Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years (IFM/DFCI2009)	April 18, 2019	Completed	2P01CA155258-06
clinical_trial	NCT01191060	Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years (IFM/DFCI2009)	April 18, 2019	Completed	2P01CA155258-06
clinical_trial	NCT01191060	Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years (IFM/DFCI2009)	April 18, 2019	Completed	2P01CA155258-06
clinical_trial	NCT01782963	Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM) (RVD Lite)	October 31, 2018	Completed	2P01CA155258-06
clinical_trial	NCT02252172	Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma	September 20, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT02252172	Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma	September 20, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT01850524	IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma	February 1, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT01850524	IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma	February 1, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT02702492	PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA) (PANAMA)	June 25, 2021	Terminated	2P01CA155258-06
clinical_trial	NCT02702492	PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA) (PANAMA)	June 25, 2021	Terminated	3P30CA125123-14S6
clinical_trial	NCT03225716	A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia	May 27, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03464916	Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients	March 17, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03274219	Study of bb21217 in Multiple Myeloma	March 18, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03274219	Study of bb21217 in Multiple Myeloma	March 18, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03318861	Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma	June 28, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03318861	Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma	June 28, 2021	Active, not recruiting	1U01CA244291-01
clinical_trial	NCT02529813	CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies	July 24, 2019	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03019666	Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL	August 5, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT03288493	P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)	September 14, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT03288493	P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)	September 14, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT03288493	P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)	September 14, 2021	Recruiting	1U01CA244291-01
clinical_trial	NCT03288493	P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)	September 14, 2021	Recruiting	3P30CA021765-41S3
clinical_trial	NCT02955550	A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)	July 22, 2020	Completed	2P01CA155258-06
clinical_trial	NCT02955550	A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)	July 22, 2020	Completed	1U01CA239258-01
clinical_trial	NCT02203825	Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands	June 1, 2018	Completed	2P01CA155258-06
clinical_trial	NCT03287804	APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma (APRIL)	October 23, 2020	Terminated	2P01CA155258-06
clinical_trial	NCT03430011	Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma (EVOLVE)	June 1, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03430011	Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma (EVOLVE)	June 1, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03090659	LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma (LEGEND-2)	September 2, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03090659	LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma (LEGEND-2)	September 2, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03090659	LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma (LEGEND-2)	September 2, 2021	Active, not recruiting	1U01CA244291-01
clinical_trial	NCT03361748	Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma (KarMMa)	August 6, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03601078	An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma (KarMMa-2)	September 1, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT02658929	Study of bb2121 in Multiple Myeloma	December 4, 2020	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT02658929	Study of bb2121 in Multiple Myeloma	December 4, 2020	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT02658929	Study of bb2121 in Multiple Myeloma	December 4, 2020	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT02658929	Study of bb2121 in Multiple Myeloma	December 4, 2020	Active, not recruiting	1U01CA244291-01
clinical_trial	NCT03445663	Study Evaluating AMG 424 in Subjects With Multiple Myeloma	May 10, 2021	Terminated	2P01CA155258-06
clinical_trial	NCT03111992	Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma	October 12, 2021	Completed	2P01CA155258-06
clinical_trial	NCT03111992	Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma	October 12, 2021	Completed	1U01CA244291-01
clinical_trial	NCT03111992	Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma	October 12, 2021	Completed	1U01CA244291-01
clinical_trial	NCT01457417	A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors	September 28, 2016	Completed	2P01CA155258-06
clinical_trial	NCT03145181	Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-1)	October 8, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT03399799	Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma	October 8, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT02252263	A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma	November 1, 2017	Completed	2P01CA155258-06
clinical_trial	NCT02252263	A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma	November 1, 2017	Completed	1U01CA244291-01
clinical_trial	NCT03489525	MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma (MEDI2228)	August 5, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03489525	MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma (MEDI2228)	August 5, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03269136	PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma	July 2, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03269136	PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma	July 2, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03582033	A Safety Study of SEA-BCMA in Patients With Multiple Myeloma	October 8, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT03379584	A Safety Study of SGN-CD48A in Patients With Multiple Myeloma	September 18, 2019	Terminated	2P01CA155258-06
clinical_trial	NCT03424603	Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies	October 19, 2020	Recruiting	2P01CA155258-06
clinical_trial	NCT03287908	A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma	August 27, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT03287908	A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma	August 27, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT03287908	A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma	August 27, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT03486067	Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma	October 6, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT03486067	Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma	October 6, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT03340883	Safety and Tolerability of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma (MM)	April 1, 2021	Terminated	2P01CA155258-06
clinical_trial	NCT01001442	Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma	July 30, 2019	Completed	2P01CA155258-06
clinical_trial	NCT01638936	BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma	July 23, 2019	Completed	2P01CA155258-06
clinical_trial	NCT01421186	A Phase I/IIa Study of Human Anti-CD38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma	September 16, 2020	Completed	2P01CA155258-06
clinical_trial	NCT01421186	A Phase I/IIa Study of Human Anti-CD38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma	September 16, 2020	Completed	2P01CA155258-06
clinical_trial	NCT03439280	A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)	March 19, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03439280	A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)	March 19, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03215030	A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-573 in Participants With Refractory Multiple Myeloma (MM)	December 21, 2020	Recruiting	2P01CA155258-06
clinical_trial	NCT01302886	Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma	December 17, 2020	Completed	2P01CA155258-06
clinical_trial	NCT01337752	Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency	December 17, 2020	Completed	2P01CA155258-06
clinical_trial	NCT03525678	A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody	October 4, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03525678	A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody	October 4, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT02462525	Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma	September 13, 2018	Terminated	2P01CA155258-06
clinical_trial	NCT01232712	A Study to Assess the Safety and Efficacy of MUC1 Peptide Vaccine and hGM-CSF in Patients With MUC1-positive Tumor Malignancies	August 9, 2013	Completed	2P01CA155258-06
clinical_trial	NCT02886065	A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM	February 24, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT02886065	A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM	February 24, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT01670994	QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma	October 28, 2016	Terminated	2P01CA155258-06
clinical_trial	NCT02978235	A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma	June 21, 2021	Terminated	2P01CA155258-06
clinical_trial	NCT02693535	TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR)	August 25, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT03091257	A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma	February 24, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT02675452	AMG 176 First in Human Trial in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia	September 16, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT02223598	A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies (CLC-102)	February 27, 2018	Terminated	2P01CA155258-06
clinical_trial	NCT01421524	Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma	September 29, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT02157636	A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma	June 7, 2018	Completed	2P01CA155258-06
clinical_trial	NCT00891280	Dose-escalation Study of Oral CX-4945	June 15, 2011	Unknown	2P01CA155258-06
clinical_trial	NCT01199718	Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma	June 15, 2011	Unknown	2P01CA155258-06
clinical_trial	NCT03110822	A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients	March 11, 2020	Recruiting	2P01CA155258-06
clinical_trial	NCT02160951	Dose Escalation Study of LGH447 in Japanese Patients With Relapsed and/or Refractory Hematologic Malignancies	December 17, 2020	Completed	2P01CA155258-06
clinical_trial	NCT01794520	Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma	October 7, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT01794520	Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma	October 7, 2021	Active, not recruiting	3P30CA013696-45S1
clinical_trial	NCT02992483	Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma	August 3, 2021	Completed	2P01CA155258-06
clinical_trial	NCT01204164	Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies (TG02-101)	May 6, 2016	Completed	2P01CA155258-06
clinical_trial	NCT02389543	Study of Selinexor (KPT- 330), Lenalidomide, &amp; Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients (SLAM)	September 3, 2015	Withdrawn	2P01CA155258-06
clinical_trial	NCT02773030	A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma	August 4, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT03374085	A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)	July 14, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT02863991	Oral ONC201 in Relapsed/Refractory Multiple Myeloma	May 6, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT01832727	Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma	July 13, 2020	Terminated	2P01CA155258-06
clinical_trial	NCT03288480	A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma	March 15, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT01997840	ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma	August 31, 2020	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT02576496	Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies	June 2, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT01955434	SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma	September 10, 2019	Completed	2P01CA155258-06
clinical_trial	NCT02952508	Study of CLR 131 in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia (CLOVER-WaM)	October 4, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT01372540	Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia	July 16, 2019	Completed	2P01CA155258-06
clinical_trial	NCT02235740	A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)	May 4, 2016	Terminated	2P01CA155258-06
clinical_trial	NCT00450814	Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma	December 16, 2019	Completed	2P01CA155258-06
clinical_trial	NCT00450814	Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma	December 16, 2019	Completed	1U01CA244291-01
clinical_trial	NCT02963493	A Study of Melphalan Flufenamide (Melflufen) in Combination With Dexamethasone in Relapsed Refractory Multiple Myeloma Patients (HORIZON)	September 2, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT01335399	Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma (ELOQUENT - 1)	October 26, 2020	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT01335399	Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma (ELOQUENT - 1)	October 26, 2020	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT02279394	E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma	September 20, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT01084252	Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies	April 20, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT01084252	Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies	April 20, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT02513186	Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation	June 4, 2020	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT02513186	Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation	June 4, 2020	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT02384083	Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients	September 10, 2021	Completed	2P01CA155258-06
clinical_trial	NCT01248923	A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma	September 30, 2020	Completed	2P01CA155258-06
clinical_trial	NCT00222053	IFM 99-02 Thalidomide in Myeloma	April 2, 2010	Completed	2P01CA155258-06
clinical_trial	NCT00367185	Treatment of Newly Diagnosed Elderly Patients With Multiple Myeloma	August 22, 2006	Completed	2P01CA155258-06
clinical_trial	NCT00200681	IFM 2005-01: Velcade/Dexamethasone Versus Vincristine/Adriamycin (Doxorubicin)/Dexamethasone (VAD) for the Treatment of Patients With Multiple Myeloma	February 5, 2009	Completed	2P01CA155258-06
clinical_trial	NCT01454297	Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile (CoMMpass)	August 16, 2018	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT01454297	Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile (CoMMpass)	August 16, 2018	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT01454297	Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile (CoMMpass)	August 16, 2018	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT01454297	Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile (CoMMpass)	August 16, 2018	Active, not recruiting	1U2CCA233303-01
clinical_trial	NCT01454297	Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile (CoMMpass)	August 16, 2018	Active, not recruiting	1U2CCA233303-01
clinical_trial	NCT01454297	Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile (CoMMpass)	August 16, 2018	Active, not recruiting	3P30CA008748-54S3
clinical_trial	NCT01454297	Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile (CoMMpass)	August 16, 2018	Active, not recruiting	3P30CA016058-44S3
clinical_trial	NCT03733717	Evaluation of Pharmacokinetics, Safety, and Preliminary Efficacy of Isatuximab in Chinese Patients With Relapsed and/or Refractory Multiple Myeloma	September 21, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT02812706	Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients (Islands)	September 29, 2020	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT02514668	A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma	September 27, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT02960555	Isatuximab in Treating Patients With High Risk Smoldering Plasma Cell Myeloma	October 6, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT01749969	SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients	September 21, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT01749969	SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients	September 21, 2021	Active, not recruiting	3P30CA082103-21S9
clinical_trial	NCT01749969	SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients	September 21, 2021	Active, not recruiting	3P30CA082103-21S6
clinical_trial	NCT02283775	SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients (PomdeSAR)	July 9, 2021	Completed	2P01CA155258-06
clinical_trial	NCT02990338	Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients (ICARIA-MM)	February 24, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT02332850	Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma	July 21, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT03275285	Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients (IKEMA)	October 8, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03319667	Clinical Benefit of SAR650984, Bortezomib, Lenalidomide and Dexamethasone Combination in NDMM Patients Not Eligible for Transplant (IMROZ)	July 12, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03319667	Clinical Benefit of SAR650984, Bortezomib, Lenalidomide and Dexamethasone Combination in NDMM Patients Not Eligible for Transplant (IMROZ)	July 12, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03617731	Trial on the Effect of Isatuximab to Lenaliodomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)	October 8, 2020	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03617731	Trial on the Effect of Isatuximab to Lenaliodomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)	October 8, 2020	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03104842	Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone	February 3, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03194867	Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients	September 23, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT04083898	Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma	April 5, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT04045795	Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)	September 21, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT02413489	An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma	June 26, 2018	Terminated	2P01CA155258-06
clinical_trial	NCT02927925	A Study to Assess the Clinical Efficacy and Safety of Daratumumab in Participants With Relapsed or Refractory Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type	January 14, 2021	Completed	2P01CA155258-06
clinical_trial	NCT02999633	Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia (ISLAY)	January 18, 2020	Terminated	2P01CA155258-06
clinical_trial	NCT03860844	Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia (ISAKIDS)	October 8, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT03499808	S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis	June 10, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03769181	A Study of Isatuximab-based Therapy in Participants With Lymphoma	September 28, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03367819	Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies	April 21, 2021	Completed	2P01CA155258-06
clinical_trial	NCT03637764	Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies	November 25, 2020	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03555149	A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)	September 29, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT03869190	Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)	October 6, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT03201965	A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis	September 20, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03201965	A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis	September 20, 2021	Active, not recruiting	3P30CA013696-45S1
clinical_trial	NCT04131309	A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis	October 7, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT03473730	Daratumumab in Treating Patients With Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer	May 13, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT04088903	Study of Daratumumab for Decreasing Circulating Antibodies in Sensitized Patients Awaiting Heart Transplantation	October 28, 2020	Withdrawn	2P01CA155258-06
clinical_trial	NCT03277105	A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma	September 20, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT02219256	A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of TAK-079 in Healthy Participants	May 3, 2017	Completed	2P01CA155258-06
clinical_trial	NCT03984097	A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)	August 5, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT02076009	A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma	October 6, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT02076009	A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma	October 6, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT02076009	A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma	October 6, 2021	Active, not recruiting	1U01CA244291-01
clinical_trial	NCT02136134	Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma	September 20, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT02136134	Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma	September 20, 2021	Active, not recruiting	1U01CA244291-01
clinical_trial	NCT02195479	A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma	October 6, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT02541383	A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma (Cassiopeia)	December 7, 2020	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT02541383	A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma (Cassiopeia)	December 7, 2020	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT00531453	A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) in Newly Diagnosed Multiple Myeloma	January 26, 2012	Completed	2P01CA155258-06
clinical_trial	NCT01818752	Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma (CLARION)	August 26, 2019	Completed	2P01CA155258-06
clinical_trial	NCT02635061	Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer	August 31, 2020	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT01091831	Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects	November 6, 2020	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT02406144	Trial Studying Maintenance Treatment With Lenalidomide and Dexamethasone Versus Lenalidomide, Dexamethasone and MLN9708 After Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly-diagnosed Symptomatic Multiple Myeloma	November 30, 2017	Completed	2P01CA155258-06
clinical_trial	NCT02253316	Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma	September 23, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT02389517	Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant	October 14, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT02659293	Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma	June 30, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT02203643	Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma. (FORTE)	April 29, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03896737	Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara	August 19, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT03901963	A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (AURIGA)	September 17, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT02874742	Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma	October 8, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT02495922	A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG-HD6)	September 10, 2021	Completed	2P01CA155258-06
clinical_trial	NCT03729804	Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA) ((COBRA))	June 8, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT03742297	Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years	March 16, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT03710603	Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma (Perseus)	August 26, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03710603	Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma (Perseus)	August 26, 2021	Active, not recruiting	1U01CA244291-01
clinical_trial	NCT03652064	A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy	September 17, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT01668719	S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma	April 6, 2020	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT01668719	S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma	April 6, 2020	Active, not recruiting	3UG1CA189828-07S1
clinical_trial	NCT02312258	A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)	November 10, 2020	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03748953	Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)	October 8, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT03720041	Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma (FiTNEss)	June 15, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT03733691	Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients	October 27, 2020	Recruiting	2P01CA155258-06
clinical_trial	NCT02891811	Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy	May 19, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT02623699	An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS) (VALOR (Part C))	July 26, 2021	Completed	2P01CA155258-06
clinical_trial	NCT00706147	Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis	January 11, 2019	Completed	2P01CA155258-06
clinical_trial	NCT02215967	Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma	October 8, 2019	Completed	2P01CA155258-06
clinical_trial	NCT02215967	Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma	October 8, 2019	Completed	1U01CA244291-01
clinical_trial	NCT03093168	BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma	February 27, 2019	Unknown	2P01CA155258-06
clinical_trial	NCT03093168	BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma	February 27, 2019	Unknown	1U01CA244291-01
clinical_trial	NCT03338972	Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma	June 10, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03338972	Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma	June 10, 2021	Active, not recruiting	1U01CA247548-01
clinical_trial	NCT02546167	CART-BCMA Cells for Multiple Myeloma	August 4, 2020	Completed	2P01CA155258-06
clinical_trial	NCT03661554	BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma (BCMA CAR-T)	September 10, 2018	Unknown	2P01CA155258-06
clinical_trial	NCT03196414	Study of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory and Relapsed Multiple Myeloma	May 2, 2019	Recruiting	2P01CA155258-06
clinical_trial	NCT03455972	Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT	May 19, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT03455972	Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT	May 19, 2021	Recruiting	1U01CA244291-01
clinical_trial	NCT03716856	Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma	October 8, 2020	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03302403	Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors	October 8, 2020	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03380039	Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma	October 12, 2020	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03548207	A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma (CARTITUDE-1)	October 8, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT02064387	Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916	August 11, 2020	Completed	2P01CA155258-06
clinical_trial	NCT02514239	Phase I Dose Escalation of i.v. BI 836909 Monotherapy in Last Line Multiple Myeloma Patients	September 29, 2021	Completed	2P01CA155258-06
clinical_trial	NCT04184050	A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and PK of HPN217 in Patients With R/R MM	September 10, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT03448978	Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma	February 10, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT03448978	Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma	February 10, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT03266692	Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma	March 30, 2020	Terminated	2P01CA155258-06
clinical_trial	NCT03651128	Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)	August 11, 2020	Recruiting	2P01CA155258-06
clinical_trial	NCT04126200	Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 5)	September 22, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT04246047	Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 7)	July 22, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03502577	BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma	August 2, 2021	Suspended	2P01CA155258-06
clinical_trial	NCT03502577	BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma	August 2, 2021	Suspended	2P01CA155258-06
clinical_trial	NCT03502577	BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma	August 2, 2021	Suspended	1U01CA244291-01
clinical_trial	NCT03502577	BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma	August 2, 2021	Suspended	1U01CA247548-01
clinical_trial	NCT04093596	Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL) (UNIVERSAL)	October 14, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT04093596	Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL) (UNIVERSAL)	October 14, 2021	Active, not recruiting	3P30CA021765-41S3
clinical_trial	NCT03940833	Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM	May 7, 2019	Recruiting	2P01CA155258-06
clinical_trial	NCT03940833	Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM	May 7, 2019	Recruiting	1U01CA239258-01
clinical_trial	NCT03848845	Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 4)	October 1, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03544281	To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 6)	May 19, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT03715478	Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex	August 10, 2020	Recruiting	2P01CA155258-06
clinical_trial	NCT04091126	Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma (DREAMM 9)	July 20, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT04196491	A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) (KarMMa-4)	May 18, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT02728102	Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)	September 9, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT02728102	Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)	September 9, 2021	Active, not recruiting	1U01CA244291-01
clinical_trial	NCT03224507	Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma (MASTER)	September 22, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT04071457	S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)	October 12, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT04513639	The Relapse From MRD Negativity as Indication for Treatment (REMNANT) Study	June 18, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT03683277	IPD in RRMM Characterized With Genomic Abnormalities of Adverse Prognostic (IFM2014-01)	September 25, 2018	Not yet recruiting	2P01CA155258-06
clinical_trial	NCT03888612	Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)	June 25, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT03888612	Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)	June 25, 2021	Recruiting	3P30CA046592-31S8
clinical_trial	NCT03888612	Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)	June 25, 2021	Recruiting	3P30CA046592-31S4
clinical_trial	NCT04144140	Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101	April 26, 2021	Recruiting	2P01CA155258-06
clinical_trial	NCT03937141	Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer	March 10, 2021	Active, not recruiting	2P01CA155258-06
clinical_trial	NCT03937141	Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer	March 10, 2021	Active, not recruiting	1U01DE028227-01
clinical_trial	NCT01946789	A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors	April 17, 2019	Completed	2UM1CA154967-07
clinical_trial	NCT01961115	Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma	June 8, 2018	Completed	2UM1CA154967-07
clinical_trial	NCT04751383	Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma	October 5, 2021	Recruiting	2UM1CA154967-07
clinical_trial	NCT04500548	Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study	October 13, 2021	Recruiting	2UM1CA154967-07
clinical_trial	NCT03513952	Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma	October 14, 2021	Recruiting	2UM1CA154967-07
clinical_trial	NCT02243579	Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome	September 20, 2019	Completed	2UM1CA154967-07
clinical_trial	NCT02243579	Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome	September 20, 2019	Completed	2UM1CA154967-07
clinical_trial	NCT01727076	Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer	September 15, 2017	Completed	2UM1CA154967-07
clinical_trial	NCT01727076	Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer	September 15, 2017	Completed	2UM1CA154967-07
clinical_trial	NCT03063632	Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and S&#233;zary Syndrome and Advanced Synovial Sarcoma	May 14, 2021	Active, not recruiting	2UM1CA154967-07
clinical_trial	NCT03063632	Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and S&#233;zary Syndrome and Advanced Synovial Sarcoma	May 14, 2021	Active, not recruiting	2UM1CA154967-07
clinical_trial	NCT03063632	Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and S&#233;zary Syndrome and Advanced Synovial Sarcoma	May 14, 2021	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT02595866	Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms	August 5, 2021	Recruiting	2UM1CA154967-07
clinical_trial	NCT02595866	Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms	August 5, 2021	Recruiting	2UM1CA154967-07
clinical_trial	NCT02595866	Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms	August 5, 2021	Recruiting	2UM1CA154967-07
clinical_trial	NCT02267603	Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer	October 4, 2021	Active, not recruiting	2UM1CA154967-07
clinical_trial	NCT02267603	Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer	October 4, 2021	Active, not recruiting	2UM1CA154967-07
clinical_trial	NCT02267603	Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer	October 4, 2021	Active, not recruiting	2UM1CA154967-07
clinical_trial	NCT02267603	Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer	October 4, 2021	Active, not recruiting	2UM1CA154967-07
clinical_trial	NCT02339558	Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer	September 13, 2019	Completed	2UM1CA154967-07
clinical_trial	NCT03271372	Adjuvant Avelumab in Merkel Cell Cancer (ADAM)	May 27, 2021	Recruiting	2UM1CA154967-07
clinical_trial	NCT02488759	An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors (CheckMate358)	September 10, 2020	Active, not recruiting	2UM1CA154967-07
clinical_trial	NCT02840058	Interest of Anti-telomerase T CD4 Immune Responses for Predicting the Effectiveness of Immunotherapies Targeting PD1 / PDL1 (ITHER)	August 2, 2021	Recruiting	2UM1CA154967-07
clinical_trial	NCT01495598	Pomalidomide for Kaposi Sarcoma in People With or Without HIV	October 14, 2021	Active, not recruiting	2UM1CA154967-07
clinical_trial	NCT02659930	Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma	September 5, 2021	Recruiting	2UM1CA154967-07
clinical_trial	NCT00006518	Specimen Collections From Patients With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer	October 14, 2021	Recruiting	2UM1CA154967-07
clinical_trial	NCT00092222	Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity	September 21, 2021	Recruiting	2UM1CA154967-07
clinical_trial	NCT01419561	History of the KSHV Inflammatory Cytokine Syndrome (KICS)	October 4, 2021	Recruiting	2UM1CA154967-07
clinical_trial	NCT03747484	Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer	July 8, 2021	Recruiting	2UM1CA154967-07
clinical_trial	NCT00400946	Treatment of Acute Lymphoblastic Leukemia in Children	November 20, 2019	Completed	3R00CA181500-04S1
clinical_trial	NCT00400946	Treatment of Acute Lymphoblastic Leukemia in Children	November 20, 2019	Completed	3P30CA016056-43S5
clinical_trial	NCT00408005	Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma	September 24, 2021	Active, not recruiting	3R00CA181500-04S1
clinical_trial	NCT03098160	Immunotherapy Study of Evofosfamide in Combination With Ipilimumab	October 30, 2017	Unknown	3R01CA187532-03S1
clinical_trial	NCT01440088	A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma	June 2, 2016	Completed	3R01CA187532-03S1
clinical_trial	NCT01746979	Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma (MAESTRO)	December 2, 2017	Completed	3R01CA187532-03S1
clinical_trial	NCT03125239	Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid Leukemia	June 30, 2020	Completed	3R01CA204396-02S1
clinical_trial	NCT02236195	Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes	September 1, 2017	Completed	3U24CA210999-02S1
clinical_trial	NCT02334527	Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy	November 16, 2018	Terminated	3U24CA210999-02S1
clinical_trial	NCT01747486	Dose Optimization Trial of CD19 Redirected Autologous T Cells	August 30, 2019	Completed	1R01CA226983-01
clinical_trial	NCT01747486	Dose Optimization Trial of CD19 Redirected Autologous T Cells	August 30, 2019	Completed	1R01CA226983-01
clinical_trial	NCT01747486	Dose Optimization Trial of CD19 Redirected Autologous T Cells	August 30, 2019	Completed	1U54CA244711-01
clinical_trial	NCT01029366	CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy	June 26, 2019	Completed	1R01CA226983-01
clinical_trial	NCT01029366	CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy	June 26, 2019	Completed	1R01CA226983-01
clinical_trial	NCT01029366	CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy	June 26, 2019	Completed	1U54CA244711-01
clinical_trial	NCT03089203	CART-PSMA-TGF&#946;RDN Cells for Castrate-Resistant Prostate Cancer	January 14, 2021	Active, not recruiting	1R01CA226983-01
clinical_trial	NCT03089203	CART-PSMA-TGF&#946;RDN Cells for Castrate-Resistant Prostate Cancer	January 14, 2021	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT03089203	CART-PSMA-TGF&#946;RDN Cells for Castrate-Resistant Prostate Cancer	January 14, 2021	Active, not recruiting	1U01CA239258-01
clinical_trial	NCT03089203	CART-PSMA-TGF&#946;RDN Cells for Castrate-Resistant Prostate Cancer	January 14, 2021	Active, not recruiting	1U01CA244452-01
clinical_trial	NCT03089203	CART-PSMA-TGF&#946;RDN Cells for Castrate-Resistant Prostate Cancer	January 14, 2021	Active, not recruiting	1U54CA244711-01
clinical_trial	NCT03089203	CART-PSMA-TGF&#946;RDN Cells for Castrate-Resistant Prostate Cancer	January 14, 2021	Active, not recruiting	3P30CA013696-45S1
clinical_trial	NCT01626495	Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma (Pedi CART19)	March 23, 2020	Completed	1R01CA226983-01
clinical_trial	NCT01626495	Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma (Pedi CART19)	March 23, 2020	Completed	1R01CA226983-01
clinical_trial	NCT01626495	Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma (Pedi CART19)	March 23, 2020	Completed	1U01CA232361-01A1
clinical_trial	NCT01626495	Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma (Pedi CART19)	March 23, 2020	Completed	1U54CA244711-01
clinical_trial	NCT02640209	Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)	May 7, 2020	Terminated	1R01CA226983-01
clinical_trial	NCT02640209	Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)	May 7, 2020	Terminated	1U54CA244711-01
clinical_trial	NCT02435849	Determine Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell ALL and High Risk B-cell ALL at First Relapse. Determine Feasibility and Safety of CTL019 Therapy in Pediatric Patients With High Risk B-cell ALL That Relapsed &lt; 6 Months Post All-HSCT. (ELIANA)	June 30, 2021	Active, not recruiting	1R01CA226983-01
clinical_trial	NCT02435849	Determine Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell ALL and High Risk B-cell ALL at First Relapse. Determine Feasibility and Safety of CTL019 Therapy in Pediatric Patients With High Risk B-cell ALL That Relapsed &lt; 6 Months Post All-HSCT. (ELIANA)	June 30, 2021	Active, not recruiting	1U54CA232561-01A1
clinical_trial	NCT02228096	Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients (ENSIGN)	November 23, 2020	Completed	1R01CA226983-01
clinical_trial	NCT02030847	Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory Acute Lymphoblastic Leukemia	August 30, 2019	Completed	1R01CA226983-01
clinical_trial	NCT04071366	A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy	September 30, 2021	Recruiting	1R01CA226983-01
clinical_trial	NCT02650414	CD22 Redirected Autologous T Cells for ALL	November 4, 2020	Recruiting	1R01CA226983-01
clinical_trial	NCT02650414	CD22 Redirected Autologous T Cells for ALL	November 4, 2020	Recruiting	1U01CA232486-01
clinical_trial	NCT02650414	CD22 Redirected Autologous T Cells for ALL	November 4, 2020	Recruiting	3P30CA125123-14S6
clinical_trial	NCT02588456	Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia	January 12, 2018	Terminated	1R01CA226983-01
clinical_trial	NCT02655041	N/A	N/A	N/A	1R01CA226983-01
clinical_trial	NCT03620058	CART22 Alone or in Combination With huCART19 for ALL	June 29, 2021	Active, not recruiting	1R01CA226983-01
clinical_trial	NCT01371981	Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia	August 5, 2021	Active, not recruiting	1U01CA232486-01
clinical_trial	NCT01371981	Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia	August 5, 2021	Active, not recruiting	1U01CA232486-01
clinical_trial	NCT03190915	Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia	October 11, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT03190915	Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia	October 11, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT00372593	Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia	March 24, 2021	Completed	1U01CA232486-01
clinical_trial	NCT00372593	Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia	March 24, 2021	Completed	1U01CA232486-01
clinical_trial	NCT03126864	Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia	November 4, 2019	Terminated	1U01CA232486-01
clinical_trial	NCT03126864	Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia	November 4, 2019	Terminated	1U01CA232486-01
clinical_trial	NCT03126864	Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia	November 4, 2019	Terminated	1U01CA232486-01
clinical_trial	NCT03126864	Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia	November 4, 2019	Terminated	1U01CA232486-01
clinical_trial	NCT00283114	A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome	December 18, 2014	Completed	1U01CA232486-01
clinical_trial	NCT00283114	A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome	December 18, 2014	Completed	1U01CA232486-01
clinical_trial	NCT03915279	N/A	N/A	N/A	1U01CA232486-01
clinical_trial	NCT03915279	N/A	N/A	N/A	1U01CA232486-01
clinical_trial	NCT03441048	Lintuzumab-Ac225 in Combination With Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia	May 18, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT03441048	Lintuzumab-Ac225 in Combination With Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia	May 18, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT02575963	Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients	November 20, 2020	Active, not recruiting	1U01CA232486-01
clinical_trial	NCT02575963	Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients	November 20, 2020	Active, not recruiting	1U01CA232486-01
clinical_trial	NCT03867682	Venetoclax and Lintuzumab-Ac225 in AML Patients	July 2, 2020	Recruiting	1U01CA232486-01
clinical_trial	NCT03867682	Venetoclax and Lintuzumab-Ac225 in AML Patients	July 2, 2020	Recruiting	1U01CA232486-01
clinical_trial	NCT01902329	A Safety Study of SGN-CD33A in AML Patients	January 5, 2018	Completed	1U01CA232486-01
clinical_trial	NCT01902329	A Safety Study of SGN-CD33A in AML Patients	January 5, 2018	Completed	1U01CA232486-01
clinical_trial	NCT02326584	A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML	May 9, 2018	Completed	1U01CA232486-01
clinical_trial	NCT02326584	A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML	May 9, 2018	Completed	1U01CA232486-01
clinical_trial	NCT02614560	A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients	January 9, 2019	Terminated	1U01CA232486-01
clinical_trial	NCT02614560	A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients	January 9, 2019	Terminated	1U01CA232486-01
clinical_trial	NCT02785900	Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia (CASCADE)	December 12, 2018	Terminated	1U01CA232486-01
clinical_trial	NCT02785900	Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia (CASCADE)	December 12, 2018	Terminated	1U01CA232486-01
clinical_trial	NCT03386513	Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN	July 12, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT03386513	Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN	July 12, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT03386513	Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN	July 12, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT02520427	A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies	July 1, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT02520427	A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies	July 1, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT02520427	A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies	July 1, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT03516760	Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia	July 9, 2020	Active, not recruiting	1U01CA232486-01
clinical_trial	NCT03516760	Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia	July 9, 2020	Active, not recruiting	1U01CA232486-01
clinical_trial	NCT02623582	CD123 Redirected Autologous T Cells for AML	October 17, 2017	Terminated	1U01CA232486-01
clinical_trial	NCT02623582	CD123 Redirected Autologous T Cells for AML	October 17, 2017	Terminated	1U01CA232486-01
clinical_trial	NCT02623582	CD123 Redirected Autologous T Cells for AML	October 17, 2017	Terminated	1U01CA232486-01
clinical_trial	NCT03766126	Lentivirally Redirected CD123 Autologous T Cells in AML	December 17, 2020	Active, not recruiting	1U01CA232486-01
clinical_trial	NCT03766126	Lentivirally Redirected CD123 Autologous T Cells in AML	December 17, 2020	Active, not recruiting	1U01CA232486-01
clinical_trial	NCT03766126	Lentivirally Redirected CD123 Autologous T Cells in AML	December 17, 2020	Active, not recruiting	1U01CA232486-01
clinical_trial	NCT03766126	Lentivirally Redirected CD123 Autologous T Cells in AML	December 17, 2020	Active, not recruiting	1U01CA232486-01
clinical_trial	NCT02159495	Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm	January 27, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT02159495	Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm	January 27, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT02159495	Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm	January 27, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT01632852	A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission	October 9, 2015	Completed	1U01CA232486-01
clinical_trial	NCT01632852	A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission	October 9, 2015	Completed	1U01CA232486-01
clinical_trial	NCT02181699	Study of KHK2823 in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)	August 2, 2019	Terminated	1U01CA232486-01
clinical_trial	NCT02181699	Study of KHK2823 in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)	August 2, 2019	Terminated	1U01CA232486-01
clinical_trial	NCT02848248	A Safety Study of SGN-CD123A in Patients With Acute Myeloid Leukemia	May 14, 2018	Terminated	1U01CA232486-01
clinical_trial	NCT02848248	A Safety Study of SGN-CD123A in Patients With Acute Myeloid Leukemia	May 14, 2018	Terminated	1U01CA232486-01
clinical_trial	NCT02270463	SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission	April 7, 2020	Completed	1U01CA232486-01
clinical_trial	NCT02270463	SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission	April 7, 2020	Completed	1U01CA232486-01
clinical_trial	NCT02152956	Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)	May 25, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT02152956	Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)	May 25, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT02152956	Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)	May 25, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT02715011	Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)	August 31, 2021	Completed	1U01CA232486-01
clinical_trial	NCT02715011	Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)	August 31, 2021	Completed	1U01CA232486-01
clinical_trial	NCT02730312	PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies	September 22, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT02730312	PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies	September 22, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT03190278	Study Evaluating Safety and Efficacy of UCART123 in Patients With Relapsed/ Refractory Acute Myeloid Leukemia (AMELI-01)	September 22, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT03190278	Study Evaluating Safety and Efficacy of UCART123 in Patients With Relapsed/ Refractory Acute Myeloid Leukemia (AMELI-01)	September 22, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT03190278	Study Evaluating Safety and Efficacy of UCART123 in Patients With Relapsed/ Refractory Acute Myeloid Leukemia (AMELI-01)	September 22, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT03190278	Study Evaluating Safety and Efficacy of UCART123 in Patients With Relapsed/ Refractory Acute Myeloid Leukemia (AMELI-01)	September 22, 2021	Recruiting	3P30CA021765-41S3
clinical_trial	NCT03203369	Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN (ABC123)	July 31, 2019	Terminated	1U01CA232486-01
clinical_trial	NCT03203369	Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN (ABC123)	July 31, 2019	Terminated	1U01CA232486-01
clinical_trial	NCT01998793	N/A	N/A	N/A	1U01CA232486-01
clinical_trial	NCT01998793	N/A	N/A	N/A	1U01CA232486-01
clinical_trial	NCT01898793	Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)	May 21, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT01898793	Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)	May 21, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT01898793	Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)	May 21, 2021	Recruiting	1U01CA232488-01
clinical_trial	NCT03068819	Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant	September 20, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT03068819	Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant	September 20, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT03068819	Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant	September 20, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT03068819	Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant	September 20, 2021	Recruiting	1U01CA239258-01
clinical_trial	NCT03326921	HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant	September 29, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT03326921	HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant	September 29, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT02828358	Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement	August 2, 2021	Active, not recruiting	1U01CA232486-01
clinical_trial	NCT02828358	Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement	August 2, 2021	Active, not recruiting	1U01CA232486-01
clinical_trial	NCT02828358	Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement	August 2, 2021	Active, not recruiting	1U01CA232486-01
clinical_trial	NCT02101853	Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia	August 25, 2021	Active, not recruiting	1U01CA232486-01
clinical_trial	NCT02101853	Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia	August 25, 2021	Active, not recruiting	1U01CA232486-01
clinical_trial	NCT02101853	Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia	August 25, 2021	Active, not recruiting	1U01CA232486-01
clinical_trial	NCT02642965	Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia	January 25, 2021	Active, not recruiting	1U01CA232486-01
clinical_trial	NCT02642965	Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia	January 25, 2021	Active, not recruiting	1U01CA232486-01
clinical_trial	NCT03739606	Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer	December 17, 2020	Withdrawn	1U01CA232486-01
clinical_trial	NCT03739606	Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer	December 17, 2020	Withdrawn	1U01CA232486-01
clinical_trial	NCT03739606	Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer	December 17, 2020	Withdrawn	1U01CA232486-01
clinical_trial	NCT02879695	Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia	June 9, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT02879695	Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia	June 9, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT03605589	Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma	April 1, 2021	Withdrawn	1U01CA232486-01
clinical_trial	NCT03605589	Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma	April 1, 2021	Withdrawn	1U01CA232486-01
clinical_trial	NCT03605589	Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma	April 1, 2021	Withdrawn	1U54CA232561-01A1
clinical_trial	NCT03825367	Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML	October 5, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT03825367	Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML	October 5, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT03384654	A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (&gt;=)1 and Less Than or Equal to (&lt;=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma	October 8, 2021	Active, not recruiting	1U01CA232486-01
clinical_trial	NCT02981628	Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia	September 20, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT03914625	A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia	October 12, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT03224819	Study of AMG 673 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia	September 27, 2021	Active, not recruiting	1U01CA232486-01
clinical_trial	NCT03541369	Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (20170528)	July 29, 2021	Active, not recruiting	1U01CA232486-01
clinical_trial	NCT02315612	Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies	September 5, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT02315612	Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies	September 5, 2021	Recruiting	1U01CA232488-01
clinical_trial	NCT02315612	Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies	September 5, 2021	Recruiting	1U54CA232561-01A1
clinical_trial	NCT02652548	N/A	N/A	N/A	1U01CA232486-01
clinical_trial	NCT03389035	Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Pediatric and Adult Patients With r/r ALL Post HSCT (CARCIK)	February 5, 2020	Recruiting	1U01CA232486-01
clinical_trial	NCT03573700	Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia	November 12, 2020	Recruiting	1U01CA232486-01
clinical_trial	NCT03467256	CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL	April 8, 2021	Active, not recruiting	1U01CA232486-01
clinical_trial	NCT02808442	Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia (PALL)	October 8, 2021	Completed	1U01CA232486-01
clinical_trial	NCT02808442	Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia (PALL)	October 8, 2021	Completed	3P30CA125123-14S6
clinical_trial	NCT02808442	Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia (PALL)	October 8, 2021	Completed	3P30CA021765-41S3
clinical_trial	NCT04049383	CAR-20/19-T Cells in Pediatric and Young Adult Patients With Relapsed/Refractory B Cell ALL (CAR-20/19-T)	February 2, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT03876769	Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients (CASSIOPEIA)	October 12, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT03792622	N/A	N/A	N/A	1U01CA232486-01
clinical_trial	NCT02772198	T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies	November 3, 2020	Recruiting	1U01CA232486-01
clinical_trial	NCT02772198	T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies	November 3, 2020	Recruiting	1U01CA232488-01
clinical_trial	NCT03373071	Anti-CD19 CAR T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and NHL	July 8, 2020	Recruiting	1U01CA232486-01
clinical_trial	NCT03373071	Anti-CD19 CAR T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and NHL	July 8, 2020	Recruiting	3P30CA016520-44S5
clinical_trial	NCT03373071	Anti-CD19 CAR T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and NHL	July 8, 2020	Recruiting	3P30CA016520-44S6
clinical_trial	NCT03938987	Anti-CD19, Dual Co-stimulatory (4-1BB, CD3&#950;) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL) (ACIT001/EXC002)	July 20, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT03016377	Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL	July 15, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT03321123	MB-CART19.1 in Patients With R/R ALL	October 25, 2017	Unknown	1U01CA232486-01
clinical_trial	NCT02374333	Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy	September 23, 2021	Completed	1U01CA232486-01
clinical_trial	NCT03555941	N/A	N/A	N/A	1U01CA232486-01
clinical_trial	NCT03853616	MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)	July 9, 2020	Recruiting	1U01CA232486-01
clinical_trial	NCT03676504	Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR	November 20, 2020	Recruiting	1U01CA232486-01
clinical_trial	NCT03601442	CTL019 Out of Specification MAP for ALL or DLBCL Patients	June 24, 2021	Available	1U01CA232486-01
clinical_trial	NCT02028455	A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia	January 29, 2021	Active, not recruiting	1U01CA232486-01
clinical_trial	NCT02028455	A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia	January 29, 2021	Active, not recruiting	1U54CA232561-01A1
clinical_trial	NCT02028455	A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia	January 29, 2021	Active, not recruiting	1U01CA247548-01
clinical_trial	NCT03186118	Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia	March 25, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT03186118	Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia	March 25, 2021	Recruiting	1U54CA232561-01A1
clinical_trial	NCT03064269	CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia	May 22, 2018	Unknown	1U01CA232486-01
clinical_trial	NCT03391739	CART-19 Cells For R/R B-ALL (CCFRRBA)	January 5, 2018	Unknown	1U01CA232486-01
clinical_trial	NCT03027739	CART-19 Cells For MRD Positive CD19+ ALL (CCFMPCA)	January 23, 2017	Unknown	1U01CA232486-01
clinical_trial	NCT03684889	CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma	February 10, 2021	Active, not recruiting	1U01CA232486-01
clinical_trial	NCT03684889	CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma	February 10, 2021	Active, not recruiting	1U01CA247548-01
clinical_trial	NCT02443831	CARPALL: Immunotherapy With CD19 CAR T-cells for CD19+ Haematological Malignancies	November 13, 2020	Active, not recruiting	1U01CA232486-01
clinical_trial	NCT03289455	CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL) (AMELIA)	February 1, 2021	Completed	1U01CA232486-01
clinical_trial	NCT03289455	CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL) (AMELIA)	February 1, 2021	Completed	1U54CA232568-01
clinical_trial	NCT03754764	A Feasibility and Safety Study of CD38 CAR-T Cell Immunotherapy for Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T Adoptive Cellular Immunotherapy	December 7, 2018	Recruiting	1U01CA232486-01
clinical_trial	NCT03142646	Safety and Efficacy Evaluation of IM19 CAR-T Cells (IM19CAR-T)	May 1, 2018	Unknown	1U01CA232486-01
clinical_trial	NCT03671460	CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.	September 14, 2018	Unknown	1U01CA232486-01
clinical_trial	NCT03366324	Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies	November 20, 2018	Unknown	1U01CA232486-01
clinical_trial	NCT03574168	CD19-CAR-T Cells in Patients With R/R B-ALL	June 29, 2018	Unknown	1U01CA232486-01
clinical_trial	NCT03544021	CART-19 FOR Relapsed/Refractory Acute Lymphoblastic Leukemia &#65288;ALL&#65289;	June 4, 2018	Unknown	1U01CA232486-01
clinical_trial	NCT04036019	A Study of C-CAR066 in Subjects With r/r B Cell Lymphoma Who Received CD19 CAR-T Therapy	July 29, 2019	Unknown	1U01CA232486-01
clinical_trial	NCT04036019	A Study of C-CAR066 in Subjects With r/r B Cell Lymphoma Who Received CD19 CAR-T Therapy	July 29, 2019	Unknown	3P30CA125123-14S6
clinical_trial	NCT02710149	A Clinical Research of CD20-Targeted CAR-T in B Cell Malignancies	June 25, 2019	Unknown	1U01CA232486-01
clinical_trial	NCT02935153	A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies	June 25, 2019	Unknown	1U01CA232486-01
clinical_trial	NCT04007978	Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy for Relapsed Refractory B-cell Malignancies	August 7, 2019	Recruiting	1U01CA232486-01
clinical_trial	NCT04007978	Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy for Relapsed Refractory B-cell Malignancies	August 7, 2019	Recruiting	3P30CA125123-14S6
clinical_trial	NCT03366350	Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell Malignancies	May 10, 2019	Unknown	1U01CA232486-01
clinical_trial	NCT03275493	Humanized CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia	May 22, 2018	Unknown	1U01CA232486-01
clinical_trial	NCT03398967	A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma	January 16, 2018	Recruiting	1U01CA232486-01
clinical_trial	NCT03398967	A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma	January 16, 2018	Recruiting	3P30CA125123-14S6
clinical_trial	NCT03398967	A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma	January 16, 2018	Recruiting	3P30CA021765-41S3
clinical_trial	NCT03232619	CD19-CART Treatment for ALL	September 22, 2020	Completed	1U01CA232486-01
clinical_trial	NCT02965092	CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies	May 10, 2019	Recruiting	1U01CA232486-01
clinical_trial	NCT03241940	Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies	August 17, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT03241940	Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies	August 17, 2021	Recruiting	1U54CA232568-01
clinical_trial	NCT03937544	Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL	May 6, 2019	Recruiting	1U01CA232486-01
clinical_trial	NCT03840317	Senl_1904A and Senl_1904B Chimeric Antigen Receptor &#65288;CAR&#65289; T-Cell in the Treatment of r/ r Acute B Lymphocytic Leukemia	January 20, 2021	Active, not recruiting	1U01CA232486-01
clinical_trial	NCT03685786	CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCT	December 7, 2018	Unknown	1U01CA232486-01
clinical_trial	NCT04016129	CAR-T Immunotherapy Targeting CD19- ALL	September 19, 2019	Recruiting	1U01CA232486-01
clinical_trial	NCT02537977	CD19-directed CAR T Cells Therapy in Relapsed/Refractory B Cell Malignancy	December 3, 2018	Unknown	1U01CA232486-01
clinical_trial	NCT03919240	CAR-T Cell Therapy Targeting to CD19 for R/R ALL	July 1, 2020	Recruiting	1U01CA232486-01
clinical_trial	NCT03068416	CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy	April 29, 2020	Active, not recruiting	1U01CA232486-01
clinical_trial	NCT03825718	A Study of GC007F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL	January 31, 2019	Unknown	1U01CA232486-01
clinical_trial	NCT04008251	Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies	August 7, 2019	Recruiting	1U01CA232486-01
clinical_trial	NCT02935257	Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia, B-cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) Using CAR T-cells to Target CD19 (ALLCAR19)	November 23, 2020	Recruiting	1U01CA232486-01
clinical_trial	NCT03825731	A Study of GC022 CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL	January 31, 2019	Unknown	1U01CA232486-01
clinical_trial	NCT03614858	CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.	July 16, 2019	Unknown	1U01CA232486-01
clinical_trial	NCT04033302	Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies	September 19, 2019	Recruiting	1U01CA232486-01
clinical_trial	NCT02349698	A Clinical Research of CAR T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma	June 25, 2019	Recruiting	1U01CA232486-01
clinical_trial	NCT03642626	MT2017-45: CAR-T Cell Therapy for Heme Malignancies	May 25, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT03050190	A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies	September 19, 2019	Unknown	1U01CA232486-01
clinical_trial	NCT03624686	Production of Clinical-grade Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory B-cell Malignancies	August 10, 2018	Unknown	1U01CA232486-01
clinical_trial	NCT03448393	CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies	September 5, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT03448393	CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies	September 5, 2021	Recruiting	1U54CA232568-01
clinical_trial	NCT03448393	CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies	September 5, 2021	Recruiting	1U54CA232561-01A1
clinical_trial	NCT03081910	Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen (MAGENTA)	October 5, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT03155191	Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia (TBI-1501)	December 28, 2020	Recruiting	1U01CA232486-01
clinical_trial	NCT01853631	Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) (SAGAN)	January 11, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT03902197	CD19 hsCAR-T for Refractory/Relapsed CD19+ B-ALL Patients	April 8, 2019	Recruiting	1U01CA232486-01
clinical_trial	NCT03265106	A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in Childhood R/R ALL and Lymphoma Subjects	February 4, 2021	Active, not recruiting	1U01CA232486-01
clinical_trial	NCT03229876	Safety and Efficacy Evaluation of CD19-UCART	May 27, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT03229876	Safety and Efficacy Evaluation of CD19-UCART	May 27, 2021	Recruiting	3P30CA021765-41S3
clinical_trial	NCT03910842	Treatment of Children CD19+ Leukemia and Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy	September 6, 2019	Recruiting	1U01CA232486-01
clinical_trial	NCT03904069	Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML	December 24, 2020	Not yet recruiting	1U01CA232486-01
clinical_trial	NCT03971799	Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia	October 14, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT03971799	Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia	October 14, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT03722775	N/A	N/A	N/A	1U01CA232486-01
clinical_trial	NCT03631576	CD123/CLL1 CAR-T Cells for R/R AML (STPHI_0001)	January 2, 2020	Recruiting	1U01CA232486-01
clinical_trial	NCT03473457	CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia (AML)	September 13, 2021	Terminated	1U01CA232486-01
clinical_trial	NCT04010877	Multiple CAR-T Cell Therapy Targeting AML	September 19, 2019	Recruiting	1U01CA232486-01
clinical_trial	NCT03585517	Safety and Efficacy Evaluation of IM23 CAR-T Cells (IM23CAR-T)	July 16, 2018	Unknown	1U01CA232486-01
clinical_trial	NCT03796390	Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Myelocytic Leukemia	January 11, 2019	Unknown	1U01CA232486-01
clinical_trial	NCT03556982	CART-123 FOR Relapsed/Refractory Acute Myelocytic Leukemia&#65288;AML&#65289;	June 14, 2018	Unknown	1U01CA232486-01
clinical_trial	NCT03330691	A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia	May 24, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT03330691	A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia	May 24, 2021	Recruiting	1U54CA232568-01
clinical_trial	NCT03330691	A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia	May 24, 2021	Recruiting	1U54CA232561-01A1
clinical_trial	NCT03330691	A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia	May 24, 2021	Recruiting	1U01CA247548-01
clinical_trial	NCT03579927	CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma	January 29, 2020	Withdrawn	1U01CA232486-01
clinical_trial	NCT03579927	CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma	January 29, 2020	Withdrawn	1U01CA239258-01
clinical_trial	NCT04024761	A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation	September 20, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT02420717	Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia	January 26, 2021	Completed	1U01CA232486-01
clinical_trial	NCT02723994	A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia	September 22, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT02723994	A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia	September 22, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT03117751	Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma	August 27, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT03571321	Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia	September 16, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT01406756	Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations	September 8, 2021	Active, not recruiting	1U01CA232486-01
clinical_trial	NCT02343939	Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML) (ENTO in AML)	November 15, 2019	Terminated	1U01CA232486-01
clinical_trial	NCT02404220	Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)	January 2, 2020	Terminated	1U01CA232486-01
clinical_trial	NCT03135028	Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults (Japanese AML)	March 6, 2020	Terminated	1U01CA232486-01
clinical_trial	NCT01141126	N/A	N/A	N/A	1U01CA232486-01
clinical_trial	NCT02141828	A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene	May 8, 2020	Completed	1U01CA232486-01
clinical_trial	NCT03705507	International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia (SeluDex)	January 19, 2021	Recruiting	1U01CA232486-01
clinical_trial	NCT00557193	Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia	March 25, 2021	Active, not recruiting	1U01CA232486-01
clinical_trial	NCT02883049	Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations	September 8, 2021	Active, not recruiting	1U01CA232486-01
clinical_trial	NCT01240538	Viral Therapy in Treating Young Patients With Relapsed or Refractory Solid Tumors	May 13, 2014	Completed	1U01CA232488-01
clinical_trial	NCT01048892	Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features	January 30, 2014	Completed	1U01CA232488-01
clinical_trial	NCT02457845	HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors	July 8, 2021	Active, not recruiting	1U01CA232488-01
clinical_trial	NCT02457845	HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors	July 8, 2021	Active, not recruiting	1U54CA232561-01A1
clinical_trial	NCT03043391	Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children	July 13, 2021	Active, not recruiting	1U01CA232488-01
clinical_trial	NCT03043391	Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children	July 13, 2021	Active, not recruiting	1U54CA232561-01A1
clinical_trial	NCT02756845	Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors	August 19, 2021	Recruiting	1U01CA232488-01
clinical_trial	NCT00931931	HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors	March 21, 2018	Completed	1U01CA232488-01
clinical_trial	NCT00931931	HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors	March 21, 2018	Completed	1U54CA232561-01A1
clinical_trial	NCT01326104	Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor (Re-MATCH)	September 24, 2021	Active, not recruiting	1U01CA232488-01
clinical_trial	NCT02932956	Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP) (GAP)	January 8, 2021	Recruiting	1U01CA232488-01
clinical_trial	NCT02932956	Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP) (GAP)	January 8, 2021	Recruiting	1U54CA232561-01A1
clinical_trial	NCT03500991	HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors	March 15, 2021	Recruiting	1U01CA232488-01
clinical_trial	NCT03500991	HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors	March 15, 2021	Recruiting	1U54CA232561-01A1
clinical_trial	NCT03638167	EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors	March 15, 2021	Recruiting	1U01CA232488-01
clinical_trial	NCT03638167	EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors	March 15, 2021	Recruiting	1U54CA232561-01A1
clinical_trial	NCT01555892	Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE (GRALE)	December 23, 2020	Recruiting	1U01CA232488-01
clinical_trial	NCT02892695	PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma	December 6, 2016	Unknown	1U01CA232488-01
clinical_trial	NCT02892695	PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma	December 6, 2016	Unknown	1U01CA239258-01
clinical_trial	NCT02573896	Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells	January 20, 2021	Recruiting	1U01CA232488-01
clinical_trial	NCT02573896	Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells	January 20, 2021	Recruiting	1U01CA232491-01
clinical_trial	NCT02573896	Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells	January 20, 2021	Recruiting	1U01CA239258-01
clinical_trial	NCT02650648	Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma	October 1, 2021	Active, not recruiting	1U01CA232488-01
clinical_trial	NCT02650648	Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma	October 1, 2021	Active, not recruiting	1U01CA232491-01
clinical_trial	NCT02650648	Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma	October 1, 2021	Active, not recruiting	1U01CA239258-01
clinical_trial	NCT03209869	Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and Hu14.18-IL2	August 5, 2021	Suspended	1U01CA232488-01
clinical_trial	NCT03420963	Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors	April 29, 2021	Recruiting	1U01CA232488-01
clinical_trial	NCT03420963	Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors	April 29, 2021	Recruiting	1U01CA232491-01
clinical_trial	NCT03420963	Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors	April 29, 2021	Recruiting	1U01CA239258-01
clinical_trial	NCT02100891	Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors (STIR)	March 24, 2021	Active, not recruiting	1U01CA232488-01
clinical_trial	NCT02100891	Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors (STIR)	March 24, 2021	Active, not recruiting	1U01CA239258-01
clinical_trial	NCT01823198	Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies	December 4, 2020	Active, not recruiting	1U01CA232488-01
clinical_trial	NCT01823198	Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies	December 4, 2020	Active, not recruiting	1U01CA239258-01
clinical_trial	NCT01904136	Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia	February 10, 2021	Active, not recruiting	1U01CA232488-01
clinical_trial	NCT02809092	Interleukin-21 (IL-21)- Expanded Natural Killer Cells for Induction of Acute Myeloid Leukemia	October 15, 2019	Unknown	1U01CA232488-01
clinical_trial	NCT02809092	Interleukin-21 (IL-21)- Expanded Natural Killer Cells for Induction of Acute Myeloid Leukemia	October 15, 2019	Unknown	1U01CA239258-01
clinical_trial	NCT01619761	NK Cells in Cord Blood Transplantation	February 11, 2020	Active, not recruiting	1U01CA232488-01
clinical_trial	NCT03077477	Study of Orally-Administered AMXT 1501 Dicaprate in Normal Healthy Volunteers	June 14, 2018	Withdrawn	1U01CA232488-01
clinical_trial	NCT02484443	Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma	August 5, 2021	Active, not recruiting	1U01CA232491-01
clinical_trial	NCT02484443	Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma	August 5, 2021	Active, not recruiting	1U54CA232561-01A1
clinical_trial	NCT01419834	Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors	August 25, 2021	Active, not recruiting	1U01CA232491-01
clinical_trial	NCT01662804	Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid Tumors	May 27, 2021	Completed	1U01CA232491-01
clinical_trial	NCT02159443	Pretreatment Anti-Therapeutic Antibodies (PATA) in Patients Treated With hu14.18K322A Antibody	November 5, 2020	Completed	1U01CA232491-01
clinical_trial	NCT00743496	A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma	August 17, 2017	Completed	1U01CA232491-01
clinical_trial	NCT02982941	Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors	January 30, 2020	Completed	1U01CA232491-01
clinical_trial	NCT00582608	Tumor Detection Using Iodine-131-Labeled Monoclonal Antibody 8H9	March 1, 2017	Terminated	1U01CA232491-01
clinical_trial	NCT02173093	Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma	January 29, 2019	Unknown	1U01CA232491-01
clinical_trial	NCT03860207	Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers	May 25, 2021	Recruiting	1U01CA232491-01
clinical_trial	NCT03665285	A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors	August 18, 2021	Recruiting	1U01CA232491-01
clinical_trial	NCT03615040	Anti-ST2 (MSTT1041A) in COPD (COPD-ST2OP) (COPD-ST2OP)	February 25, 2021	Completed	1U01CA232491-01
clinical_trial	NCT03985852	Broadening the Reach, Impact, and Delivery of Genetic Services (BRIDGE)	August 27, 2021	Enrolling by invitation	1U01CA232826-01
clinical_trial	NCT00058474	Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer	March 23, 2016	Unknown	1U01CA232859-01
clinical_trial	NCT00058474	Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer	March 23, 2016	Unknown	1U01CA232859-01
clinical_trial	NCT01522443	Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer (COMET-2)	May 23, 2018	Terminated	1U01CA233046-01
clinical_trial	NCT01522443	Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer (COMET-2)	May 23, 2018	Terminated	1U01CA233046-01
clinical_trial	NCT00238238	Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab	March 15, 2017	Completed	1U01CA233046-01
clinical_trial	NCT02066181	Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis	August 27, 2021	Active, not recruiting	1U01CA233046-01
clinical_trial	NCT02060188	An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread (CheckMate142)	November 6, 2019	Active, not recruiting	1U01CA233056-01
clinical_trial	NCT02460198	Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)	March 22, 2021	Completed	1U01CA233056-01
clinical_trial	NCT03631641	Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy	May 15, 2020	Active, not recruiting	1U01CA233056-01
clinical_trial	NCT01461148	Vaccination Against MSI Colorectal Cancer	June 23, 2015	Completed	1U01CA233056-01
clinical_trial	NCT01461148	Vaccination Against MSI Colorectal Cancer	June 23, 2015	Completed	1U01CA233056-01
clinical_trial	NCT01461148	Vaccination Against MSI Colorectal Cancer	June 23, 2015	Completed	1U01CA233097-01
clinical_trial	NCT01885702	Dendritic Cell Vaccination in Patients With Lynch Syndrome or Colorectal Cancer With MSI	September 22, 2021	Active, not recruiting	1U01CA233056-01
clinical_trial	NCT04131413	HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia	July 6, 2021	Recruiting	1U01CA233056-01
clinical_trial	NCT04131413	HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia	July 6, 2021	Recruiting	1U01CA233097-01
clinical_trial	NCT00648648	A Dose Escalation Study of MK-1775 in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001)	April 5, 2019	Completed	1U01CA233084-01
clinical_trial	NCT04025216	A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers	April 29, 2021	Recruiting	1U01CA233084-01
clinical_trial	NCT03422094	Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma	April 23, 2021	Terminated	1U01CA233100-01
clinical_trial	NCT03361852	Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma	August 25, 2021	Not yet recruiting	1U01CA233100-01
clinical_trial	NCT03219450	A Personalized Neoantigen Cancer Vaccine in Treatment Na&#239;ve, Asymptomatic Patients With IGHV Unmutated CLL.	September 21, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT02614456	Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors	November 29, 2019	Completed	1U01CA233100-01
clinical_trial	NCT02646748	Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors	December 4, 2020	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT03012230	Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer	May 25, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT03425006	Pembrolizumab and Itacitinib (INCB039110) for NSCLC	September 16, 2021	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT03147287	Palbociclib After CDK and Endocrine Therapy (PACE)	August 23, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT03573648	Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer (ImmunoADAPT)	June 2, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT03294694	Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer	December 29, 2020	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT02779751	A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer	March 4, 2021	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT02947165	Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.	July 8, 2021	Completed	1U01CA233100-01
clinical_trial	NCT02517398	MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors	March 22, 2021	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT03620201	M7824 in Treating Patients With Stage II-III HER2 Positive Breast Cancer	October 14, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT03631706	M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)	October 20, 2020	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT00064129	Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer	July 30, 2020	Completed	1U01CA233100-01
clinical_trial	NCT01363206	Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma (GIPI)	March 19, 2020	Completed	1U01CA233100-01
clinical_trial	NCT02451423	Neoadjuvant Atezolizumab in Localized Bladder Cancer	March 30, 2020	Recruiting	1U01CA233100-01
clinical_trial	NCT02451423	Neoadjuvant Atezolizumab in Localized Bladder Cancer	March 30, 2020	Recruiting	1U01CA244452-01
clinical_trial	NCT01338012	Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer (mCRPC)	June 5, 2017	Terminated	1U01CA233100-01
clinical_trial	NCT01981122	A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer	October 24, 2018	Completed	1U01CA233100-01
clinical_trial	NCT00779402	PROvenge Treatment and Early Cancer Treatment (PROTECT)	January 29, 2018	Completed	1U01CA233100-01
clinical_trial	NCT01693562	A Phase 1/2 Study to Evaluate MEDI4736	May 13, 2021	Completed	1U01CA233100-01
clinical_trial	NCT01942837	Phase II Trial of Enzalutamide for CRPC With Correlative Assessment of Androgen Receptor Signaling	January 12, 2021	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT02703623	Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer	October 1, 2021	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT02703623	Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer	October 1, 2021	Active, not recruiting	1U01CA244452-01
clinical_trial	NCT01688492	Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-na&#239;ve Patients With Progressive Metastatic Castration-resistant Prostate Cancer	September 10, 2021	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT01688492	Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-na&#239;ve Patients With Progressive Metastatic Castration-resistant Prostate Cancer	September 10, 2021	Active, not recruiting	1U01CA244452-01
clinical_trial	NCT04388852	DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers	October 8, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT04388852	DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers	October 8, 2021	Recruiting	1U01CA244452-01
clinical_trial	NCT02787005	Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(MK-3475-199/KEYNOTE-199)	August 23, 2021	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT02787005	Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(MK-3475-199/KEYNOTE-199)	August 23, 2021	Active, not recruiting	1U01CA244452-01
clinical_trial	NCT03834493	Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)	October 11, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT03834493	Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)	October 11, 2021	Recruiting	1U01CA244452-01
clinical_trial	NCT02312557	Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide	May 17, 2021	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT02312557	Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide	May 17, 2021	Active, not recruiting	1U01CA244452-01
clinical_trial	NCT03770455	Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC	October 19, 2020	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT03770455	Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC	October 19, 2020	Active, not recruiting	1U01CA244452-01
clinical_trial	NCT03338790	An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CheckMate 9KD)	August 30, 2021	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT03338790	An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CheckMate 9KD)	August 30, 2021	Active, not recruiting	1U01CA244452-01
clinical_trial	NCT02861573	Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)	October 8, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT02861573	Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)	October 8, 2021	Recruiting	1U01CA244452-01
clinical_trial	NCT03658447	PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr) (PRINCE)	December 23, 2020	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT03658447	PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr) (PRINCE)	December 23, 2020	Active, not recruiting	1U01CA244452-01
clinical_trial	NCT03093428	Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC	July 28, 2021	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT03093428	Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC	July 28, 2021	Active, not recruiting	1U01CA244452-01
clinical_trial	NCT03834506	Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-na&#239;ve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)	June 9, 2021	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT03834506	Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-na&#239;ve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)	June 9, 2021	Active, not recruiting	1U01CA244452-01
clinical_trial	NCT03248570	Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects	May 26, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT03248570	Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects	May 26, 2021	Recruiting	1U01CA244452-01
clinical_trial	NCT02998567	Combination Study of Guadecitabine and Pembrolizumab. (HyPeR)	November 17, 2020	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT02998567	Combination Study of Guadecitabine and Pembrolizumab. (HyPeR)	November 17, 2020	Active, not recruiting	1U01CA244452-01
clinical_trial	NCT03572478	Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer	March 9, 2021	Terminated	1U01CA233100-01
clinical_trial	NCT03572478	Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer	March 9, 2021	Terminated	1U01CA244452-01
clinical_trial	NCT03834519	Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010) (KEYLYNK-010)	September 16, 2021	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT03834519	Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010) (KEYLYNK-010)	September 16, 2021	Active, not recruiting	1U01CA244452-01
clinical_trial	NCT02484404	Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...	October 5, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT02484404	Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...	October 5, 2021	Recruiting	1U01CA244452-01
clinical_trial	NCT03330405	Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors	September 24, 2021	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT03330405	Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors	September 24, 2021	Active, not recruiting	1U01CA244452-01
clinical_trial	NCT04446117	Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC (CONTACT-02)	September 17, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT04446117	Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC (CONTACT-02)	September 17, 2021	Recruiting	1U01CA244452-01
clinical_trial	NCT03849469	A Study of XmAb&#174;22841 Monotherapy &amp; in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4)	August 18, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT03849469	A Study of XmAb&#174;22841 Monotherapy &amp; in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4)	August 18, 2021	Recruiting	1U01CA244452-01
clinical_trial	NCT03406858	Pembrolizumab and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer	March 1, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT03406858	Pembrolizumab and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer	March 1, 2021	Recruiting	1U01CA244452-01
clinical_trial	NCT03217747	Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies	October 30, 2020	Recruiting	1U01CA233100-01
clinical_trial	NCT03217747	Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies	October 30, 2020	Recruiting	1U01CA244452-01
clinical_trial	NCT03821246	Atezolizumab With or Without Tocilizumab in Treating Men With Prostate Cancer Before Radical Prostatectomy	November 12, 2020	Recruiting	1U01CA233100-01
clinical_trial	NCT03821246	Atezolizumab With or Without Tocilizumab in Treating Men With Prostate Cancer Before Radical Prostatectomy	November 12, 2020	Recruiting	1U01CA244452-01
clinical_trial	NCT03473925	Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)	July 2, 2021	Completed	1U01CA233100-01
clinical_trial	NCT03473925	Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)	July 2, 2021	Completed	1U01CA244452-01
clinical_trial	NCT04020094	Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate Cancer (AtezoVax)	September 22, 2021	Withdrawn	1U01CA233100-01
clinical_trial	NCT04020094	Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate Cancer (AtezoVax)	September 22, 2021	Withdrawn	1U01CA244452-01
clinical_trial	NCT03835533	Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations (PORTER)	August 3, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT03835533	Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations (PORTER)	August 3, 2021	Recruiting	1U01CA244452-01
clinical_trial	NCT04090775	A Phase 2 Trial for Men With Metastatic Prostatic Adenocarcinoma	October 11, 2019	Recruiting	1U01CA233100-01
clinical_trial	NCT04090775	A Phase 2 Trial for Men With Metastatic Prostatic Adenocarcinoma	October 11, 2019	Recruiting	1U01CA244452-01
clinical_trial	NCT03518606	Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours (MOVIE)	September 16, 2021	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT03518606	Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours (MOVIE)	September 16, 2021	Active, not recruiting	1U01CA244452-01
clinical_trial	NCT03532217	Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer	September 17, 2021	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT03532217	Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer	September 17, 2021	Active, not recruiting	1U01CA244452-01
clinical_trial	NCT03204812	Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer	April 15, 2021	Completed	1U01CA233100-01
clinical_trial	NCT03204812	Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer	April 15, 2021	Completed	1U01CA244452-01
clinical_trial	NCT02985957	Study of Nivolumab Plus Ipilimumab, Ipilimumab or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)	April 23, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT02985957	Study of Nivolumab Plus Ipilimumab, Ipilimumab or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)	April 23, 2021	Recruiting	1U01CA244452-01
clinical_trial	NCT03879122	A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer	September 22, 2021	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT03879122	A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer	September 22, 2021	Active, not recruiting	1U01CA244452-01
clinical_trial	NCT03866382	Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors	October 14, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT03866382	Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors	October 14, 2021	Recruiting	1U01CA244452-01
clinical_trial	NCT03454451	CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers	July 27, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT03454451	CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers	July 27, 2021	Recruiting	1U01CA244452-01
clinical_trial	NCT04089553	An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer	August 3, 2021	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT04089553	An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer	August 3, 2021	Active, not recruiting	1U01CA244452-01
clinical_trial	NCT02740985	A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies	July 30, 2021	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT02740985	A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies	July 30, 2021	Active, not recruiting	1U01CA244452-01
clinical_trial	NCT04381832	Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer (ARC-6)	October 7, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT04381832	Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer (ARC-6)	October 7, 2021	Recruiting	1U01CA244452-01
clinical_trial	NCT03792841	Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC	October 4, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT03792841	Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC	October 4, 2021	Recruiting	1U01CA244452-01
clinical_trial	NCT04631601	Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)	October 7, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT04631601	Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)	October 7, 2021	Recruiting	1U01CA244452-01
clinical_trial	NCT03972657	Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer	July 12, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT03972657	Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer	July 12, 2021	Recruiting	1U01CA244452-01
clinical_trial	NCT04702737	A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer	October 7, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT04702737	A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer	October 7, 2021	Recruiting	1U01CA244452-01
clinical_trial	NCT04221542	Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer	September 2, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT04221542	Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer	September 2, 2021	Recruiting	1U01CA244452-01
clinical_trial	NCT03577028	Study of HPN424 in Patients With Advanced Prostate Cancer	October 5, 2020	Recruiting	1U01CA233100-01
clinical_trial	NCT03577028	Study of HPN424 in Patients With Advanced Prostate Cancer	October 5, 2020	Recruiting	1U01CA244452-01
clinical_trial	NCT04397276	A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors	October 8, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT04397276	A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors	October 8, 2021	Recruiting	1U01CA244452-01
clinical_trial	NCT03873805	PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer	March 10, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT03873805	PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer	March 10, 2021	Recruiting	1U01CA244452-01
clinical_trial	NCT03873805	PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer	March 10, 2021	Recruiting	3P30CA013696-45S1
clinical_trial	NCT03753243	Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer	September 23, 2020	Recruiting	1U01CA233100-01
clinical_trial	NCT03753243	Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer	September 23, 2020	Recruiting	1U01CA244452-01
clinical_trial	NCT03810105	A Study of Olaparib and Durvalumab in Prostate Cancer	September 16, 2021	Recruiting	1U01CA233100-01
clinical_trial	NCT03810105	A Study of Olaparib and Durvalumab in Prostate Cancer	September 16, 2021	Recruiting	1U01CA244452-01
clinical_trial	NCT03016312	A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen (IMbassador250)	August 19, 2021	Active, not recruiting	1U01CA233100-01
clinical_trial	NCT03016312	A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen (IMbassador250)	August 19, 2021	Active, not recruiting	1U01CA244452-01
clinical_trial	NCT01804465	Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer	August 18, 2021	Completed	1U01CA233100-01
clinical_trial	NCT01804465	Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer	August 18, 2021	Completed	1U01CA244452-01
clinical_trial	NCT02221739	Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)	May 11, 2020	Completed	1U01CA233102-01
clinical_trial	NCT03958383	IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma	October 8, 2021	Recruiting	1U01CA233102-01
clinical_trial	NCT03958383	IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma	October 8, 2021	Recruiting	1U01CA233102-01
clinical_trial	NCT03958383	IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma	October 8, 2021	Recruiting	1U01CA233102-01
clinical_trial	NCT03958383	IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma	October 8, 2021	Recruiting	1U01CA233102-01
clinical_trial	NCT03958383	IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma	October 8, 2021	Recruiting	1U54CA232568-01
clinical_trial	NCT00879866	EMD 521873 Plus Radiotherapy in Non Small Cell Lung Cancer (NSCLC)	June 23, 2014	Completed	1U01CA233102-01
clinical_trial	NCT03275597	Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition	August 26, 2021	Active, not recruiting	1U01CA233102-01
clinical_trial	NCT02504372	Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091) (PEARLS)	July 17, 2020	Active, not recruiting	1U01CA233102-01
clinical_trial	NCT02998528	A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) (CheckMate 816)	August 26, 2020	Active, not recruiting	1U01CA233102-01
clinical_trial	NCT04025879	A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer	September 21, 2021	Recruiting	1U01CA233102-01
clinical_trial	NCT04214262	Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer	October 14, 2021	Recruiting	1U01CA233102-01
clinical_trial	NCT03294954	GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma (GINAKIT2)	January 15, 2021	Recruiting	1U01CA239258-01
clinical_trial	NCT03294954	GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma (GINAKIT2)	January 15, 2021	Recruiting	3P30CA021765-41S3
clinical_trial	NCT03545815	Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors.	August 10, 2020	Recruiting	1U01CA239258-01
clinical_trial	NCT03545815	Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors.	August 10, 2020	Recruiting	3P30CA021765-41S3
clinical_trial	NCT02414269	Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin	April 1, 2021	Recruiting	1U01CA239258-01
clinical_trial	NCT04003649	IL13Ralpha2-Targeted Chimeric Antigen Receptor (CAR) T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With Recurrent or Refractory Glioblastoma	December 9, 2020	Recruiting	1U01CA239258-01
clinical_trial	NCT02498912	Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors	February 8, 2021	Active, not recruiting	1U01CA239258-01
clinical_trial	NCT02498912	Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors	February 8, 2021	Active, not recruiting	1U54CA244438-01
clinical_trial	NCT04093648	T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR)	May 20, 2020	Withdrawn	1U01CA239258-01
clinical_trial	NCT03721068	Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma	July 7, 2021	Recruiting	1U01CA239258-01
clinical_trial	NCT00720785	Natural Killer Cells and Bortezomib to Treat Cancer	October 14, 2021	Completed	1U01CA239258-01
clinical_trial	NCT02185781	Phase I Study of Adoptive Immunotherapy With Enriched and Expanded Autologous Natural Killer (NK) Cells for Patients With Ph+ Acute Lymphoblastic Leukemia (ALL)	August 6, 2018	Unknown	1U01CA239258-01
clinical_trial	NCT02271711	Expanded Natural Killer Cell Infusion in Treating Younger Patients With Recurrent/Refractory Brain Tumors	September 2, 2020	Completed	1U01CA239258-01
clinical_trial	NCT02661685	Safety Study of Adoptive Transfer of Autologous IKDC-like Cells	February 18, 2021	Completed	1U01CA239258-01
clinical_trial	NCT03410368	NK Cell-based Immunotherapy as Maintenance Therapy for Small-Cell Lung Cancer.	July 17, 2018	Unknown	1U01CA239258-01
clinical_trial	NCT03415100	Pilot Study of NKG2D-Ligand Targeted CAR-NK Cells in Patients With Metastatic Solid Tumours	August 1, 2018	Unknown	1U01CA239258-01
clinical_trial	NCT03499834	A Study to Evaluate the Safety and Efficacy of Ex Vivo Expanded Autologous Immune Killer Cells (IKC) in Stage IV Non-small Cell Lung Cancer (NSCLC) in Patients Who Failed Chemotherapy or Target Therapy (IVY03)	April 16, 2020	Completed	1U01CA239258-01
clinical_trial	NCT03592706	Autologous Immune Killer Cells to Treat Liver Cancer Patients as an Adjunct Therapy	April 16, 2020	Recruiting	1U01CA239258-01
clinical_trial	NCT03662477	Effect of NK Cell Immunotherapy on Advanced Lung Adenocarcinoma Adenocarcinoma With EGFR Mutation	December 6, 2019	Recruiting	1U01CA239258-01
clinical_trial	NCT03941262	Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy	May 3, 2021	Recruiting	1U01CA239258-01
clinical_trial	NCT03958097	A Pilot Study of NK Cell Combined With PD-1 Antibody as Second Line Therapy for Advanced Driver Mutation Negative Non-small Cell Lung Cancer	May 21, 2019	Unknown	1U01CA239258-01
clinical_trial	NCT00900809	QUILT-3.018: Neukoplast&#8482; (NK-92) for the Treatment of Refractory or Relapsed Acute Myeloid Leukemia	June 13, 2018	Completed	1U01CA239258-01
clinical_trial	NCT00990717	Safety Study Looking at the Use of a Natural Killer Cell Line Against Hematological Malignancies	June 23, 2016	Completed	1U01CA239258-01
clinical_trial	NCT01040026	Expanded Natural Killer (NK) Cells for Multiple Myeloma Study	November 15, 2019	Active, not recruiting	1U01CA239258-01
clinical_trial	NCT01700946	Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma	August 24, 2021	Completed	1U01CA239258-01
clinical_trial	NCT01700946	Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma	August 24, 2021	Completed	1U54CA232561-01A1
clinical_trial	NCT01729091	Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma	July 14, 2021	Recruiting	1U01CA239258-01
clinical_trial	NCT01807468	Haploidentical Stem Cell Transplantation and NK Cell Therapy in Patients With High-risk Solid Tumors	September 18, 2018	Unknown	1U01CA239258-01
clinical_trial	NCT02229266	Randomised Controlled Phase-2 Trial to Determine the Efficacy of Adoptive Immunotherapy With NK Cells in High-risk AML (HINKL)	August 16, 2021	Terminated	1U01CA239258-01
clinical_trial	NCT02409576	Pilot Study of Expanded , Activated Haploidentical Natural Killer Cell Infusions for Sarcomas (NKEXPSARC)	April 16, 2019	Unknown	1U01CA239258-01
clinical_trial	NCT02452697	Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From Donors Following Allogeneic SCT (NK-DCI)	February 25, 2021	Recruiting	1U01CA239258-01
clinical_trial	NCT02465957	QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC)	August 14, 2020	Active, not recruiting	1U01CA239258-01
clinical_trial	NCT02727803	Personalized NK Cell Therapy After Chemotherapy and Cord Blood Transplant in Treating Patients With Myelodysplastic Syndrome, Leukemia, Lymphoma or Multiple Myeloma	August 7, 2020	Recruiting	1U01CA239258-01
clinical_trial	NCT02742727	CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma	December 6, 2016	Unknown	1U01CA239258-01
clinical_trial	NCT02763475	NK Cells as Consolidation Therapy of Acute Myeloid Leukemia in Children/Adolescents	October 5, 2020	Completed	1U01CA239258-01
clinical_trial	NCT02944162	CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML	December 6, 2016	Unknown	1U01CA239258-01
clinical_trial	NCT03019640	Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma	August 16, 2021	Active, not recruiting	1U01CA239258-01
clinical_trial	NCT03027128	QUILT-3.028: Study of haNK&#8482; for Infusion in Subjects With Metastatic or Locally Advanced Solid Tumors	August 28, 2019	Completed	1U01CA239258-01
clinical_trial	NCT03136406	QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy	August 12, 2020	Active, not recruiting	1U01CA239258-01
clinical_trial	NCT03167164	QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy	March 19, 2021	Withdrawn	1U01CA239258-01
clinical_trial	NCT03167177	QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy	March 19, 2021	Withdrawn	1U01CA239258-01
clinical_trial	NCT03169738	QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors	March 19, 2021	Withdrawn	1U01CA239258-01
clinical_trial	NCT03169764	QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy	March 19, 2021	Withdrawn	1U01CA239258-01
clinical_trial	NCT03169777	QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC	March 18, 2021	Withdrawn	1U01CA239258-01
clinical_trial	NCT03169790	QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL	March 18, 2021	Withdrawn	1U01CA239258-01
clinical_trial	NCT03175666	QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy	March 18, 2021	Withdrawn	1U01CA239258-01
clinical_trial	NCT03197571	QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy	March 18, 2021	Withdrawn	1U01CA239258-01
clinical_trial	NCT03197584	QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy	March 18, 2021	Withdrawn	1U01CA239258-01
clinical_trial	NCT03300492	Expanded Natural Killer Cells Following Haploidentical HSCT for AML/MDS	December 2, 2020	Recruiting	1U01CA239258-01
clinical_trial	NCT03329248	QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy	August 11, 2020	Active, not recruiting	1U01CA239258-01
clinical_trial	NCT03383978	Intracranial Injection of NK-92/5.28.z Cells in Patients With Recurrent HER2-positive Glioblastoma (CAR2BRAIN)	September 25, 2020	Recruiting	1U01CA239258-01
clinical_trial	NCT03383978	Intracranial Injection of NK-92/5.28.z Cells in Patients With Recurrent HER2-positive Glioblastoma (CAR2BRAIN)	September 25, 2020	Recruiting	3P30CA021765-41S3
clinical_trial	NCT03387085	QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.	May 17, 2019	Unknown	1U01CA239258-01
clinical_trial	NCT03387098	QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy	July 16, 2019	Unknown	1U01CA239258-01
clinical_trial	NCT03387111	QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed	August 11, 2020	Active, not recruiting	1U01CA239258-01
clinical_trial	NCT03539406	Intraperitoneal Infusion of ex Vivo-cultured Allogeneic NK Cells in Recurrent Ovarian Carcinoma Patients (INTRO)	September 16, 2019	Unknown	1U01CA239258-01
clinical_trial	NCT03554109	QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine (TNBC)	May 14, 2019	Withdrawn	1U01CA239258-01
clinical_trial	NCT03563144	QUILT-3.088: NANT Pancreatic Cancer Vaccine	March 18, 2021	Withdrawn	1U01CA239258-01
clinical_trial	NCT03563157	QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine	September 18, 2020	Active, not recruiting	1U01CA239258-01
clinical_trial	NCT03563170	QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine	March 18, 2021	Withdrawn	1U01CA239258-01
clinical_trial	NCT03574649	QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer	August 28, 2019	Withdrawn	1U01CA239258-01
clinical_trial	NCT03586869	QUILT-3.080: NANT Pancreatic Cancer Vaccine	July 16, 2019	Unknown	1U01CA239258-01
clinical_trial	NCT03647423	QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.	March 19, 2021	Withdrawn	1U01CA239258-01
clinical_trial	NCT03656705	CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma	April 8, 2021	Enrolling by invitation	1U01CA239258-01
clinical_trial	NCT03669172	Efectiveness of Donor IL-15-stimulated NK Cells Post Transplant Infusion in in Acute Leukemia	September 5, 2021	Completed	1U01CA239258-01
clinical_trial	NCT03778619	MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin	July 28, 2020	Active, not recruiting	1U01CA239258-01
clinical_trial	NCT03821519	Infusion of Donor Derived Cytokine Induced Killer (CIK) Cells in Hematological Patients Relapsed After Haploidentical Stem Cell Transplant (Haplo-CIK)	January 31, 2019	Recruiting	1U01CA239258-01
clinical_trial	NCT03853317	QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy	October 8, 2021	Terminated	1U01CA239258-01
clinical_trial	NCT03937895	Allogeneic NK Cell (&quot;SMT-NK&quot;) in Combination With Pembrolizumab in Advanced Biliary Tract Cancer	January 18, 2020	Unknown	1U01CA239258-01
clinical_trial	NCT04162158	Safety and Efficacy of Allogeneic NK Cells Therapy in Patients With Advanced Hepatocellular Carcinoma	November 14, 2019	Recruiting	1U01CA239258-01
clinical_trial	NCT04309084	Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma	October 6, 2021	Active, not recruiting	1U01CA239258-01
clinical_trial	NCT04310592	Natural Killer Cell (CYNK-001) Infusions in Adults With AML (CYNK001AML01)	March 2, 2021	Recruiting	1U01CA239258-01
clinical_trial	NCT00625729	Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia	December 28, 2017	Terminated	1U01CA239258-01
clinical_trial	NCT00877110	Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma	January 10, 2019	Completed	1U01CA239258-01
clinical_trial	NCT01576692	Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma	November 15, 2018	Completed	1U01CA239258-01
clinical_trial	NCT02845999	Allogenic Immunotherapy Based on Natural Killer (NK) Cell Adoptive Transfer in Metastatic Gastrointestinal Carcinoma Treated With Cetuximab (NK-EGFR01)	July 27, 2016	Completed	1U01CA239258-01
clinical_trial	NCT03554889	Immunotherapy of Advanced Cancer Using a Combination Nimotuzumab and NK Cells	June 13, 2018	Unknown	1U01CA239258-01
clinical_trial	NCT04074746	Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas	June 3, 2021	Recruiting	1U01CA239258-01
clinical_trial	NCT04211675	NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab (STING)	April 1, 2021	Not yet recruiting	1U01CA239258-01
clinical_trial	NCT04245722	FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies	August 10, 2021	Recruiting	1U01CA239258-01
clinical_trial	NCT04245722	FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies	August 10, 2021	Recruiting	3P30CA021765-41S3
clinical_trial	NCT03412877	Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer	January 29, 2021	Suspended	1U01DE028227-01
clinical_trial	NCT02843165	Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation in Advanced Metastatic Disease	January 25, 2021	Recruiting	1U01DE028227-01
clinical_trial	NCT02014909	A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors	July 24, 2017	Completed	1U01DE028227-01
clinical_trial	NCT03254927	A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma	April 28, 2021	Completed	1U01DE028227-01
clinical_trial	NCT03637491	A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors	July 23, 2021	Terminated	1U01DE028233-01
clinical_trial	NCT03598270	Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer (ANITA)	August 13, 2021	Recruiting	1U01DE028233-01
clinical_trial	NCT01069081	Docetaxel and Cisplatin Chemotherapy With or Without High Dose Proton Pump Inhibitor in Metastatic Breast Cancer	March 6, 2015	Completed	1U01DE028233-01
clinical_trial	NCT02595372	Inhibiting Fatty Acid Synthase to Improve Efficacy of Neoadjuvant Chemotherapy	April 8, 2021	Completed	1U01DE028233-01
clinical_trial	NCT04317092	Tocilizumab in COVID-19 Pneumonia (TOCIVID-19) (TOCIVID-19)	March 3, 2021	Active, not recruiting	1U24CA233032-01
clinical_trial	NCT04315298	Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19	September 23, 2021	Completed	1U24CA233032-01
clinical_trial	NCT04106817	Single Ascending Dose Challenge Study to Determine Safety and Reactogenicity of an Influenza Challenge Virus	January 14, 2020	Completed	1U2CCA233195-01
clinical_trial	NCT04106817	Single Ascending Dose Challenge Study to Determine Safety and Reactogenicity of an Influenza Challenge Virus	January 14, 2020	Completed	1U2CCA233238-01
clinical_trial	NCT03447769	Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T&gt;5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A (Canopy-A)	September 13, 2021	Recruiting	1U2CCA233238-01
clinical_trial	NCT03631199	Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects (CANOPY-1)	September 13, 2021	Active, not recruiting	1U2CCA233238-01
clinical_trial	NCT03300817	MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer	October 11, 2021	Recruiting	1U2CCA233238-01
clinical_trial	NCT03634241	Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study	October 6, 2021	Recruiting	1U2CCA233238-01
clinical_trial	NCT02927301	A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)	May 17, 2021	Active, not recruiting	1U2CCA233238-01
clinical_trial	NCT02716038	Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC	April 15, 2021	Active, not recruiting	1U2CCA233238-01
clinical_trial	NCT03546361	CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer	July 8, 2021	Recruiting	1U2CCA233238-01
clinical_trial	NCT02639546	Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors (iMATRIXcobi)	September 30, 2021	Active, not recruiting	1U2CCA233262-01
clinical_trial	NCT03095248	Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors (SEL-TH-1601)	July 23, 2021	Recruiting	1U2CCA233262-01
clinical_trial	NCT02523014	Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas	October 12, 2021	Recruiting	1U2CCA233262-01
clinical_trial	NCT02831257	AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas	December 22, 2020	Completed	1U2CCA233262-01
clinical_trial	NCT03071874	Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas	January 20, 2021	Active, not recruiting	1U2CCA233262-01
clinical_trial	NCT02457910	Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer	February 23, 2021	Active, not recruiting	1U2CCA233280-01
clinical_trial	NCT02456857	Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative	April 13, 2021	Active, not recruiting	1U2CCA233280-01
clinical_trial	NCT03805399	FUSCC Refractory TNBC Umbrella (FUTURE) (FUTURE)	February 5, 2020	Recruiting	1U2CCA233280-01
clinical_trial	NCT03487666	OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease	September 16, 2021	Active, not recruiting	1U2CCA233280-01
clinical_trial	NCT01042379	I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY)	August 27, 2021	Recruiting	1U2CCA233280-01
clinical_trial	NCT03801369	Olaparib and Durvalumab in Treating Patients With Metastatic Triple Negative Breast Cancer	June 11, 2021	Recruiting	1U2CCA233280-01
clinical_trial	NCT01928576	Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC. (NA_00084192)	June 7, 2021	Recruiting	1U2CCA233280-01
clinical_trial	NCT03220477	Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.	August 6, 2021	Active, not recruiting	1U2CCA233280-01
clinical_trial	NCT02215850	Safety Study of SLC-0111 in Subjects With Advanced Solid Tumours	May 17, 2016	Completed	1U2CCA233280-01
clinical_trial	NCT03450018	A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects Positive for CAIX (SLC-0111-17-01)	March 15, 2021	Recruiting	1U2CCA233280-01
clinical_trial	NCT03375086	A Study of APX3330 in Patients With Advanced Solid Tumors (APX3330)	September 7, 2020	Completed	1U2CCA233280-01
clinical_trial	NCT02884102	MMRF Molecular Profiling Protocol	March 19, 2019	Recruiting	1U2CCA233303-01
clinical_trial	NCT03600649	Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas	September 30, 2021	Recruiting	1U54CA231641-01
clinical_trial	NCT03600649	Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas	September 30, 2021	Recruiting	3R01CA204915-02S1
clinical_trial	NCT01023386	A Clinical Pharmacological Study of YM155 After Intravenous Infusion in Patients With Advanced Cancer	April 13, 2010	Completed	1U54CA231652-01
clinical_trial	NCT00818480	An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155	September 4, 2015	Completed	1U54CA231652-01
clinical_trial	NCT01007292	A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment	October 19, 2015	Completed	1U54CA231652-01
clinical_trial	NCT01009775	A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma	September 4, 2015	Completed	1U54CA231652-01
clinical_trial	NCT01038804	A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer	September 18, 2013	Completed	1U54CA231652-01
clinical_trial	NCT00498914	Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects	September 4, 2015	Terminated	1U54CA231652-01
clinical_trial	NCT01100931	A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II)	October 19, 2015	Completed	1U54CA231652-01
clinical_trial	NCT00514267	An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors	August 13, 2015	Completed	1U54CA231652-01
clinical_trial	NCT00281541	A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma	June 7, 2012	Completed	1U54CA231652-01
clinical_trial	NCT00328588	LUCY: A Study for the Treatment of Non-Small Cell Lung Cancer (NSCLC) in Patients Previously Treated With Chemotherapy	January 2, 2008	Completed	1U54CA231652-01
clinical_trial	NCT00257478	A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy	June 7, 2012	Completed	1U54CA231652-01
clinical_trial	NCT00902044	Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma	August 24, 2021	Active, not recruiting	1U54CA232568-01
clinical_trial	NCT00902044	Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma	August 24, 2021	Active, not recruiting	1U54CA232561-01A1
clinical_trial	NCT02453594	Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)	April 19, 2021	Active, not recruiting	1U54CA232568-01
clinical_trial	NCT02992964	Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers	February 15, 2021	Active, not recruiting	1U54CA232568-01
clinical_trial	NCT02311621	Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01	April 27, 2021	Recruiting	1U54CA232568-01
clinical_trial	NCT02311621	Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01	April 27, 2021	Recruiting	1U54CA232561-01A1
clinical_trial	NCT02311621	Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01	April 27, 2021	Recruiting	1U54CA244438-01
clinical_trial	NCT03233854	CD19/CD22 Chimeric Antigen Receptor(CAR) T Cells in Adults With Recurrent/Refractory B Cell Malignancies	August 17, 2021	Recruiting	1U54CA232568-01
clinical_trial	NCT03233854	CD19/CD22 Chimeric Antigen Receptor(CAR) T Cells in Adults With Recurrent/Refractory B Cell Malignancies	August 17, 2021	Recruiting	3P30CA125123-14S6
clinical_trial	NCT03233854	CD19/CD22 Chimeric Antigen Receptor(CAR) T Cells in Adults With Recurrent/Refractory B Cell Malignancies	August 17, 2021	Recruiting	3P30CA016520-44S5
clinical_trial	NCT03233854	CD19/CD22 Chimeric Antigen Receptor(CAR) T Cells in Adults With Recurrent/Refractory B Cell Malignancies	August 17, 2021	Recruiting	3P30CA016520-44S6
clinical_trial	NCT04088890	Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies	August 3, 2021	Recruiting	1U54CA232568-01
clinical_trial	NCT04088890	Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies	August 3, 2021	Recruiting	3P30CA125123-14S6
clinical_trial	NCT01850628	NSABP Biospecimen Discovery Project	October 5, 2021	Active, not recruiting	1U54CA233223-01
clinical_trial	NCT04410302	Patient-Derived Xenografts to Reduce Cancer Health Disparities	July 13, 2021	Recruiting	1U54CA233306-01
clinical_trial	NCT02569723	Oxaliplatin Microdosing Assay in Predicting Exposure and Sensitivity to Oxaliplatin-Based Chemotherapy	March 30, 2021	Completed	1U54CA233306-01
clinical_trial	NCT02807805	Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer	March 19, 2021	Recruiting	1U54CA233306-01
clinical_trial	NCT04514341	Implementing a Multilevel Intervention to Accelerate Colorectal Cancer Screening and Follow-up	August 14, 2020	Not yet recruiting	1UG3CA233229-01
clinical_trial	NCT04514341	Implementing a Multilevel Intervention to Accelerate Colorectal Cancer Screening and Follow-up	August 14, 2020	Not yet recruiting	1UG3CA233229-01
clinical_trial	NCT04406714	Scaling CRC Screening Through Outreach, Referral, and Engagement (SCORE) (SCORE)	May 12, 2021	Recruiting	1UG3CA233251-01
clinical_trial	NCT04427527	Accelerating Colorectal Cancer Screening Through Implementation Science in Appalachia (ACCSIS)	May 3, 2021	Recruiting	1UG3CA233282-01
clinical_trial	NCT04427527	Accelerating Colorectal Cancer Screening Through Implementation Science in Appalachia (ACCSIS)	May 3, 2021	Recruiting	1UG3CA233282-01
clinical_trial	NCT04427527	Accelerating Colorectal Cancer Screening Through Implementation Science in Appalachia (ACCSIS)	May 3, 2021	Recruiting	3P30CA016058-44S3
clinical_trial	NCT04427527	Accelerating Colorectal Cancer Screening Through Implementation Science in Appalachia (ACCSIS)	May 3, 2021	Recruiting	3P30CA177558-08S2
clinical_trial	NCT03892967	Enhanced, EHR-facilitated Cancer Symptom Control (E2C2) Pragmatic Clinical Trial (E2C2)	August 13, 2021	Recruiting	1UM1CA233033-01
clinical_trial	NCT03988543	Bilingual Electronic Symptom Management Program Across Multi-site, Comprehensive Cancer Center (NU IMPACT)	March 3, 2021	Recruiting	1UM1CA233035-01
clinical_trial	NCT03850912	Symptom Management Implementation of Patient Reported Outcomes in Oncology (SIMPRO)	September 16, 2020	Recruiting	1UM1CA233080-01
clinical_trial	NCT04199026	Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma	October 14, 2021	Not yet recruiting	3R01CA180279-05S1
clinical_trial	NCT01231906	Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma	May 6, 2021	Active, not recruiting	3R01CA204915-02S1
clinical_trial	NCT02579226	A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors.	May 1, 2020	Completed	3R01CA204915-02S1
clinical_trial	NCT02657005	TK216 in Patients With Relapsed or Refractory Ewing Sarcoma	August 23, 2021	Recruiting	3R01CA204915-02S1
clinical_trial	NCT00070109	Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors	September 14, 2018	Completed	3R01CA204915-02S1
clinical_trial	NCT01610570	Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma	March 2, 2018	Terminated	3R01CA204915-02S1
clinical_trial	NCT01610570	Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma	March 2, 2018	Terminated	3P30CA177558-08S2
clinical_trial	NCT03456700	Auranofin and Sirolimus in Treating Participants With Ovarian Cancer	March 16, 2021	Active, not recruiting	3U54CA224065-01S1
clinical_trial	NCT03414034	Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer	March 23, 2021	Recruiting	3U54CA224065-01S1
clinical_trial	NCT03303339	Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML)	May 27, 2021	Active, not recruiting	3U54CA224065-01S1
clinical_trial	NCT02864992	Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)	September 22, 2021	Active, not recruiting	3U54CA224065-01S1
clinical_trial	NCT03066206	Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC	September 9, 2021	Recruiting	3U54CA224065-01S1
clinical_trial	NCT03065387	Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation	January 25, 2021	Recruiting	3U54CA224065-01S1
clinical_trial	NCT00983424	Cyclosporine A in Combination With Nab-Paclitaxel in Patients With Metastatic Breast Cancer	September 16, 2013	Completed	3U54CA224065-01S1
clinical_trial	NCT02188264	Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer	April 2, 2021	Active, not recruiting	3U54CA224065-01S1
clinical_trial	NCT00003950	Irinotecan and Cyclosporine in Treating Patients With Metastatic, Advanced or Locally Recurrent Colorectal Cancer	March 7, 2014	Completed	3U54CA224065-01S1
clinical_trial	NCT03538938	Improving Quitline Support Study (IQS)	October 12, 2021	Enrolling by invitation	5R01CA218156-02
clinical_trial	NCT02936609	Assessing Community Cancer Care After Insurance ExpanSionS (ACCESS)	August 30, 2021	Completed	1P50CA244289-01
clinical_trial	NCT03545763	Evaluating Control of Hypertension - Effect of Social Determinants (ECHOES)	March 23, 2021	Active, not recruiting	1P50CA244289-01
clinical_trial	NCT03607617	ASCEND: ApproacheS to CHC ImplEmeNtation of SDH Data Collection and Action (ASCEND)	June 15, 2021	Active, not recruiting	1P50CA244289-01
clinical_trial	NCT04314284	Patient-Centered Intervention to Reduce Cancer Patients' Financial Toxicity	January 14, 2021	Recruiting	1P50CA244431-01
clinical_trial	NCT12345678	N/A	N/A	N/A	1P50CA244431-01
clinical_trial	NCT03799432	Collaborative Organizational Approach to Selecting and Tailoring Implementation Strategies (COAST-IS)	January 8, 2021	Active, not recruiting	1P50CA244431-01
clinical_trial	NCT04585919	Paired Promotion of Colorectal Cancer and Social Determinants of Health Screening	April 1, 2021	Enrolling by invitation	1P50CA244433-01
clinical_trial	NCT04302675	Adapting Motivational Interviewing for Maternal Immunizations (MI4MI) (MI4MI)	July 26, 2021	Active, not recruiting	1P50CA244688-01
clinical_trial	NCT05021133	Tele-Navigation of Lung Cancer Screening (Tele-Navi LCS)	August 31, 2021	Not yet recruiting	1P50CA244693-01
clinical_trial	NCT04337203	Shared Healthcare Actions and Reflections Electronic Systems in Survivorship	June 18, 2021	Recruiting	1P50CA244693-01
clinical_trial	NCT04746794	Early Detection of GEnetic Risk (EDGE)	February 10, 2021	Recruiting	1U01CA232795-01A1
clinical_trial	NCT04323774	Intervention For AYAS With Cancer Risk Syndromes (AYA-RISE)	April 13, 2021	Recruiting	1U01CA243688-01
clinical_trial	NCT00480363	QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression (QUIREDEX)	July 31, 2013	Completed	1U01CA244291-01
clinical_trial	NCT01169337	Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma	May 18, 2021	Active, not recruiting	1U01CA244291-01
clinical_trial	NCT02681302	Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence (CPIT001)	May 4, 2021	Active, not recruiting	1U01CA244291-01
clinical_trial	NCT02654132	An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)	July 14, 2020	Active, not recruiting	1U01CA244291-01
clinical_trial	NCT02289222	1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma	November 5, 2019	Terminated	1U01CA244291-01
clinical_trial	NCT02036502	A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023)	April 8, 2021	Terminated	1U01CA244291-01
clinical_trial	NCT02726581	An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma (CheckMate 602)	August 6, 2021	Active, not recruiting	1U01CA244291-01
clinical_trial	NCT02431208	A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)	April 2, 2021	Completed	1U01CA244291-01
clinical_trial	NCT01592370	An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma	June 18, 2021	Active, not recruiting	1U01CA244291-01
clinical_trial	NCT03357952	A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma	September 20, 2021	Active, not recruiting	1U01CA244291-01
clinical_trial	NCT03015922	Viral Immunotherapy in Relapsed/Refractory Multiple Myeloma (MUKeleven)	January 22, 2020	Active, not recruiting	1U01CA244291-01
clinical_trial	NCT02514382	Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma	May 3, 2019	Unknown	1U01CA244291-01
clinical_trial	NCT02101944	Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma	August 13, 2021	Recruiting	1U01CA244291-01
clinical_trial	NCT02192775	UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus	October 19, 2020	Completed	1U01CA244291-01
clinical_trial	NCT03017820	VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma	September 27, 2021	Recruiting	1U01CA244291-01
clinical_trial	NCT01858558	Tadalafil and Lenalidomide Maintenance With or Without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma	June 29, 2020	Completed	1U01CA244291-01
clinical_trial	NCT03672318	Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma	June 30, 2021	Recruiting	1U01CA244291-01
clinical_trial	NCT03958656	T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma	September 9, 2021	Completed	1U01CA244291-01
clinical_trial	NCT02181413	A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant	March 9, 2021	Active, not recruiting	1U01CA244291-01
clinical_trial	NCT00114101	Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant	June 23, 2021	Active, not recruiting	1U01CA244291-01
clinical_trial	NCT04939597	A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor	June 25, 2021	Not yet recruiting	1U01CA246568-01
clinical_trial	NCT04789720	Using Information Technology to Improve Outcomes for Children Living With Cancer (SyMon-SAYS)	June 18, 2021	Recruiting	1U01CA246612-01
clinical_trial	NCT04089358	Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors, the StepByStep Study	August 25, 2021	Recruiting	1U01CA246665-01
clinical_trial	NCT02369874	Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer (EAGLE)	February 10, 2021	Completed	1U01DE029188-01
clinical_trial	NCT00404339	Vaccine Therapy in Treating Patients With Head and Neck Cancer	April 18, 2016	Completed	1U01DE029188-01
clinical_trial	NCT00257738	0804 GCC: MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck	October 17, 2019	Completed	1U01DE029188-01
clinical_trial	NCT02426892	Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors	February 17, 2020	Active, not recruiting	1U01DE029188-01
clinical_trial	NCT01147991	Vaccine Therapy in Treating Patients With Epstein-Barr Virus-Related Cancer	February 28, 2012	Completed	1U01DE029188-01
clinical_trial	NCT03821272	A Phase I/II Clinical Trial of PepCan in Head and Neck Cancer Patients	May 13, 2021	Recruiting	1U01DE029188-01
clinical_trial	NCT02002182	ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer	July 2, 2021	Active, not recruiting	1U01DE029188-01
clinical_trial	NCT02865135	Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer	September 9, 2021	Active, not recruiting	1U01DE029188-01
clinical_trial	NCT03260023	Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers	June 29, 2021	Recruiting	1U01DE029188-01
clinical_trial	NCT03418480	HPV Anti-CD40 RNA Vaccine (HARE-40)	May 6, 2021	Active, not recruiting	1U01DE029188-01
clinical_trial	NCT04369937	HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for &quot;Intermediate Risk&quot; HPV-16-associated Head and Neck Squamous Cell Carcinoma	September 20, 2021	Recruiting	1U01DE029188-01
clinical_trial	NCT02544880	PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC	June 15, 2021	Completed	1U01DE029188-01
clinical_trial	NCT04247282	Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection	June 9, 2021	Suspended	1U01DE029188-01
clinical_trial	NCT02999646	Personalized and Cell-based Antitumor Immunization MVX-ONCO-1 in Advanced HNSCC	September 22, 2021	Recruiting	1U01DE029188-01
clinical_trial	NCT03568058	Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers	December 9, 2020	Active, not recruiting	1U01DE029188-01
clinical_trial	NCT04266730	Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab (PANDA-VAC)	July 8, 2021	Not yet recruiting	1U01DE029188-01
clinical_trial	NCT03689192	Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors	February 12, 2020	Recruiting	1U01DE029188-01
clinical_trial	NCT00019110	Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer	April 29, 2015	Completed	1U01DE029188-01
clinical_trial	NCT00019331	Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors	June 20, 2013	Completed	1U01DE029188-01
clinical_trial	NCT00021424	Vaccine Therapy in Treating Patients With Stage IV Head and Neck Cancer	April 30, 2015	Completed	1U01DE029188-01
clinical_trial	NCT00027534	Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer	September 8, 2014	Completed	1U01DE029188-01
clinical_trial	NCT01462838	Immune Therapy of HPV-induced Cancers	June 23, 2015	Completed	1U01DE029188-01
clinical_trial	NCT01998542	Safety and Tolerability Study of AlloVax(TM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck (HNC)	January 23, 2020	Completed	1U01DE029188-01
clinical_trial	NCT02163057	Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma	January 22, 2021	Completed	1U01DE029188-01
clinical_trial	NCT02291055	Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combo In Cervical or HPV+ Head &amp; Neck Cancer	February 19, 2020	Active, not recruiting	1U01DE029188-01
clinical_trial	NCT02526316	Cisplatin-based Chemotherapy Combined With P16_37-63 Peptide Vaccination in Patients With HPV-positive Cancers (VICORYX-2)	July 2, 2017	Completed	1U01DE029188-01
clinical_trial	NCT03162224	Safety and Efficacy of MEDI0457 and Durvalumab in Patients With HPV Associated Recurrent/Metastatic Head and Neck Cancer	April 27, 2021	Completed	1U01DE029188-01
clinical_trial	NCT03019003	Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients	December 1, 2020	Recruiting	1U01DE029188-01
clinical_trial	NCT03525795	ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors	January 11, 2021	Completed	1U01DE029188-01
clinical_trial	NCT03854474	Tazemetostat and Pembrolizumab in Treating Patients With Locally Advanced or Metastatic Urothelial Carcinoma	October 12, 2021	Recruiting	1U01DE029188-01
clinical_trial	NCT03635164	Radiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma	May 20, 2021	Active, not recruiting	1U01DE029255-01
clinical_trial	NCT01120288	A Pilot Study of EZN-2968, an Antisense Oligonucleotide Inhibitor of HIF-1alpha, in Adults With Advanced Solid Tumors With Liver Metastases	July 5, 2018	Completed	1U01DE029255-01
clinical_trial	NCT00466583	Phase 1 Study of EZN-2968 Weekly in Adult Patients With Advanced Solid Tumors or Lymphoma	July 7, 2011	Completed	1U01DE029255-01
clinical_trial	NCT01750580	Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor	July 22, 2015	Completed	1U54CA232561-01A1
clinical_trial	NCT02331875	Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral Cavity	January 4, 2017	Terminated	1U54CA232561-01A1
clinical_trial	NCT02141451	ADAM17 Inhibitor/ Rituximab After Auto HCT for DLBCL	February 19, 2020	Completed	1U54CA232561-01A1
clinical_trial	NCT02393859	Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)	December 8, 2020	Active, not recruiting	1U54CA232561-01A1
clinical_trial	NCT02559778	Pediatric Precision Laboratory Advanced Neuroblastoma Therapy (PEDS-PLAN)	October 11, 2021	Recruiting	1U54CA232561-01A1
clinical_trial	NCT03837899	Durvalumab and Tremelimumab for Pediatric Malignancies	September 22, 2021	Recruiting	1U54CA232561-01A1
clinical_trial	NCT04044378	Famitinib Plus Camrelizumab &amp; Famitinib Alone &amp; Famitinib Plus Ifosfamide in Advanced Osteosarcoma	May 19, 2020	Withdrawn	1U54CA232561-01A1
clinical_trial	NCT03130959	An Investigational Immuno-therapy Study of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Patients With High Grade Primary CNS Malignancies (CheckMate 908)	April 1, 2021	Active, not recruiting	1U54CA232561-01A1
clinical_trial	NCT03618381	EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults	April 19, 2021	Recruiting	1U54CA232561-01A1
clinical_trial	NCT03618381	EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults	April 19, 2021	Recruiting	1UG3CA244687-01
clinical_trial	NCT03334305	Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas (ACTION)	August 12, 2021	Recruiting	1U54CA232561-01A1
clinical_trial	NCT01192555	Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma (ATOMIC)	March 10, 2021	Active, not recruiting	1U54CA232561-01A1
clinical_trial	NCT03703050	Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2) (NIVO-ALCL)	July 7, 2021	Recruiting	1U54CA232561-01A1
clinical_trial	NCT03907488	Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma	October 13, 2021	Recruiting	1U54CA232561-01A1
clinical_trial	NCT02789228	Research Study Utilizing Expanded Multi-antigen Specific Lymphocytes for the Treatment of Solid Tumors (REST)	February 25, 2021	Recruiting	1U54CA232561-01A1
clinical_trial	NCT03396575	Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I) (BRAVO)	July 13, 2021	Recruiting	1U54CA232561-01A1
clinical_trial	NCT03911388	HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors	July 8, 2021	Recruiting	1U54CA232561-01A1
clinical_trial	NCT02962167	Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT	June 30, 2021	Recruiting	1U54CA232561-01A1
clinical_trial	NCT02444546	Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors	August 18, 2021	Active, not recruiting	1U54CA232561-01A1
clinical_trial	NCT03495921	Vigil + Irinotecan and Temozolomide in Ewing's Sarcoma (VITA)	August 18, 2021	Active, not recruiting	1U54CA232561-01A1
clinical_trial	NCT00790413	Haploidentical Stem Cell Transplantation in Neuroblastoma	February 21, 2021	Active, not recruiting	1U54CA232561-01A1
clinical_trial	NCT02793466	Durvalumab in Pediatric and Adolescent Patients	January 30, 2019	Unknown	1U54CA232561-01A1
clinical_trial	NCT01860937	T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia	July 6, 2021	Active, not recruiting	1U54CA232561-01A1
clinical_trial	NCT03006848	A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma	September 16, 2021	Active, not recruiting	1U54CA232561-01A1
clinical_trial	NCT00634231	A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors	January 27, 2021	Active, not recruiting	1U54CA232561-01A1
clinical_trial	NCT02511132	A Two-part Phase IIb Trial of Vigil in Ewing's Sarcoma	February 4, 2021	Completed	1U54CA232561-01A1
clinical_trial	NCT03299309	PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma (PRiME)	May 25, 2021	Suspended	1U54CA232561-01A1
clinical_trial	NCT03643276	Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017	July 7, 2021	Recruiting	1U54CA232561-01A1
clinical_trial	NCT03244306	A Phase 1 Study of CD22-CAR TCell Immunotherapy for CD22+ Leukemia and Lymphoma (PLAT-04)	January 19, 2021	Active, not recruiting	1U54CA232561-01A1
clinical_trial	NCT03244306	A Phase 1 Study of CD22-CAR TCell Immunotherapy for CD22+ Leukemia and Lymphoma (PLAT-04)	January 19, 2021	Active, not recruiting	1U01CA247548-01
clinical_trial	NCT03769467	Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)	September 24, 2021	Completed	1U54CA232561-01A1
clinical_trial	NCT02960230	H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas	August 25, 2021	Recruiting	1U54CA232561-01A1
clinical_trial	NCT01169584	Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients	January 21, 2016	Completed	1U54CA232561-01A1
clinical_trial	NCT03359018	Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma (APFAO)	May 19, 2020	Completed	1U54CA232561-01A1
clinical_trial	NCT02403778	Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma	September 29, 2021	Active, not recruiting	1U54CA232561-01A1
clinical_trial	NCT02541370	Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133	December 17, 2019	Completed	1U54CA244438-01
clinical_trial	NCT02862704	A Study of MG7 Redirected Autologous T Cells for Advanced MG7 Positive Liver Metastases(MG7-CART)	August 11, 2016	Unknown	1U54CA244438-01
clinical_trial	NCT04045847	CD147-CART Cells in Patients With Recurrent Malignant Glioma.	May 7, 2020	Recruiting	1U54CA244438-01
clinical_trial	NCT03198052	HER2/Mesothelin/Lewis-Y/PSCA/MUC1/GPC3/AXL/EGFR/B7-H3/Claudin18.2-CAR-T Cells Immunotherapy Against Cancers	December 1, 2020	Recruiting	1U54CA244438-01
clinical_trial	NCT01373047	CEA-Expressing Liver Metastases Safety Study of Intrahepatic Infusions of Anti-CEA Designer T Cells (HITM)	July 30, 2013	Completed	1U54CA244438-01
clinical_trial	NCT03159819	Clinical Study of CAR-CLD18 T Cells in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma	March 12, 2018	Recruiting	1U54CA244438-01
clinical_trial	NCT02331693	CAR T Cells in Treating Patients With Malignant Gliomas Overexpressing EGFR	January 6, 2015	Unknown	1U54CA244438-01
clinical_trial	NCT02915445	EpCAM CAR-T for Treatment of Nasopharyngeal Carcinoma and Breast Cancer	April 8, 2019	Recruiting	1U54CA244438-01
clinical_trial	NCT03423992	Personalized Chimeric Antigen Receptor T Cell Immunotherapy for Patients With Recurrent Malignant Gliomas	June 15, 2021	Recruiting	1U54CA244438-01
clinical_trial	NCT01722149	Re-directed T Cells for the Treatment (FAP)-Positive Malignant Pleural Mesothelioma	August 7, 2019	Completed	1U54CA244438-01
clinical_trial	NCT00019136	Gene Therapy and Biological Therapy in Treating Patients With Ovarian Epithelial Cancer	April 29, 2015	Completed	1U54CA244438-01
clinical_trial	NCT00085930	Blood T-Cells and EBV Specific CTLs Expressing GD-2 Specific Chimeric T Cell Receptors to Neuroblastoma Patients (NESTLES)	January 8, 2021	Active, not recruiting	1U54CA244438-01
clinical_trial	NCT02959151	A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy	November 8, 2016	Unknown	1U54CA244438-01
clinical_trial	NCT02442297	T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS Tumors (iCAR)	September 10, 2021	Recruiting	1U54CA244438-01
clinical_trial	NCT02930993	Anti-mesothelin CAR T Cells for Patients With Recurrent or Metastatic Malignant Tumors	October 12, 2016	Unknown	1U54CA244438-01
clinical_trial	NCT01837602	cMet CAR RNA T Cells Targeting Breast Cancer	October 19, 2018	Completed	1U54CA244438-01
clinical_trial	NCT02617134	CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor	December 6, 2016	Unknown	1U54CA244438-01
clinical_trial	NCT02744287	Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors	April 26, 2021	Recruiting	1U54CA244438-01
clinical_trial	NCT02744287	Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors	April 26, 2021	Recruiting	3P30CA013696-45S1
clinical_trial	NCT01929239	Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning	June 17, 2016	Suspended	1U54CA244438-01
clinical_trial	NCT02706392	Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies	July 8, 2021	Recruiting	1U54CA244438-01
clinical_trial	NCT02706392	Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies	July 8, 2021	Recruiting	1U01CA247548-01
clinical_trial	NCT03225105	M3541 in Combination With Radiotherapy in Subjects With Solid Tumors	September 14, 2020	Completed	1U54CA244719-01
clinical_trial	NCT02494583	Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)	March 10, 2021	Active, not recruiting	1U54CA244719-01
clinical_trial	NCT03189719	First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)	September 20, 2021	Active, not recruiting	1U54CA244719-01
clinical_trial	NCT04941300	ColoRectal Cancer Screening for Southern California Community Health Centers	July 19, 2021	Enrolling by invitation	1UG3CA233314-01A1
clinical_trial	NCT04890054	Screening More Patients for Colorectal Cancer Through Adapting and Refining Targeted Evidence-Based Interventions in Rural Settings, SMARTER CRC (SMARTER CRC)	July 15, 2021	Recruiting	1UG3CA244298-01
clinical_trial	NCT03433183	SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors	September 18, 2020	Recruiting	1UG3CA244687-01
clinical_trial	NCT02008877	SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)	May 15, 2019	Completed	1UG3CA244687-01
clinical_trial	NCT02584647	PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors (PLX3397)	August 31, 2021	Recruiting	1UG3CA244687-01
clinical_trial	NCT03009201	Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery	June 15, 2021	Active, not recruiting	1UG3CA244687-01
clinical_trial	NCT02691026	A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery	June 23, 2021	Terminated	1UG3CA244687-01
clinical_trial	NCT02834013	Nivolumab and Ipilimumab in Treating Patients With Rare Tumors	October 14, 2021	Recruiting	1UG3CA244687-01
clinical_trial	NCT04222413	Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors	September 30, 2021	Recruiting	1UG3CA244687-01
clinical_trial	NCT03880123	Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma	November 27, 2020	Withdrawn	1UG3CA244687-01
clinical_trial	NCT01924689	Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies	September 9, 2019	Completed	1UG3CA244687-01
clinical_trial	NCT04745754	The Engaging Primary Care in Cancer Survivorship (EPICS) Study (EPICS)	August 4, 2021	Not yet recruiting	1R01CA249419-01
clinical_trial	NCT04358276	Technology-Enabled Activation of Skin Cancer Screening for Stem Cell Transplant Survivors and Their Primary Care Providers, TEACH Study	February 16, 2021	Recruiting	1R01CA249460-01
clinical_trial	NCT05006482	Geriatric Evaluation and Management With Survivorship Health Education (GEMS) for Older Survivors of Cancer	August 31, 2021	Not yet recruiting	1R01CA249467-01
clinical_trial	NCT04428905	Self-Management Survivorship Care in Stage I-III Non-small Cell Lung Cancer or Colorectal Cancer	February 16, 2021	Recruiting	1R01CA249501-01
clinical_trial	NCT04494945	Identifying and Caring for Individuals With Inherited Cancer Syndrome	September 27, 2021	Recruiting	1U01CA232819-01A1
clinical_trial	NCT01865617	Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia	July 20, 2021	Completed	1U01CA247548-01
clinical_trial	NCT03103971	huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia	September 10, 2021	Recruiting	1U01CA247548-01
clinical_trial	NCT02631044	Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)	June 21, 2021	Recruiting	1U01CA247548-01
clinical_trial	NCT03277729	A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas	July 13, 2021	Recruiting	1U01CA247548-01
clinical_trial	NCT03277729	A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas	July 13, 2021	Recruiting	3P30CA125123-14S6
clinical_trial	NCT03105336	A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5)	August 5, 2021	Active, not recruiting	1U01CA247548-01
clinical_trial	NCT02614066	A Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3) (ZUMA-3)	June 28, 2021	Active, not recruiting	1U01CA247548-01
clinical_trial	NCT03331198	Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)	May 7, 2021	Recruiting	1U01CA247548-01
clinical_trial	NCT03575351	A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas (TRANSFORM)	June 10, 2021	Active, not recruiting	1U01CA247548-01
clinical_trial	NCT03153462	Axicabtagene Ciloleucel Expanded Access Study (ZUMA-9)	May 17, 2021	Approved for marketing	1U01CA247576-01
clinical_trial	NCT04365257	Prazosin to Prevent COVID-19 (PREVENT-COVID Trial) (PREVENT)	June 9, 2021	Recruiting	1U01CA247576-01
clinical_trial	NCT01684150	A Phase 1, Open-Label, Dose-Escalation &amp; Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK &amp; PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving	August 4, 2016	Completed	5R01CA176745-09
clinical_trial	NCT03701295	Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement	September 9, 2021	Completed	5R01CA176745-09
clinical_trial	NCT03724084	Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement	September 8, 2021	Active, not recruiting	5R01CA176745-09
clinical_trial	NCT04065399	A Study of SNDX-5613 in R/R Leukemias Including Those With an MLLr/KMT2A Gene Rearrangement or NPM1 Mutation (AUGMENT-101)	May 6, 2021	Recruiting	5R01CA176745-09
clinical_trial	NCT04067336	First in Human Study of KO-539 in Relapsed or Refractory Acute Myeloid Leukemia	October 7, 2021	Recruiting	5R01CA176745-09
clinical_trial	NCT02698176	A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006)	January 27, 2021	Terminated	5R01CA176745-09
clinical_trial	NCT02259114	A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)	January 26, 2021	Completed	5R01CA176745-09
clinical_trial	NCT02296476	A Dose-finding Study of Birabresib (MK-8628) in Participants With Recurrent Glioblastoma Multiforme (MK-8628-002)	January 26, 2021	Terminated	5R01CA176745-09
clinical_trial	NCT03068351	Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma	February 7, 2020	Completed	5R01CA176745-09
clinical_trial	NCT01987362	A Two Part Study of RO6870810. Dose-Escalation Study in Participants With Advanced Solid Tumors and Expansion Study in Participants With Selected Malignancies	January 5, 2018	Completed	5R01CA176745-09
clinical_trial	NCT03292172	A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer	November 6, 2020	Terminated	5R01CA176745-09
clinical_trial	NCT03255096	A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6	January 28, 2021	Completed	5R01CA176745-09
clinical_trial	NCT04597359	To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring	September 20, 2021	Recruiting	3UG1CA189828-07S1
clinical_trial	NCT04467021	Cancer and Blood Pressure Management, CARISMA Study	March 5, 2021	Recruiting	3UG1CA189828-07S1
clinical_trial	NCT04438382	Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis	August 20, 2021	Recruiting	3UG1CA189828-07S1
clinical_trial	NCT04239573	Comparing Two Methods to Follow Patients With Pancreatic Cysts	August 6, 2021	Recruiting	3UG1CA189828-07S1
clinical_trial	NCT04239573	Comparing Two Methods to Follow Patients With Pancreatic Cysts	August 6, 2021	Recruiting	3UG1CA189828-07S1
clinical_trial	NCT04001829	Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer	September 20, 2021	Recruiting	3UG1CA189828-07S1
clinical_trial	NCT03804255	Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting	November 3, 2020	Active, not recruiting	3UG1CA189828-07S1
clinical_trial	NCT02352883	MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ	October 26, 2020	Active, not recruiting	3UG1CA189828-07S1
clinical_trial	NCT03253848	Simplified Patient Care Strategy in Decreasing Early Death in Patients With Acute Promyelocytic Leukemia	March 9, 2021	Recruiting	3UG1CA189828-07S1
clinical_trial	NCT02933489	Abbreviated Breast MRI and Digital Tomosynthesis Mammography in Screening Women With Dense Breasts	February 5, 2021	Active, not recruiting	3UG1CA189828-07S1
clinical_trial	NCT04321616	The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients	April 14, 2020	Recruiting	3UG1CA189828-07S1
clinical_trial	NCT04321616	The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients	April 14, 2020	Recruiting	3P30CA054174-25S2
clinical_trial	NCT04321616	The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients	April 14, 2020	Recruiting	3P30CA013696-45S1
clinical_trial	NCT04321616	The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients	April 14, 2020	Recruiting	3P30CA054174-25S1
clinical_trial	NCT04381936	Randomised Evaluation of COVID-19 Therapy (RECOVERY)	July 30, 2021	Recruiting	3UG1CA189828-07S1
clinical_trial	NCT04381936	Randomised Evaluation of COVID-19 Therapy (RECOVERY)	July 30, 2021	Recruiting	3P30CA054174-25S2
clinical_trial	NCT04381936	Randomised Evaluation of COVID-19 Therapy (RECOVERY)	July 30, 2021	Recruiting	3P30CA013696-45S1
clinical_trial	NCT04381936	Randomised Evaluation of COVID-19 Therapy (RECOVERY)	July 30, 2021	Recruiting	3P30CA054174-25S1
clinical_trial	NCT04381936	Randomised Evaluation of COVID-19 Therapy (RECOVERY)	July 30, 2021	Recruiting	3P30CA006516-55S9
clinical_trial	NCT04356937	Efficacy of Tocilizumab on Patients With COVID-19	July 27, 2021	Completed	3UG1CA189828-07S1
clinical_trial	NCT04356937	Efficacy of Tocilizumab on Patients With COVID-19	July 27, 2021	Completed	3P30CA054174-25S2
clinical_trial	NCT04356937	Efficacy of Tocilizumab on Patients With COVID-19	July 27, 2021	Completed	3P30CA013696-45S1
clinical_trial	NCT04356937	Efficacy of Tocilizumab on Patients With COVID-19	July 27, 2021	Completed	3P30CA054174-25S1
clinical_trial	NCT04372186	A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia (EMPACTA)	September 27, 2021	Active, not recruiting	3UG1CA189828-07S1
clinical_trial	NCT04372186	A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia (EMPACTA)	September 27, 2021	Active, not recruiting	3P30CA054174-25S2
clinical_trial	NCT04372186	A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia (EMPACTA)	September 27, 2021	Active, not recruiting	3P30CA013696-45S1
clinical_trial	NCT04372186	A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia (EMPACTA)	September 27, 2021	Active, not recruiting	3P30CA054174-25S1
clinical_trial	NCT04370834	Tocilizumab for Patients With Cancer and COVID-19 Disease	July 20, 2021	Terminated	3UG1CA189828-07S1
clinical_trial	NCT04370834	Tocilizumab for Patients With Cancer and COVID-19 Disease	July 20, 2021	Terminated	3P30CA054174-25S2
clinical_trial	NCT04370834	Tocilizumab for Patients With Cancer and COVID-19 Disease	July 20, 2021	Terminated	3P30CA013696-45S1
clinical_trial	NCT04370834	Tocilizumab for Patients With Cancer and COVID-19 Disease	July 20, 2021	Terminated	3P30CA054174-25S1
clinical_trial	NCT04354701	COVID-19 and Cancer Consortium Registry (CCC19)	September 9, 2021	Recruiting	3UG1CA189828-07S1
clinical_trial	NCT04354701	COVID-19 and Cancer Consortium Registry (CCC19)	September 9, 2021	Recruiting	3P30CA168524-09S3
clinical_trial	NCT04354701	COVID-19 and Cancer Consortium Registry (CCC19)	September 9, 2021	Recruiting	3P30CA054174-25S2
clinical_trial	NCT04354701	COVID-19 and Cancer Consortium Registry (CCC19)	September 9, 2021	Recruiting	3P30CA054174-25S2
clinical_trial	NCT04354701	COVID-19 and Cancer Consortium Registry (CCC19)	September 9, 2021	Recruiting	3P30CA046592-31S8
clinical_trial	NCT04354701	COVID-19 and Cancer Consortium Registry (CCC19)	September 9, 2021	Recruiting	3P30CA016058-44S3
clinical_trial	NCT04354701	COVID-19 and Cancer Consortium Registry (CCC19)	September 9, 2021	Recruiting	3P30CA046592-31S4
clinical_trial	NCT04354701	COVID-19 and Cancer Consortium Registry (CCC19)	September 9, 2021	Recruiting	3P30CA013696-45S1
clinical_trial	NCT04354701	COVID-19 and Cancer Consortium Registry (CCC19)	September 9, 2021	Recruiting	3P30CA013696-45S1
clinical_trial	NCT04354701	COVID-19 and Cancer Consortium Registry (CCC19)	September 9, 2021	Recruiting	3P30CA054174-25S1
clinical_trial	NCT04354701	COVID-19 and Cancer Consortium Registry (CCC19)	September 9, 2021	Recruiting	3P30CA054174-25S1
clinical_trial	NCT04354701	COVID-19 and Cancer Consortium Registry (CCC19)	September 9, 2021	Recruiting	3P30CA177558-08S2
clinical_trial	NCT04354701	COVID-19 and Cancer Consortium Registry (CCC19)	September 9, 2021	Recruiting	3P30CA177558-08S2
clinical_trial	NCT01642251	Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer	February 5, 2019	Completed	3UG1CA189828-07S1
clinical_trial	NCT02289690	Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer	May 14, 2020	Completed	3UG1CA189828-07S1
clinical_trial	NCT01863550	Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma	December 2, 2020	Active, not recruiting	3UG1CA189828-07S1
clinical_trial	NCT00088907	Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer	May 6, 2015	Terminated	3UG1CA189828-07S1
clinical_trial	NCT00309933	Quality of Life in Female Breast Cancer Survivors and Their Spouse, Partner, or Acquaintance	February 3, 2021	Active, not recruiting	3UG1CA189828-07S1
clinical_trial	NCT03765918	Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)	October 11, 2021	Recruiting	3U24CA237719-02S1
clinical_trial	NCT03904862	Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery	September 22, 2021	Recruiting	2UM1CA081457-21
clinical_trial	NCT03904862	Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery	September 22, 2021	Recruiting	2UM1CA081457-21
clinical_trial	NCT03033992	Feasibility Trial of Optune for Children With Recurrent or Progressive Supratentorial High-Grade Glioma and Ependymoma	September 16, 2021	Recruiting	2UM1CA081457-21
clinical_trial	NCT01836549	Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors	July 20, 2018	Terminated	2UM1CA081457-21
clinical_trial	NCT00503724	Enzastaurin in Treating Young Patients With Refractory Primary CNS Tumors	March 6, 2012	Completed	2UM1CA081457-21
clinical_trial	NCT00357253	Capecitabine and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Nonmetastatic Brain Stem Glioma or High-Grade Glioma	January 10, 2013	Completed	2UM1CA081457-21
clinical_trial	NCT00112619	Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors	June 30, 2011	Terminated	2UM1CA081457-21
clinical_trial	NCT01158300	PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors	May 4, 2015	Completed	2UM1CA081457-21
clinical_trial	NCT00572182	MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer	March 6, 2012	Terminated	2UM1CA081457-21
clinical_trial	NCT00021229	Imatinib Mesylate With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed or Recurrent Glioma	July 31, 2014	Terminated	2UM1CA081457-21
clinical_trial	NCT01514201	Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas	August 13, 2019	Completed	2UM1CA081457-21
clinical_trial	NCT00770471	ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme	June 27, 2018	Completed	2UM1CA081457-21
clinical_trial	NCT01964300	Peginterferon Alfa-2b in Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By Surgery	February 24, 2020	Terminated	2UM1CA081457-21
clinical_trial	NCT05071209	Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors	October 8, 2021	Not yet recruiting	5UM1CA228823-03
clinical_trial	NCT04870944	CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma	August 26, 2021	Not yet recruiting	5UM1CA228823-03
clinical_trial	NCT04851119	Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors	September 5, 2021	Not yet recruiting	5UM1CA228823-03
clinical_trial	NCT04158739	Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia	September 9, 2021	Active, not recruiting	5UM1CA228823-03
clinical_trial	NCT04335136	Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19 (APN01-COVID-19)	August 2, 2021	Completed	3P30CA082103-21S9
clinical_trial	NCT04335136	Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19 (APN01-COVID-19)	August 2, 2021	Completed	3P30CA082103-21S6
clinical_trial	NCT03575819	A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)	August 19, 2021	Recruiting	3P30CA082103-21S9
clinical_trial	NCT03575819	A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)	August 19, 2021	Recruiting	3P30CA082103-21S6
clinical_trial	NCT02073994	Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation	August 18, 2021	Active, not recruiting	3P30CA082103-21S9
clinical_trial	NCT02073994	Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation	August 18, 2021	Active, not recruiting	3P30CA082103-21S6
clinical_trial	NCT03343197	Study of AG-120 and AG-881 in Subjects With Low Grade Glioma	August 24, 2021	Active, not recruiting	3P30CA082103-21S9
clinical_trial	NCT03343197	Study of AG-120 and AG-881 in Subjects With Low Grade Glioma	August 24, 2021	Active, not recruiting	3P30CA082103-21S6
clinical_trial	NCT02481154	Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation	August 24, 2021	Active, not recruiting	3P30CA082103-21S9
clinical_trial	NCT02481154	Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation	August 24, 2021	Active, not recruiting	3P30CA082103-21S6
clinical_trial	NCT04164901	Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)	June 25, 2021	Recruiting	3P30CA082103-21S9
clinical_trial	NCT04164901	Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)	June 25, 2021	Recruiting	3P30CA082103-21S6
clinical_trial	NCT02746081	Phase I Study of BAY1436032 in IDH1-mutant Advanced Solid Tumors	September 23, 2021	Active, not recruiting	3P30CA082103-21S9
clinical_trial	NCT02746081	Phase I Study of BAY1436032 in IDH1-mutant Advanced Solid Tumors	September 23, 2021	Active, not recruiting	3P30CA082103-21S6
clinical_trial	NCT02273739	Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation	February 23, 2021	Completed	3P30CA082103-21S9
clinical_trial	NCT02273739	Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation	February 23, 2021	Completed	3P30CA082103-21S6
clinical_trial	NCT03684811	A Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation	March 29, 2021	Active, not recruiting	3P30CA082103-21S9
clinical_trial	NCT03684811	A Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation	March 29, 2021	Active, not recruiting	3P30CA082103-21S6
clinical_trial	NCT04106219	A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma	October 5, 2021	Recruiting	3P30CA082103-21S9
clinical_trial	NCT04106219	A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma	October 5, 2021	Recruiting	3P30CA125123-14S6
clinical_trial	NCT04106219	A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma	October 5, 2021	Recruiting	3P30CA082103-21S6
clinical_trial	NCT02413320	Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer (NeoSTOP)	May 10, 2021	Completed	3P30CA168524-09S3
clinical_trial	NCT03639948	Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer (NeoPACT)	May 3, 2021	Recruiting	3P30CA168524-09S3
clinical_trial	NCT03158896	Evaluation of Umbilical Cord-Derived Wharton's Jelly Stem Cells for the Treatment of Acute Graft Versus Host Disease	April 19, 2021	Recruiting	3P30CA168524-09S3
clinical_trial	NCT03348514	Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors	September 1, 2020	Recruiting	3P30CA168524-09S3
clinical_trial	NCT04608045	Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors	October 30, 2020	Recruiting	3P30CA168524-09S3
clinical_trial	NCT04525131	Safety, Dose Tolerance, Pharmacokinetics, Pharmacodynamics of CPX-POM in Patients With Newly Diagnosed or Recurrent Bladder Tumors	December 19, 2020	Recruiting	3P30CA168524-09S3
clinical_trial	NCT02186821	Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE) (SIGNATURE)	April 8, 2021	Terminated	3P30CA168524-09S3
clinical_trial	NCT00291096	Protocol for Women at Increased Risk of Developing Breast Cancer	December 31, 2020	Recruiting	3P30CA168524-09S3
clinical_trial	NCT02101970	Weight Loss Plus Omega-3 Fatty Acids or Placebo in High Risk Women	February 6, 2019	Completed	3P30CA168524-09S3
clinical_trial	NCT01031953	Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy	May 9, 2017	Terminated	3P30CA069533-22S5
clinical_trial	NCT01913015	Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate Cancer	April 28, 2017	Terminated	3P30CA069533-22S5
clinical_trial	NCT01649505	Fibrin Sealant in Preventing Fluid Build Up During Surgery in Patients Undergoing Breast Reconstruction	March 15, 2013	Terminated	3P30CA069533-22S5
clinical_trial	NCT01005914	Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia	March 4, 2015	Terminated	3P30CA069533-22S5
clinical_trial	NCT00900302	OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer	February 10, 2016	Completed	3P30CA069533-22S5
clinical_trial	NCT00899795	Evaluating Cell Damage in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, or Fanconi Anemia; in Patients Who Were Exposed to Alkylating Agents; and in Healthy Volunteers	December 4, 2017	Completed	3P30CA069533-22S5
clinical_trial	NCT03677531	Video Distraction to Decrease Use of Sedation in Pediatric Participants During Radiation Therapy	May 4, 2020	Completed	3P30CA069533-22S5
clinical_trial	NCT03479268	Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma	July 7, 2021	Recruiting	3P30CA069533-22S5
clinical_trial	NCT03261180	Nestle Impact Advanced Recovery in Improving Surgery Recovery in Patients With Head and Neck Cancer	February 25, 2020	Withdrawn	3P30CA069533-22S5
clinical_trial	NCT00482274	Docetaxel in Treating Patients With Relapsed Prostate Cancer	April 28, 2017	Terminated	3P30CA069533-22S5
clinical_trial	NCT03406013	Internet-Based Exercise and Diet Support in Prostate Cancer Survivors	July 29, 2020	Completed	3P30CA069533-22S5
clinical_trial	NCT03406013	Internet-Based Exercise and Diet Support in Prostate Cancer Survivors	July 29, 2020	Completed	3P30CA069533-22S5
clinical_trial	NCT03630354	EXERCISING TOGETHER for Couples Coping With Cancer	September 24, 2021	Recruiting	3P30CA069533-22S5
clinical_trial	NCT04053673	RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors , FIH, MAD Study	August 26, 2021	Recruiting	3P30CA069533-22S5
clinical_trial	NCT00932126	This Is The First Study Using Escalating Doses Of PF-03758309, An Oral Compound, In Patients With Advanced Solid Tumors	October 28, 2015	Terminated	3P30CA125123-14S6
clinical_trial	NCT03610724	Phase II Open Label Trial to Determine Safety &amp; Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients (BIANCA)	October 12, 2021	Active, not recruiting	3P30CA125123-14S6
clinical_trial	NCT02625480	Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (ZUMA-4)	September 27, 2021	Recruiting	3P30CA125123-14S6
clinical_trial	NCT03743246	A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)	August 27, 2021	Recruiting	3P30CA125123-14S6
clinical_trial	NCT03310619	A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (PLATFORM) (PLATFORM)	May 3, 2021	Recruiting	3P30CA125123-14S6
clinical_trial	NCT03630159	Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients (PORTIA)	September 30, 2021	Completed	3P30CA125123-14S6
clinical_trial	NCT04316624	A Study of C-CAR066 in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy	March 20, 2020	Recruiting	3P30CA125123-14S6
clinical_trial	NCT04169932	The Clinical Study of CD20 CAR-T Cells in Patients With Relapsed and Refractory B Cell Non-Hodgkin Lymphoma	November 20, 2019	Recruiting	3P30CA125123-14S6
clinical_trial	NCT04088864	CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies	May 5, 2021	Recruiting	3P30CA125123-14S6
clinical_trial	NCT03262298	Anti-CD22 CAR-T Cell Therapy Targeting B Cell Malignancies	February 9, 2021	Recruiting	3P30CA125123-14S6
clinical_trial	NCT04186520	CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies	August 12, 2021	Recruiting	3P30CA125123-14S6
clinical_trial	NCT04007029	Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia	August 12, 2021	Recruiting	3P30CA125123-14S6
clinical_trial	NCT04215016	Safety of Autologous Humanized Anti-CD19 and Anti-CD20 Dual Specific CAR-T Cells in Adult Patients With Diffuse Large B-cell Lymphoma (A-02)	January 2, 2020	Recruiting	3P30CA125123-14S6
clinical_trial	NCT03881761	CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma	March 21, 2019	Recruiting	3P30CA125123-14S6
clinical_trial	NCT03097770	Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20	September 2, 2020	Completed	3P30CA125123-14S6
clinical_trial	NCT04204161	A Clinical Study of CAR-T Cells Treatment for Children With CD19+/CD22+ R/R ALL and Lymphoma	February 4, 2021	Recruiting	3P30CA125123-14S6
clinical_trial	NCT03287817	CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma (ALEXANDER)	June 9, 2021	Recruiting	3P30CA125123-14S6
clinical_trial	NCT03774654	CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)	August 16, 2021	Recruiting	3P30CA125123-14S6
clinical_trial	NCT03774654	CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)	August 16, 2021	Recruiting	3P30CA021765-41S3
clinical_trial	NCT01858922	Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A (TXCH-HD-12A)	January 7, 2021	Active, not recruiting	3P30CA125123-14S6
clinical_trial	NCT03064048	Nitric Oxide Supplementation on Neurocognitive Functions in Patients With ASLD	August 19, 2021	Recruiting	3P30CA125123-14S6
clinical_trial	NCT03740256	Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors (VISTA)	July 23, 2021	Recruiting	3P30CA125123-14S6
clinical_trial	NCT00265759	Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer	February 12, 2020	Completed	3P30CA125123-14S6
clinical_trial	NCT01059071	Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide	November 18, 2020	Completed	3P30CA125123-14S6
clinical_trial	NCT02395666	Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission	November 18, 2020	Active, not recruiting	3P30CA125123-14S6
clinical_trial	NCT03536728	Oral AMXT 1501 Dicaprate in Combination With DFMO	May 13, 2020	Recruiting	3P30CA125123-14S6
clinical_trial	NCT00567229	Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma	November 20, 2015	Terminated	3P30CA008748-54S3
clinical_trial	NCT00550628	Fludeoxyglucose F 18 PET Imaging in Determining Protein and Gene Expression Signatures in Patients With Premalignant Polyps or Colon Cancer	December 23, 2015	Completed	3P30CA008748-54S3
clinical_trial	NCT00541034	Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia	August 11, 2017	Completed	3P30CA008748-54S3
clinical_trial	NCT00519974	Factors Affecting Decisions About Breast Reconstruction After Mastectomy in Black and Latina Women	October 1, 2015	Completed	3P30CA008748-54S3
clinical_trial	NCT00514254	Risk Factors for Endometrial Cancer in Black Women	August 10, 2021	Active, not recruiting	3P30CA008748-54S3
clinical_trial	NCT00483678	Couples Therapy to Enhance Intimacy Between Patients With Advanced or Recurrent Prostate Cancer and Their Partners	March 6, 2018	Completed	3P30CA008748-54S3
clinical_trial	NCT00471679	Ethanol-Lock Treatment in Preventing Central Venous Catheter Infections in Patients With High-Risk Neuroblastoma	March 5, 2013	Completed	3P30CA008748-54S3
clinical_trial	NCT00471601	Development of a Questionnaire to Evaluate Patient Expectations for Breast Reconstruction in Women With Breast Cancer or Other Conditions	October 4, 2021	Active, not recruiting	3P30CA008748-54S3
clinical_trial	NCT00470574	Vaccine Therapy and QS21 in Treating Patients With Metastatic Breast Cancer	November 18, 2020	Completed	3P30CA008748-54S3
clinical_trial	NCT00462982	Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma	December 30, 2015	Completed	3P30CA008748-54S3
clinical_trial	NCT02684032	A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer	September 27, 2021	Active, not recruiting	3P30CA008748-54S3
clinical_trial	NCT03535701	Ketogenic Diet and Chemotherapy in Affecting Recurrence in Patients With Stage IV Breast Cancer (KETO-CARE)	September 8, 2021	Completed	3P30CA008748-54S3
clinical_trial	NCT02399085	A Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL (L-MIND)	September 29, 2021	Active, not recruiting	3P30CA008748-54S3
clinical_trial	NCT04150328	Lenalidomide Monotherapy in R/R DLBCL (RE-MIND)	September 16, 2020	Completed	3P30CA008748-54S3
clinical_trial	NCT04697160	Observational Retrospective Cohort Study of Systemic Therapies for R/R DLBCL (RE-MIND2)	January 6, 2021	Active, not recruiting	3P30CA008748-54S3
clinical_trial	NCT02763319	A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) (B-MIND)	June 10, 2021	Active, not recruiting	3P30CA008748-54S3
clinical_trial	NCT00425802	Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia	October 31, 2017	Completed	3P30CA008748-54S3
clinical_trial	NCT00387959	Chemotherapy, Radiation Therapy, Rituximab, and Umbilical Cord Blood Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma	February 1, 2016	Completed	3P30CA008748-54S3
clinical_trial	NCT00739141	Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies.	September 2, 2021	Active, not recruiting	3P30CA008748-54S3
clinical_trial	NCT01027000	Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	August 18, 2021	Active, not recruiting	3P30CA008748-54S3
clinical_trial	NCT04556266	A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for the Treatment of CD19 Malignancies	September 1, 2021	Recruiting	3P30CA008748-54S3
clinical_trial	NCT03013491	PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas	August 5, 2021	Active, not recruiting	3P30CA008748-54S3
clinical_trial	NCT03013491	PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas	August 5, 2021	Active, not recruiting	3P30CA008748-54S3
clinical_trial	NCT01775072	Genomic Profiling in Cancer Patients	July 2, 2021	Recruiting	3P30CA008748-54S3
clinical_trial	NCT03371420	PET Imaging of Subjects Using 124I-PU-AD	June 11, 2019	Completed	3P30CA008748-54S3
clinical_trial	NCT03935568	A Single and Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of PU-AD in Healthy Subjects	December 26, 2019	Completed	3P30CA008748-54S3
clinical_trial	NCT04311515	To Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild AD Dementia	October 12, 2020	Active, not recruiting	3P30CA008748-54S3
clinical_trial	NCT04505358	Evaluate PU-AD in Subjects With Amyotrophic Lateral Sclerosis (ALS)	September 22, 2021	Not yet recruiting	3P30CA008748-54S3
clinical_trial	NCT04782609	Study of Icapamespib (PU-AD) in Patients With Recurrent Malignant Glioma (Glio)	September 22, 2021	Not yet recruiting	3P30CA008748-54S3
clinical_trial	NCT01269593	PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study	November 20, 2020	Active, not recruiting	3P30CA008748-54S3
clinical_trial	NCT01888601	TRAcking Non-small Cell Lung Cancer Evolution Through Therapy (Rx) (TRACERx)	January 27, 2020	Recruiting	3P30CA008748-54S3
clinical_trial	NCT02201992	Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)	May 21, 2020	Recruiting	3P30CA008748-54S3
clinical_trial	NCT02193282	Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)	September 28, 2021	Active, not recruiting	3P30CA008748-54S3
clinical_trial	NCT03456076	A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer	September 20, 2021	Recruiting	3P30CA008748-54S3
clinical_trial	NCT04385368	Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC) (MERMAID-1)	September 10, 2021	Recruiting	3P30CA008748-54S3
clinical_trial	NCT04642469	Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy. (MERMAID-2)	September 10, 2021	Recruiting	3P30CA008748-54S3
clinical_trial	NCT04351555	A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer (NeoADAURA)	October 7, 2021	Recruiting	3P30CA008748-54S3
clinical_trial	NCT04712877	Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung Cancers	March 4, 2021	Not yet recruiting	3P30CA008748-54S3
clinical_trial	NCT02194738	Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)	October 14, 2021	Recruiting	3P30CA008748-54S3
clinical_trial	NCT01865747	A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma (METEOR)	April 27, 2021	Completed	3P30CA008748-54S3
clinical_trial	NCT00562640	Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009)	August 6, 2021	Completed	3P30CA008748-54S3
clinical_trial	NCT02550535	A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS &amp; AML Patients	October 2, 2018	Completed	3P30CA008748-54S3
clinical_trial	NCT02408016	Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma	September 13, 2021	Terminated	3P30CA008748-54S3
clinical_trial	NCT03130569	Skin Health Online for Melanoma: Better Risk Assessment (SOMBRA)	October 6, 2017	Completed	3P30CA008748-54S3
clinical_trial	NCT01458548	Sequential Treatment of CD20-positive Posttransplant Lymphoproliferative Disorder (PTLD)	October 25, 2011	Terminated	3P30CA008748-54S3
clinical_trial	NCT00066469	Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation	August 6, 2019	Completed	3P30CA008748-54S3
clinical_trial	NCT01058239	Bortezomib Plus Rituximab for EBV+ PTLD	February 15, 2018	Completed	3P30CA008748-54S3
clinical_trial	NCT02753062	Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell Lymphoma (PTLD)	April 27, 2016	Recruiting	3P30CA008748-54S3
clinical_trial	NCT02973113	Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE) (PREVALE)	July 21, 2021	Completed	3P30CA008748-54S3
clinical_trial	NCT01805037	Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas	September 1, 2021	Terminated	3P30CA008748-54S3
clinical_trial	NCT01075321	Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma	October 22, 2020	Completed	3P30CA008748-54S3
clinical_trial	NCT00918333	Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma	March 10, 2020	Completed	3P30CA008748-54S3
clinical_trial	NCT03397706	Dose Escalation &amp; Expansion Study of Oral VRx-3996 &amp; Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies	July 28, 2021	Recruiting	3P30CA008748-54S3
clinical_trial	NCT03397706	Dose Escalation &amp; Expansion Study of Oral VRx-3996 &amp; Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies	July 28, 2021	Recruiting	3P30CA016520-44S5
clinical_trial	NCT03397706	Dose Escalation &amp; Expansion Study of Oral VRx-3996 &amp; Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies	July 28, 2021	Recruiting	3P30CA016520-44S6
clinical_trial	NCT01261247	Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma	October 20, 2020	Active, not recruiting	3P30CA008748-54S3
clinical_trial	NCT03394365	Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)	September 27, 2021	Recruiting	3P30CA008748-54S3
clinical_trial	NCT03394365	Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)	September 27, 2021	Recruiting	3P30CA016520-44S5
clinical_trial	NCT03394365	Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)	September 27, 2021	Recruiting	3P30CA016520-44S6
clinical_trial	NCT03131934	Immunotherapy With Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease After Solid Organ Transplant (ITREC)	March 31, 2020	Recruiting	3P30CA008748-54S3
clinical_trial	NCT02779439	Partially HLA-matched Third Party Antigen Specific T-cells for Infection Post-stem Cell or Solid Organ Transplantation (R3ACT)	July 21, 2016	Unknown	3P30CA008748-54S3
clinical_trial	NCT02900976	Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder	April 30, 2021	Active, not recruiting	3P30CA008748-54S3
clinical_trial	NCT02822495	Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies	September 30, 2020	Available	3P30CA008748-54S3
clinical_trial	NCT01774071	Study of 89Zr-DFO-MSTP2109A in Patients With Prostate Cancer	February 4, 2021	Active, not recruiting	3P30CA008748-54S3
clinical_trial	NCT03451383	Older Breast Cancer Patients: Risk for Cognitive Decline (TLC)	July 30, 2021	Recruiting	3P30CA008748-54S3
clinical_trial	NCT00933517	Assessment of the Efficacy of the Neoadjuvant Combination: &quot;Chemotherapy-Targeted Therapy&quot; in Breast Cancer. (TVA)	March 21, 2014	Completed	3P30CA008748-54S3
clinical_trial	NCT00600249	Assessment of the Efficacy of a Neoadjuvant Combination: &quot;Chemotherapy-targeted Therapy&quot; in Breast Cancer.	March 20, 2014	Completed	3P30CA008748-54S3
clinical_trial	NCT04258280	Improving Genetic Counseling for BRCA+ Mothers (PCS IV)	October 28, 2020	Recruiting	3P30CA008748-54S3
clinical_trial	NCT04248257	Peer Support For Young Adult Women With High Breast Cancer Risk	August 17, 2021	Recruiting	3P30CA008748-54S3
clinical_trial	NCT02494206	Immunotherapy for the Treatment of Breast Cancer Related Upper Extremity Lymphedema (BCRL)	November 8, 2018	Completed	3P30CA008748-54S3
clinical_trial	NCT02851407	Study Comparing Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients	October 22, 2020	Completed	3P30CA008748-54S3
clinical_trial	NCT03339297	An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD)	August 18, 2021	Completed	3P30CA008748-54S3
clinical_trial	NCT03954106	A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity	May 27, 2021	Terminated	3P30CA008748-54S3
clinical_trial	NCT03805581	Defibrotide in Sickle Cell Disease-Related Acute Chest Syndrome	February 21, 2021	Active, not recruiting	3P30CA008748-54S3
clinical_trial	NCT01418495	Pharmacokinetics of Ch14.18 in Younger Patients With High-Risk Neuroblastoma	October 1, 2019	Completed	3P30CA016520-44S5
clinical_trial	NCT01418495	Pharmacokinetics of Ch14.18 in Younger Patients With High-Risk Neuroblastoma	October 1, 2019	Completed	3P30CA016520-44S6
clinical_trial	NCT00679094	Bowman-Birk Inhibitor Concentrate in Healthy Men	December 29, 2016	Completed	3P30CA016520-44S5
clinical_trial	NCT00679094	Bowman-Birk Inhibitor Concentrate in Healthy Men	December 29, 2016	Completed	3P30CA016520-44S6
clinical_trial	NCT04464759	A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma (LIMIT)	September 16, 2021	Recruiting	3P30CA016520-44S5
clinical_trial	NCT04058470	Toripalimab in Combination With R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma	March 15, 2021	Recruiting	3P30CA016520-44S5
clinical_trial	NCT04058470	Toripalimab in Combination With R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma	March 15, 2021	Recruiting	3P30CA016520-44S6
clinical_trial	NCT04181489	Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOS	November 29, 2019	Recruiting	3P30CA016520-44S5
clinical_trial	NCT04181489	Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOS	November 29, 2019	Recruiting	3P30CA016520-44S6
clinical_trial	NCT04084626	PD1 Antibody and Lenalidomide as a Treatment for EBV-HLH or CAEBV	June 30, 2021	Recruiting	3P30CA016520-44S5
clinical_trial	NCT04084626	PD1 Antibody and Lenalidomide as a Treatment for EBV-HLH or CAEBV	June 30, 2021	Recruiting	3P30CA016520-44S6
clinical_trial	NCT03586024	Pembrolizumab in Relapsed or Refractory Extranodal NK/T- Cell Lymphoma, Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas	May 7, 2021	Withdrawn	3P30CA016520-44S5
clinical_trial	NCT03586024	Pembrolizumab in Relapsed or Refractory Extranodal NK/T- Cell Lymphoma, Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas	May 7, 2021	Withdrawn	3P30CA016520-44S6
clinical_trial	NCT03258567	Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas	September 22, 2021	Recruiting	3P30CA016520-44S5
clinical_trial	NCT03258567	Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas	September 22, 2021	Recruiting	3P30CA016520-44S6
clinical_trial	NCT03038672	Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas	September 17, 2021	Recruiting	3P30CA016520-44S5
clinical_trial	NCT03038672	Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas	September 17, 2021	Recruiting	3P30CA016520-44S6
clinical_trial	NCT04156217	EBV-TCR-T Cells for EB Virus Infection After HSCT	August 13, 2020	Recruiting	3P30CA016520-44S5
clinical_trial	NCT04156217	EBV-TCR-T Cells for EB Virus Infection After HSCT	August 13, 2020	Recruiting	3P30CA016520-44S6
clinical_trial	NCT03789617	Clinical Trial to Evaluate the Efficacy and Safety of Epstein-Barr Virus Induced Natural T Lymphocyte(EBViNT) Cell in Patients With Progressive EBV Positive Extranodal NK/T-cell Lymphoma Where Standard Treatments Have Failed	May 18, 2021	Recruiting	3P30CA016520-44S5
clinical_trial	NCT03789617	Clinical Trial to Evaluate the Efficacy and Safety of Epstein-Barr Virus Induced Natural T Lymphocyte(EBViNT) Cell in Patients With Progressive EBV Positive Extranodal NK/T-cell Lymphoma Where Standard Treatments Have Failed	May 18, 2021	Recruiting	3P30CA016520-44S6
clinical_trial	NCT03671850	VT-EBV-N for Treatment of Severe in EBV Positive Extranodal NK/T Cell Lymphoma Patients	November 6, 2019	Recruiting	3P30CA016520-44S5
clinical_trial	NCT03671850	VT-EBV-N for Treatment of Severe in EBV Positive Extranodal NK/T Cell Lymphoma Patients	November 6, 2019	Recruiting	3P30CA016520-44S6
clinical_trial	NCT03392142	Tabelecleucel for Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab (MATCH)	March 26, 2021	Completed	3P30CA016520-44S5
clinical_trial	NCT03392142	Tabelecleucel for Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab (MATCH)	March 26, 2021	Completed	3P30CA016520-44S6
clinical_trial	NCT03044743	PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies	May 2, 2017	Recruiting	3P30CA016520-44S5
clinical_trial	NCT03044743	PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies	May 2, 2017	Recruiting	3P30CA016520-44S6
clinical_trial	NCT01956084	Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma (ALCI2)	February 24, 2021	Active, not recruiting	3P30CA016520-44S5
clinical_trial	NCT01956084	Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma (ALCI2)	February 24, 2021	Active, not recruiting	3P30CA016520-44S6
clinical_trial	NCT02924402	Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies	March 25, 2021	Recruiting	3P30CA016520-44S5
clinical_trial	NCT02924402	Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies	March 25, 2021	Recruiting	3P30CA016520-44S6
clinical_trial	NCT02670616	Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma	October 22, 2020	Completed	3P30CA016520-44S5
clinical_trial	NCT02670616	Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma	October 22, 2020	Completed	3P30CA016520-44S6
clinical_trial	NCT04220775	Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer	May 8, 2020	Recruiting	3P30CA016520-44S5
clinical_trial	NCT04220775	Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer	May 8, 2020	Recruiting	3P30CA016520-44S6
clinical_trial	NCT03083288	Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Breast Cancer	May 14, 2021	Active, not recruiting	3P30CA016520-44S5
clinical_trial	NCT03083288	Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Breast Cancer	May 14, 2021	Active, not recruiting	3P30CA016520-44S6
clinical_trial	NCT03846167	Imaging of Primary or Recurrent Breast Cancer With 18F-FluorThanatrace PET/CT (FTT 2)	August 6, 2021	Recruiting	3P30CA016520-44S5
clinical_trial	NCT03846167	Imaging of Primary or Recurrent Breast Cancer With 18F-FluorThanatrace PET/CT (FTT 2)	August 6, 2021	Recruiting	3P30CA016520-44S6
clinical_trial	NCT02651246	Optional Sub-study to Intraoperative Imaging With ICG Registry	June 24, 2021	Completed	3P30CA016520-44S5
clinical_trial	NCT02651246	Optional Sub-study to Intraoperative Imaging With ICG Registry	June 24, 2021	Completed	3P30CA016520-44S6
clinical_trial	NCT01873833	Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer	August 26, 2021	Terminated	3P30CA014089-45S6
clinical_trial	NCT04981834	Robot-Assisted Radical Prostatectomy With or Without Vesicopexy in Patients With Prostate Cancer	July 29, 2021	Not yet recruiting	3P30CA014089-45S6
clinical_trial	NCT04941430	7T MRI Scan for the Early Detection of Melanoma Brain Metastases	June 28, 2021	Not yet recruiting	3P30CA014089-45S6
clinical_trial	NCT04927559	Health Literacy in Understanding Radiation Therapy Information in Patients Undergoing Definitive Radiation Therapy	June 16, 2021	Recruiting	3P30CA014089-45S6
clinical_trial	NCT04832763	Medical and Psychosocial Issues in Adolescents and Young Adults With Colorectal Cancer	April 6, 2021	Recruiting	3P30CA014089-45S6
clinical_trial	NCT04830735	Dasatinib for the Treatment of Moderate and Severe COVID-19	June 10, 2021	Not yet recruiting	3P30CA014089-45S6
clinical_trial	NCT04752267	18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases	March 17, 2021	Recruiting	3P30CA014089-45S6
clinical_trial	NCT04387084	Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy	April 5, 2021	Recruiting	3P30CA014089-45S6
clinical_trial	NCT04387071	CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma	April 5, 2021	Not yet recruiting	3P30CA014089-45S6
clinical_trial	NCT04373044	Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19	May 26, 2021	Terminated	3P30CA014089-45S6
clinical_trial	NCT02189486	Prostate Cancer Upgrading Reference Set	June 30, 2021	Recruiting	3P30CA054174-25S2
clinical_trial	NCT02189486	Prostate Cancer Upgrading Reference Set	June 30, 2021	Recruiting	3P30CA054174-25S1
clinical_trial	NCT00055822	Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer	July 4, 2012	Completed	3P30CA054174-25S2
clinical_trial	NCT00055822	Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer	July 4, 2012	Completed	3P30CA054174-25S1
clinical_trial	NCT00003709	Chemotherapy in Treating Patients With Advanced Solid Tumors	August 9, 2012	Completed	3P30CA054174-25S2
clinical_trial	NCT00003709	Chemotherapy in Treating Patients With Advanced Solid Tumors	August 9, 2012	Completed	3P30CA054174-25S1
clinical_trial	NCT00003760	Irofulvene in Treating Patients With Stage III or Stage IV Pancreatic Cancer	August 9, 2012	Completed	3P30CA054174-25S2
clinical_trial	NCT00003760	Irofulvene in Treating Patients With Stage III or Stage IV Pancreatic Cancer	August 9, 2012	Completed	3P30CA054174-25S1
clinical_trial	NCT00003708	Chemotherapy in Treating Patients With Advanced Solid Tumors	August 9, 2012	Completed	3P30CA054174-25S2
clinical_trial	NCT00003708	Chemotherapy in Treating Patients With Advanced Solid Tumors	August 9, 2012	Completed	3P30CA054174-25S1
clinical_trial	NCT00003710	Irinotecan Plus Mitomycin in Treating Patients With Advanced Solid Tumors	August 9, 2012	Completed	3P30CA054174-25S2
clinical_trial	NCT00003710	Irinotecan Plus Mitomycin in Treating Patients With Advanced Solid Tumors	August 9, 2012	Completed	3P30CA054174-25S1
clinical_trial	NCT00003706	LY231514 in Treating Patients With Locally Advanced or Metastatic Solid Tumors and Varying Degrees of Kidney Function	June 28, 2012	Completed	3P30CA054174-25S2
clinical_trial	NCT00003706	LY231514 in Treating Patients With Locally Advanced or Metastatic Solid Tumors and Varying Degrees of Kidney Function	June 28, 2012	Completed	3P30CA054174-25S1
clinical_trial	NCT00003712	CCI-779 in Treating Patients With Advanced Solid Tumors	August 9, 2012	Completed	3P30CA054174-25S2
clinical_trial	NCT00003712	CCI-779 in Treating Patients With Advanced Solid Tumors	August 9, 2012	Completed	3P30CA054174-25S1
clinical_trial	NCT00003707	Combination Chemotherapy in Treating Patients With Advanced Cancer	June 28, 2012	Completed	3P30CA054174-25S2
clinical_trial	NCT00003707	Combination Chemotherapy in Treating Patients With Advanced Cancer	June 28, 2012	Completed	3P30CA054174-25S1
clinical_trial	NCT00003721	Chemotherapy in Treating Patients With Advanced Solid Tumors	June 29, 2012	Completed	3P30CA054174-25S2
clinical_trial	NCT00003721	Chemotherapy in Treating Patients With Advanced Solid Tumors	June 29, 2012	Completed	3P30CA054174-25S1
clinical_trial	NCT03160274	Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions	August 26, 2021	Recruiting	3P30CA054174-25S2
clinical_trial	NCT03160274	Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions	August 26, 2021	Recruiting	3P30CA054174-25S1
clinical_trial	NCT01043575	High Dose Rifapentine Pharmacokinetics, Tolerability and Safety Dosage Rifapentine for Treatment of Tuberculosis (TBTC-29PK)	August 17, 2012	Completed	3P30CA054174-25S2
clinical_trial	NCT01043575	High Dose Rifapentine Pharmacokinetics, Tolerability and Safety Dosage Rifapentine for Treatment of Tuberculosis (TBTC-29PK)	August 17, 2012	Completed	3P30CA054174-25S1
clinical_trial	NCT02342379	TH-302 in Combination With Bevacizumab for Glioblastoma	April 10, 2020	Completed	3P30CA054174-25S2
clinical_trial	NCT02342379	TH-302 in Combination With Bevacizumab for Glioblastoma	April 10, 2020	Completed	3P30CA054174-25S2
clinical_trial	NCT02342379	TH-302 in Combination With Bevacizumab for Glioblastoma	April 10, 2020	Completed	3P30CA054174-25S1
clinical_trial	NCT02342379	TH-302 in Combination With Bevacizumab for Glioblastoma	April 10, 2020	Completed	3P30CA054174-25S1
clinical_trial	NCT01434316	Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors	July 20, 2021	Recruiting	3P30CA054174-25S2
clinical_trial	NCT01434316	Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors	July 20, 2021	Recruiting	3P30CA054174-25S1
clinical_trial	NCT02753309	A Study of Rapamycin Combined With Intravesical BCG in Patients With Non-muscle Invasive Bladder Cancer	March 19, 2021	Completed	3P30CA054174-25S2
clinical_trial	NCT02753309	A Study of Rapamycin Combined With Intravesical BCG in Patients With Non-muscle Invasive Bladder Cancer	March 19, 2021	Completed	3P30CA054174-25S1
clinical_trial	NCT04375813	Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention	July 21, 2021	Recruiting	3P30CA054174-25S2
clinical_trial	NCT04375813	Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention	July 21, 2021	Recruiting	3P30CA054174-25S1
clinical_trial	NCT04444674	COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infection	November 27, 2020	Active, not recruiting	3P30CA054174-25S2
clinical_trial	NCT04444674	COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infection	November 27, 2020	Active, not recruiting	3P30CA046592-31S8
clinical_trial	NCT04444674	COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infection	November 27, 2020	Active, not recruiting	3P30CA046592-31S4
clinical_trial	NCT04444674	COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infection	November 27, 2020	Active, not recruiting	3P30CA054174-25S1
clinical_trial	NCT01971515	First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies	September 19, 2018	Completed	3P30CA054174-25S2
clinical_trial	NCT01971515	First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies	September 19, 2018	Completed	3P30CA054174-25S1
clinical_trial	NCT02298998	Surveillance for Low and Low-Intermediate Risk Non-muscle Invasive Bladder Cancer: A Pilot Study	June 14, 2021	Completed	3P30CA054174-25S2
clinical_trial	NCT02298998	Surveillance for Low and Low-Intermediate Risk Non-muscle Invasive Bladder Cancer: A Pilot Study	June 14, 2021	Completed	3P30CA054174-25S1
clinical_trial	NCT00064272	UMCCOP 02-01 Ginger in Treating Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer (IRB 2003-551)	October 21, 2016	Completed	3P30CA046592-31S8
clinical_trial	NCT00064272	UMCCOP 02-01 Ginger in Treating Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer (IRB 2003-551)	October 21, 2016	Completed	3P30CA046592-31S4
clinical_trial	NCT00098969	UMCC 2003-064 Resveratrol in Preventing Cancer in Healthy Participants (IRB 2004-535)	December 17, 2012	Completed	3P30CA046592-31S8
clinical_trial	NCT00098969	UMCC 2003-064 Resveratrol in Preventing Cancer in Healthy Participants (IRB 2004-535)	December 17, 2012	Completed	3P30CA046592-31S4
clinical_trial	NCT00967824	Tamoxifen Citrate Decision Aids for Women at Increased Risk of Breast Cancer	March 24, 2011	Completed	3P30CA046592-31S8
clinical_trial	NCT00967824	Tamoxifen Citrate Decision Aids for Women at Increased Risk of Breast Cancer	March 24, 2011	Completed	3P30CA046592-31S4
clinical_trial	NCT00955188	Computer-Based Tailored or Standard Information for Colorectal Cancer Screening	December 21, 2012	Completed	3P30CA046592-31S8
clinical_trial	NCT00955188	Computer-Based Tailored or Standard Information for Colorectal Cancer Screening	December 21, 2012	Completed	3P30CA046592-31S4
clinical_trial	NCT00900094	UMCC 003 Cancer-Related Protein Biomarkers in Blood and Tumor Tissue of Patients With Cancer (IRB 2000-294)	February 7, 2012	Completed	3P30CA046592-31S8
clinical_trial	NCT00900094	UMCC 003 Cancer-Related Protein Biomarkers in Blood and Tumor Tissue of Patients With Cancer (IRB 2000-294)	February 7, 2012	Completed	3P30CA046592-31S4
clinical_trial	NCT00003076	Eflornithine to Prevent Cancer in Patients With Barrett's Esophagus	December 19, 2012	Completed	3P30CA046592-31S8
clinical_trial	NCT00003076	Eflornithine to Prevent Cancer in Patients With Barrett's Esophagus	December 19, 2012	Completed	3P30CA046592-31S4
clinical_trial	NCT00005598	Azacitidine Plus Amifostine in Treating Patients With Myelodysplastic Syndrome	December 21, 2012	Completed	3P30CA046592-31S8
clinical_trial	NCT00005598	Azacitidine Plus Amifostine in Treating Patients With Myelodysplastic Syndrome	December 21, 2012	Completed	3P30CA046592-31S4
clinical_trial	NCT00003598	UMCC 9609 Tretinoin in Preventing Cancer of the Cervix in Patients With Cervical Neoplasia (IRB 1996-0189)	September 22, 2010	Completed	3P30CA046592-31S8
clinical_trial	NCT00003598	UMCC 9609 Tretinoin in Preventing Cancer of the Cervix in Patients With Cervical Neoplasia (IRB 1996-0189)	September 22, 2010	Completed	3P30CA046592-31S4
clinical_trial	NCT00027495	Curcumin for the Prevention of Colon Cancer	December 21, 2012	Completed	3P30CA046592-31S8
clinical_trial	NCT00027495	Curcumin for the Prevention of Colon Cancer	December 21, 2012	Completed	3P30CA046592-31S4
clinical_trial	NCT02007200	Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery	October 24, 2016	Completed	3P30CA046592-31S8
clinical_trial	NCT02007200	Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery	October 24, 2016	Completed	3P30CA046592-31S4
clinical_trial	NCT01860352	Effects of Fish Oil on the Colon Mucosa	March 1, 2017	Completed	3P30CA046592-31S8
clinical_trial	NCT01860352	Effects of Fish Oil on the Colon Mucosa	March 1, 2017	Completed	3P30CA046592-31S4
clinical_trial	NCT03330847	To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.	September 9, 2021	Active, not recruiting	3P30CA046592-31S8
clinical_trial	NCT03330847	To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.	September 9, 2021	Active, not recruiting	3P30CA046592-31S4
clinical_trial	NCT02576444	OLAParib COmbinations (OLAPCO)	September 16, 2021	Active, not recruiting	3P30CA046592-31S8
clinical_trial	NCT02576444	OLAParib COmbinations (OLAPCO)	September 16, 2021	Active, not recruiting	3P30CA046592-31S4
clinical_trial	NCT01196936	Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors (LDTam)	April 29, 2021	Active, not recruiting	3P30CA046592-31S8
clinical_trial	NCT01196936	Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors (LDTam)	April 29, 2021	Active, not recruiting	3P30CA046592-31S4
clinical_trial	NCT04456049	Randomized Open Label Phase II Study to Evaluate the Efficacy of Enzalutamide in High Risk Male Outpatients With COVID-19	July 2, 2020	Not yet recruiting	3P30CA046592-31S8
clinical_trial	NCT04456049	Randomized Open Label Phase II Study to Evaluate the Efficacy of Enzalutamide in High Risk Male Outpatients With COVID-19	July 2, 2020	Not yet recruiting	3P30CA046592-31S4
clinical_trial	NCT04475601	Enzalutamide Treatment in COVID-19 (COVIDENZA)	August 26, 2021	Terminated	3P30CA046592-31S8
clinical_trial	NCT04475601	Enzalutamide Treatment in COVID-19 (COVIDENZA)	August 26, 2021	Terminated	3P30CA046592-31S4
clinical_trial	NCT04509999	Bicalutamide to Block TMPRSS2 in Males With COVID-19 Infection	July 1, 2021	Withdrawn	3P30CA046592-31S8
clinical_trial	NCT04509999	Bicalutamide to Block TMPRSS2 in Males With COVID-19 Infection	July 1, 2021	Withdrawn	3P30CA046592-31S4
clinical_trial	NCT04374279	Trial to Promote Recovery From COVID-19 With Endocrine Therapy (RECOVER)	March 5, 2021	Withdrawn	3P30CA046592-31S8
clinical_trial	NCT04374279	Trial to Promote Recovery From COVID-19 With Endocrine Therapy (RECOVER)	March 5, 2021	Withdrawn	3P30CA046592-31S4
clinical_trial	NCT04397718	Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization (HITCH)	July 2, 2021	Completed	3P30CA046592-31S8
clinical_trial	NCT04397718	Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization (HITCH)	July 2, 2021	Completed	3P30CA046592-31S4
clinical_trial	NCT04446429	Anti-Androgen Treatment for COVID-19	June 16, 2021	Completed	3P30CA046592-31S8
clinical_trial	NCT04446429	Anti-Androgen Treatment for COVID-19	June 16, 2021	Completed	3P30CA046592-31S4
clinical_trial	NCT04353284	Camostat Mesylate in COVID-19 Outpatients	October 8, 2021	Completed	3P30CA046592-31S8
clinical_trial	NCT04353284	Camostat Mesylate in COVID-19 Outpatients	October 8, 2021	Completed	3P30CA046592-31S4
clinical_trial	NCT04524663	Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 Patients (COPS-2003)	June 11, 2021	Completed	3P30CA046592-31S8
clinical_trial	NCT04524663	Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 Patients (COPS-2003)	June 11, 2021	Completed	3P30CA046592-31S4
clinical_trial	NCT04470544	Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19 (RECOVER)	January 11, 2021	Recruiting	3P30CA046592-31S8
clinical_trial	NCT04470544	Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19 (RECOVER)	January 11, 2021	Recruiting	3P30CA046592-31S4
clinical_trial	NCT04352400	Efficacy of Nafamostat in Covid-19 Patients (RACONA Study) (RACONA)	June 9, 2021	Recruiting	3P30CA046592-31S8
clinical_trial	NCT04352400	Efficacy of Nafamostat in Covid-19 Patients (RACONA Study) (RACONA)	June 9, 2021	Recruiting	3P30CA046592-31S4
clinical_trial	NCT04418128	Clinical Efficacy of Nafamostat Mesylate for COVID-19 Pneumonia	June 9, 2020	Not yet recruiting	3P30CA046592-31S8
clinical_trial	NCT04418128	Clinical Efficacy of Nafamostat Mesylate for COVID-19 Pneumonia	June 9, 2020	Not yet recruiting	3P30CA046592-31S4
clinical_trial	NCT04390594	Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal (SEN-CoV-Fadj)	September 7, 2020	Recruiting	3P30CA046592-31S8
clinical_trial	NCT04390594	Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal (SEN-CoV-Fadj)	September 7, 2020	Recruiting	3P30CA046592-31S4
clinical_trial	NCT04473053	DEFINE - Evaluating Therapies for COVID-19 (DEFINE)	September 16, 2021	Active, not recruiting	3P30CA046592-31S8
clinical_trial	NCT04473053	DEFINE - Evaluating Therapies for COVID-19 (DEFINE)	September 16, 2021	Active, not recruiting	3P30CA046592-31S4
clinical_trial	NCT04424134	BromhexIne And Spironolactone For Coron&#1072;VirUs Infection Requiring HospiTalization (BISCUIT)	June 9, 2020	Recruiting	3P30CA046592-31S8
clinical_trial	NCT04424134	BromhexIne And Spironolactone For Coron&#1072;VirUs Infection Requiring HospiTalization (BISCUIT)	June 9, 2020	Recruiting	3P30CA046592-31S4
clinical_trial	NCT04355026	Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia	April 21, 2020	Recruiting	3P30CA046592-31S8
clinical_trial	NCT04355026	Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia	April 21, 2020	Recruiting	3P30CA046592-31S4
clinical_trial	NCT04273763	Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)	May 1, 2020	Active, not recruiting	3P30CA046592-31S8
clinical_trial	NCT04273763	Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)	May 1, 2020	Active, not recruiting	3P30CA046592-31S4
clinical_trial	NCT04340349	Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals (ELEVATE)	June 29, 2021	Enrolling by invitation	3P30CA046592-31S8
clinical_trial	NCT04340349	Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals (ELEVATE)	June 29, 2021	Enrolling by invitation	3P30CA046592-31S4
clinical_trial	NCT04405999	Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease	September 3, 2020	Completed	3P30CA046592-31S8
clinical_trial	NCT04405999	Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease	September 3, 2020	Completed	3P30CA046592-31S4
clinical_trial	NCT04426695	Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19	August 26, 2021	Completed	3P30CA046592-31S8
clinical_trial	NCT04426695	Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19	August 26, 2021	Completed	3P30CA046592-31S4
clinical_trial	NCT04425629	Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19	October 8, 2021	Recruiting	3P30CA046592-31S8
clinical_trial	NCT04425629	Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19	October 8, 2021	Recruiting	3P30CA046592-31S4
clinical_trial	NCT04592549	Study of Monoclonal Antibody Cocktail Being Tested for the Prevention of COVID-19	September 24, 2021	Recruiting	3P30CA046592-31S8
clinical_trial	NCT04592549	Study of Monoclonal Antibody Cocktail Being Tested for the Prevention of COVID-19	September 24, 2021	Recruiting	3P30CA046592-31S4
clinical_trial	NCT00603057	Using Imaging and Molecular Markers to Predict Tumor Response and Lung Toxicity in Lung Cancer	October 14, 2019	Completed	3P30CA046592-31S8
clinical_trial	NCT00603057	Using Imaging and Molecular Markers to Predict Tumor Response and Lung Toxicity in Lung Cancer	October 14, 2019	Completed	3P30CA046592-31S4
clinical_trial	NCT01750190	A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving Dialysis	October 1, 2021	Completed	3P30CA046592-31S8
clinical_trial	NCT01750190	A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving Dialysis	October 1, 2021	Completed	3P30CA046592-31S4
clinical_trial	NCT02333890	A Phase 2 Randomized, Double-blind Trial Evaluating the Effects of Chloroquine in Breast Cancer (CUBiC)	November 18, 2016	Unknown	3P30CA046592-31S8
clinical_trial	NCT02333890	A Phase 2 Randomized, Double-blind Trial Evaluating the Effects of Chloroquine in Breast Cancer (CUBiC)	November 18, 2016	Unknown	3P30CA046592-31S4
clinical_trial	NCT02378532	The Addition of Chloroquine to Chemoradiation for Glioblastoma (CHLOROBRAIN)	January 23, 2020	Completed	3P30CA046592-31S8
clinical_trial	NCT02378532	The Addition of Chloroquine to Chemoradiation for Glioblastoma (CHLOROBRAIN)	January 23, 2020	Completed	3P30CA046592-31S4
clinical_trial	NCT03400865	Cabergoline Combined Hydroxychloroquine/Chloroquine to Treat Resistant Prolactinomas	October 16, 2018	Unknown	3P30CA046592-31S8
clinical_trial	NCT03400865	Cabergoline Combined Hydroxychloroquine/Chloroquine to Treat Resistant Prolactinomas	October 16, 2018	Unknown	3P30CA046592-31S4
clinical_trial	NCT02784288	Phase II Treatment Stratification Trial Using Neck Dissection-Driven Selection to Improve Quality of Life for Low Risk Patients With HPV+ Oropharyngeal Squamous Cell Cancer	June 30, 2021	Active, not recruiting	3P30CA046592-31S8
clinical_trial	NCT02784288	Phase II Treatment Stratification Trial Using Neck Dissection-Driven Selection to Improve Quality of Life for Low Risk Patients With HPV+ Oropharyngeal Squamous Cell Cancer	June 30, 2021	Active, not recruiting	3P30CA046592-31S4
clinical_trial	NCT01700959	Melatonin Intervention For Neurocognitive Deficits in the St. Jude Lifetime Cohort	June 28, 2018	Completed	3P30CA021765-41S3
clinical_trial	NCT00004006	Combination Chemotherapy, Radiation Therapy, and Bone Marrow Transplantation in Treating Patients With Retinoblastoma	October 4, 2011	Completed	3P30CA021765-41S3
clinical_trial	NCT00004005	Irinotecan Followed By Fluorouracil and Leucovorin in Treating Patients With Stage III or Stage IV Colorectal Carcinoma (Cancer), Other Refractory Carcinoma, or Metastatic Adenoma (Cancer) of Unknown Primary Origin	April 26, 2017	Completed	3P30CA021765-41S3
clinical_trial	NCT00137111	Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia	September 11, 2020	Completed	3P30CA021765-41S3
clinical_trial	NCT00137111	Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia	September 11, 2020	Completed	3P30CA021765-41S3
clinical_trial	NCT00137111	Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia	September 11, 2020	Completed	3P30CA021765-41S3
clinical_trial	NCT00576472	Learning Impairments Among Survivors of Childhood Cancer	May 30, 2017	Completed	3P30CA021765-41S3
clinical_trial	NCT00002794	Carboplatin Plus Vincristine in Treating Children With Retinoblastoma	October 4, 2011	Completed	3P30CA021765-41S3
clinical_trial	NCT00004068	Irinotecan Followed by Radiation Therapy and Temozolomide in Treating Children With Newly Diagnosed Brain Tumor	October 4, 2011	Completed	3P30CA021765-41S3
clinical_trial	NCT00002748	Gene Therapy in Treating Children With Refractory or Recurrent Neuroblastoma	October 4, 2011	Completed	3P30CA021765-41S3
clinical_trial	NCT00101205	Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma	February 24, 2014	Terminated	3P30CA021765-41S3
clinical_trial	NCT02098863	Sickle Cell Clinical Research and Intervention Program	March 1, 2021	Recruiting	3P30CA021765-41S3
clinical_trial	NCT02098863	Sickle Cell Clinical Research and Intervention Program	March 1, 2021	Recruiting	3P30CA021765-41S3
clinical_trial	NCT00669305	Bone Marrow for Hemoglobinopathy Research	February 25, 2020	Completed	3P30CA021765-41S3
clinical_trial	NCT02729298	First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors	January 25, 2021	Active, not recruiting	3P30CA021765-41S3
clinical_trial	NCT03572634	Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL	February 2, 2021	Terminated	3P30CA021765-41S3
clinical_trial	NCT03572634	Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL	February 2, 2021	Terminated	3P30CA013696-45S1
clinical_trial	NCT00002514	Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission	November 22, 2012	Completed	3P30CA021765-41S3
clinical_trial	NCT00760656	Establishment of a Lifetime of Cohort of Adults Surviving Childhood Cancer (SJLIFE)	August 2, 2021	Recruiting	3P30CA021765-41S3
clinical_trial	NCT00760656	Establishment of a Lifetime of Cohort of Adults Surviving Childhood Cancer (SJLIFE)	August 2, 2021	Recruiting	3P30CA021765-41S3
clinical_trial	NCT04244656	A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma	October 8, 2021	Recruiting	3P30CA021765-41S3
clinical_trial	NCT04264078	Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies	June 28, 2021	Recruiting	3P30CA021765-41S3
clinical_trial	NCT03939026	Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma (ALPHA)	October 14, 2021	Active, not recruiting	3P30CA021765-41S3
clinical_trial	NCT04416984	Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma (ALPHA-2) (ALPHA-2)	October 14, 2021	Active, not recruiting	3P30CA021765-41S3
clinical_trial	NCT04173988	Study of alloCART-19 Cell Therapy in Pediatric Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia	November 30, 2020	Recruiting	3P30CA021765-41S3
clinical_trial	NCT03166878	A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma	June 23, 2017	Recruiting	3P30CA021765-41S3
clinical_trial	NCT04035434	A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)	October 6, 2021	Recruiting	3P30CA021765-41S3
clinical_trial	NCT04384393	Safety and Efficacy of ThisCART19 in Patients With Refractory or Relapsed B Cell Malignancies	December 1, 2020	Recruiting	3P30CA021765-41S3
clinical_trial	NCT04264039	Anti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic Malignancies	February 11, 2020	Not yet recruiting	3P30CA021765-41S3
clinical_trial	NCT04227015	A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy	December 28, 2020	Recruiting	3P30CA021765-41S3
clinical_trial	NCT03666000	Dose-escalation Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL	September 16, 2021	Recruiting	3P30CA021765-41S3
clinical_trial	NCT04166838	The Clinical Study of CD19 UCAR-T Cells in Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL)	November 18, 2019	Recruiting	3P30CA021765-41S3
clinical_trial	NCT04176913	Study of LUCAR-20S in Patients With R/R NHL	August 25, 2021	Recruiting	3P30CA021765-41S3
clinical_trial	NCT04030195	Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL	April 29, 2021	Recruiting	3P30CA021765-41S3
clinical_trial	NCT04150497	Phase 1 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)	September 22, 2021	Recruiting	3P30CA021765-41S3
clinical_trial	NCT04502446	A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)	July 15, 2021	Recruiting	3P30CA021765-41S3
clinical_trial	NCT04438083	A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC)	May 14, 2021	Recruiting	3P30CA021765-41S3
clinical_trial	NCT04142619	Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01)	September 23, 2021	Recruiting	3P30CA021765-41S3
clinical_trial	NCT03692429	alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells (alloSHRINK)	November 20, 2020	Recruiting	3P30CA021765-41S3
clinical_trial	NCT01430390	In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies	August 5, 2021	Recruiting	3P30CA021765-41S3
clinical_trial	NCT04288726	Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas	April 1, 2021	Recruiting	3P30CA021765-41S3
clinical_trial	NCT04107142	Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted &#947;&#948; T Cells for Relapsed or Refractory Solid Tumour	September 27, 2019	Unknown	3P30CA021765-41S3
clinical_trial	NCT03389230	Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma	August 12, 2021	Recruiting	3P30CA021765-41S3
clinical_trial	NCT02146924	Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia	March 30, 2021	Recruiting	3P30CA021765-41S3
clinical_trial	NCT02051257	Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma	June 15, 2021	Active, not recruiting	3P30CA021765-41S3
clinical_trial	NCT02746952	Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia (CALM)	October 1, 2021	Completed	3P30CA021765-41S3
clinical_trial	NCT03841110	FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors	November 2, 2020	Recruiting	3P30CA021765-41S3
clinical_trial	NCT01185886	Study of Blood and Tissue Samples in Children With Newly Diagnosed Acute Lymphoblastic Leukemia	July 28, 2017	Unknown	3P30CA021765-41S3
clinical_trial	NCT03655678	A Safety and Efficacy Study Evaluating CTX001 in Subjects With Transfusion-Dependent &#946;-Thalassemia	February 16, 2021	Recruiting	3P30CA021765-41S3
clinical_trial	NCT03745287	A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease	January 22, 2021	Recruiting	3P30CA021765-41S3
clinical_trial	NCT03712358	PVSRIPO for Patients With Unresectable Melanoma	January 14, 2021	Active, not recruiting	3P30CA021765-41S3
clinical_trial	NCT02848001	A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes	July 22, 2021	Recruiting	3P30CA021765-41S3
clinical_trial	NCT04341311	Phase I Study of Marizomib + Panobinostat for Children With DIPG (DIPG)	May 11, 2021	Active, not recruiting	3P30CA021765-41S3
clinical_trial	NCT01922076	Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas	May 17, 2021	Active, not recruiting	3P30CA021765-41S3
clinical_trial	NCT00549848	Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia	March 19, 2021	Active, not recruiting	3P30CA021765-41S3
clinical_trial	NCT00549848	Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia	March 19, 2021	Active, not recruiting	3P30CA021765-41S3
clinical_trial	NCT02193724	Feasibility of Generating Pluripotent Stem Cells From Patients With Familial Retinoblastoma	October 23, 2020	Completed	3P30CA021765-41S3
clinical_trial	NCT02261480	A New Reagent Assay Examining Natural Parvovirus B19 Infection in Sickle Cell Disease	September 19, 2016	Completed	3P30CA021765-41S3
clinical_trial	NCT01050296	Molecular Analysis Of Solid Tumors (MAST)	August 26, 2021	Recruiting	3P30CA021765-41S3
clinical_trial	NCT00124657	Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Glioma	December 4, 2015	Completed	3P30CA021765-41S3
clinical_trial	NCT04662645	Embedded Palliative Care in Managing Symptoms in Participants With Recurrent Stage III-IV Thoracic Malignancies and Their Caregivers	December 10, 2020	Recruiting	3P30CA016058-44S3
clinical_trial	NCT04602026	Re-Defining Frailty and Improving Outcomes Through Prehabilitation in Patients With Pancreatic, Liver, or Gastric Cancer, The RIOT Trial (RIOT)	October 27, 2020	Recruiting	3P30CA016058-44S3
clinical_trial	NCT04329962	Metabolism and Absorption of Anthocyanins From Extract and Whole Blueberry Powder Confections in Healthy Adults	September 24, 2021	Active, not recruiting	3P30CA016058-44S3
clinical_trial	NCT04269837	Sexual Health Counseling Intervention During Radiation Therapy in Improving Quality of Life for Women With Gynecologic Cancer	December 8, 2020	Recruiting	3P30CA016058-44S3
clinical_trial	NCT04229381	Resiliency Among Older Adults Receiving Lung Cancer Treatment (ROAR-LCT)	January 18, 2020	Recruiting	3P30CA016058-44S3
clinical_trial	NCT04220684	Off-the-shelf Third Party Expanded NK Cells in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome	June 4, 2020	Recruiting	3P30CA016058-44S3
clinical_trial	NCT04205071	Lorcaserin in Treating Chemotherapy-Induced Peripheral Neuropathy in Patients With Stage I-IV Gastrointestinal or Breast Cancer	January 19, 2021	Withdrawn	3P30CA016058-44S3
clinical_trial	NCT04164069	Dasatinib in Preventing Oxaliplatin-Induced Peripheral Neuropathy in Patients With Colorectal Cancer Receiving FOLFOX and Bevacizumab	July 8, 2021	Recruiting	3P30CA016058-44S3
clinical_trial	NCT04120454	Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer	October 9, 2020	Recruiting	3P30CA016058-44S3
clinical_trial	NCT04115163	Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer	September 17, 2020	Recruiting	3P30CA016058-44S3
clinical_trial	NCT01771107	Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma	August 2, 2021	Active, not recruiting	3P30CA016058-44S3
clinical_trial	NCT04166318	Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study	September 10, 2021	Recruiting	3P30CA016058-44S3
clinical_trial	NCT04166318	Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study	September 10, 2021	Recruiting	3P30CA016058-44S3
clinical_trial	NCT02505529	The UNCODE Study: Unravelling the Neural Contributors Of Dynapenia in Elders	March 13, 2019	Completed	3P30CA016058-44S3
clinical_trial	NCT00048958	Cytogenetic Studies in Acute Leukemia and Multiple Myeloma	August 17, 2021	Active, not recruiting	3P30CA016058-44S3
clinical_trial	NCT00048958	Cytogenetic Studies in Acute Leukemia and Multiple Myeloma	August 17, 2021	Active, not recruiting	3P30CA016058-44S3
clinical_trial	NCT00899223	Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes	July 20, 2021	Active, not recruiting	3P30CA016058-44S3
clinical_trial	NCT00900224	Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia	October 12, 2020	Active, not recruiting	3P30CA016058-44S3
clinical_trial	NCT00900224	Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia	October 12, 2020	Active, not recruiting	3P30CA016058-44S3
clinical_trial	NCT01611623	Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies	April 2, 2013	Completed	3P30CA016058-44S3
clinical_trial	NCT01635712	Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies	April 26, 2017	Completed	3P30CA016058-44S3
clinical_trial	NCT02973399	Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL	February 22, 2019	Terminated	3P30CA016058-44S3
clinical_trial	NCT02914327	Safety and Activity of SNX-5422 Plus Ibrutinib in CLL	July 30, 2018	Withdrawn	3P30CA016058-44S3
clinical_trial	NCT00416598	Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia	February 19, 2019	Completed	3P30CA016058-44S3
clinical_trial	NCT00651261	Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia	August 18, 2021	Active, not recruiting	3P30CA016058-44S3
clinical_trial	NCT00006363	Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia	June 4, 2013	Completed	3P30CA016058-44S3
clinical_trial	NCT02717611	A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy	September 5, 2021	Active, not recruiting	3P30CA016058-44S3
clinical_trial	NCT02477696	Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk CLL	August 30, 2021	Active, not recruiting	3P30CA016058-44S3
clinical_trial	NCT01408225	Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource (B-SCR-MM)	January 13, 2020	Recruiting	3P30CA016058-44S3
clinical_trial	NCT03824327	Papaverine and Stereotactic Body Radiotherapy (SBRT) for Non Small Cell Lung Cancer (NSCLC) or Lung Metastases	February 9, 2021	Recruiting	3P30CA016058-44S3
clinical_trial	NCT03018418	Proton Therapy in Reducing Toxicity in Anal Cancer	July 1, 2021	Active, not recruiting	3P30CA016058-44S3
clinical_trial	NCT03690921	LET-IMPT and Standard Chemotherapy in Treating Patients With Newly Diagnosed Stage I-III Anal Canal Squamous Cell Cancer	January 30, 2020	Recruiting	3P30CA016058-44S3
clinical_trial	NCT03117920	A Phase II, International Open Label Trial of Minnelide&#8482; in Patients With Refractory Pancreatic Cancer (MinPAC)	September 2, 2020	Completed	3P30CA016058-44S3
clinical_trial	NCT03886831	A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies	July 30, 2021	Recruiting	3P30CA016058-44S3
clinical_trial	NCT03573310	A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS	October 8, 2021	Active, not recruiting	3P30CA016058-44S3
clinical_trial	NCT02783300	An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma (Meteor 1)	May 17, 2021	Recruiting	3P30CA016058-44S3
clinical_trial	NCT01738438	Cabozantinib for Metastatic Triple Negative BrCa	December 6, 2016	Completed	3P30CA016058-44S3
clinical_trial	NCT00003190	Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia	June 4, 2013	Completed	3P30CA016058-44S3
clinical_trial	NCT00085124	Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia	June 5, 2013	Completed	3P30CA016058-44S3
clinical_trial	NCT00742625	Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia	September 12, 2014	Completed	3P30CA016058-44S3
clinical_trial	NCT01420926	Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia	September 28, 2021	Active, not recruiting	3P30CA016058-44S3
clinical_trial	NCT00039377	Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia	November 24, 2014	Completed	3P30CA016058-44S3
clinical_trial	NCT01253070	Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia	September 16, 2021	Active, not recruiting	3P30CA016058-44S3
clinical_trial	NCT04317040	CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007) (SAC-COVID)	July 22, 2021	Completed	3P30CA016058-44S3
clinical_trial	NCT04315948	Trial of Treatments for COVID-19 in Hospitalized Adults (DisCoVeRy)	October 11, 2021	Recruiting	3P30CA016058-44S3
clinical_trial	NCT04162873	Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer	September 8, 2021	Recruiting	3P30CA042014-31S5
clinical_trial	NCT04106856	Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (SHAPER) (SHAPER)	July 16, 2021	Recruiting	3P30CA042014-31S5
clinical_trial	NCT03987217	Resistance Training +/- Creatine for Metastatic Prostate Cancer Patients	January 13, 2021	Recruiting	3P30CA042014-31S5
clinical_trial	NCT03972943	CPAP in Treating Obstructive Sleep Apnea in Patients With Polycythemia Vera or Essential Thrombocythemia	April 22, 2021	Recruiting	3P30CA042014-31S5
clinical_trial	NCT00335491	Exercise in Improving Mobility and Reducing Fatigue and/or Weakness in Older Cancer Survivors	September 30, 2011	Completed	3P30CA042014-31S5
clinical_trial	NCT05067777	Massage for Prostate Cancer-Related Fatigue, mPROSTATE Study (mPROSTATE)	October 5, 2021	Not yet recruiting	3P30CA042014-31S5
clinical_trial	NCT00026468	Exisulind in Preventing Polyps in Patients With Familial Adenomatous Polyposis	July 24, 2013	Withdrawn	3P30CA042014-31S5
clinical_trial	NCT02337517	Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease	July 19, 2021	Terminated	3P30CA042014-31S5
clinical_trial	NCT03732950	Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer	January 15, 2021	Recruiting	3P30CA042014-31S5
clinical_trial	NCT03363867	BEACON - ABC in Recurrent Platinum Resistant HGSOC (BEACON)	December 20, 2019	Recruiting	3P30CA042014-31S5
clinical_trial	NCT03188159	Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer	March 29, 2018	Recruiting	3P30CA042014-31S5
clinical_trial	NCT02328677	ColoCare Study - Colorectal Cancer Cohort	October 19, 2020	Recruiting	3P30CA042014-31S5
clinical_trial	NCT02328677	ColoCare Study - Colorectal Cancer Cohort	October 19, 2020	Recruiting	3P30CA042014-31S5
clinical_trial	NCT02328677	ColoCare Study - Colorectal Cancer Cohort	October 19, 2020	Recruiting	3P30CA042014-31S5
clinical_trial	NCT03825289	Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer (THREAD)	November 13, 2020	Recruiting	3P30CA042014-31S5
clinical_trial	NCT03979651	MEK and Autophagy Inhibition in Metastatic/Locally Advanced, Unresectable Neuroblastoma RAS (NRAS) Melanoma (CHLOROTRAMMEL)	May 8, 2020	Recruiting	3P30CA042014-31S5
clinical_trial	NCT04132505	Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer	March 9, 2021	Recruiting	3P30CA042014-31S5
clinical_trial	NCT04357613	IMATINIB IN COVID-19 DISEASE IN AGED PATIENTS. (IMAGE-19)	August 7, 2020	Not yet recruiting	3P30CA042014-31S5
clinical_trial	NCT04394416	Trial of Imatinib for Hospitalized Adults With COVID-19	August 12, 2021	Recruiting	3P30CA042014-31S5
clinical_trial	NCT02821013	Duration of Anti-PD-1 Therapy in Metastatic Melanoma (STOP-GAP)	September 14, 2021	Recruiting	3P30CA042014-31S5
clinical_trial	NCT03553836	Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)	August 24, 2021	Active, not recruiting	3P30CA042014-31S5
clinical_trial	NCT04874831	Domatinostat in Combination With Avelumab in Patients With Treatment-na&#239;ve Metastatic Merkel Cell Carcinoma (MERKLIN 1)	July 6, 2021	Not yet recruiting	3P30CA042014-31S5
clinical_trial	NCT04393753	Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1 (MERKLIN2)	June 29, 2021	Recruiting	3P30CA042014-31S5
clinical_trial	NCT04871594	Checkpoint Inhibition With or Without Domatinostat in Urothelial Cancer (TURANDOT)	September 1, 2021	Recruiting	3P30CA042014-31S5
clinical_trial	NCT04133948	Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma (DONIMI)	June 1, 2020	Recruiting	3P30CA042014-31S5
clinical_trial	NCT03812796	Epigenetic Modulation of the immunE Response in GastrointEstinal Cancers (EMERGE) (EMERGE)	February 5, 2019	Recruiting	3P30CA042014-31S5
clinical_trial	NCT01091974	Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy	February 9, 2017	Completed	3P30CA042014-31S5
clinical_trial	NCT02159755	Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma	May 21, 2021	Active, not recruiting	3P30CA013696-45S1
clinical_trial	NCT00233935	Defined Green Tea Catechin Extract in Preventing Esophageal Cancer in Patients With Barrett's Esophagus	September 11, 2014	Completed	3P30CA013696-45S1
clinical_trial	NCT04356716	Sildenafil for Treatment of Choroidal Ischemia	April 22, 2020	Recruiting	3P30CA013696-45S1
clinical_trial	NCT03496012	Efficacy and Safety of BIIB111 for the Treatment of Choroideremia (STAR)	December 23, 2020	Completed	3P30CA013696-45S1
clinical_trial	NCT03496012	Efficacy and Safety of BIIB111 for the Treatment of Choroideremia (STAR)	December 23, 2020	Completed	3P30CA013696-45S1
clinical_trial	NCT01367444	Phase I/IIA Study of SAR422459 in Participants With Stargardt's Macular Degeneration	June 5, 2020	Terminated	3P30CA013696-45S1
clinical_trial	NCT01367444	Phase I/IIA Study of SAR422459 in Participants With Stargardt's Macular Degeneration	June 5, 2020	Terminated	3P30CA013696-45S1
clinical_trial	NCT01736592	Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration	August 11, 2020	Active, not recruiting	3P30CA013696-45S1
clinical_trial	NCT01736592	Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration	August 11, 2020	Active, not recruiting	3P30CA013696-45S1
clinical_trial	NCT02652767	Efficacy Study of GS010 for the Treatment of Vision Loss up to 6 Months From Onset in LHON Due to the ND4 Mutation (RESCUE)	January 28, 2020	Completed	3P30CA013696-45S1
clinical_trial	NCT02652767	Efficacy Study of GS010 for the Treatment of Vision Loss up to 6 Months From Onset in LHON Due to the ND4 Mutation (RESCUE)	January 28, 2020	Completed	3P30CA013696-45S1
clinical_trial	NCT02652780	Efficacy Study of GS010 for Treatment of Vision Loss From 7 Months to 1 Year From Onset in LHON Due to the ND4 Mutation (REVERSE) (REVERSE)	January 23, 2020	Completed	3P30CA013696-45S1
clinical_trial	NCT02652780	Efficacy Study of GS010 for Treatment of Vision Loss From 7 Months to 1 Year From Onset in LHON Due to the ND4 Mutation (REVERSE) (REVERSE)	January 23, 2020	Completed	3P30CA013696-45S1
clinical_trial	NCT02556736	RST-001 Phase I/II Trial for Advanced Retinitis Pigmentosa	September 29, 2021	Active, not recruiting	3P30CA013696-45S1
clinical_trial	NCT03326336	Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa (PIONEER)	February 4, 2021	Recruiting	3P30CA013696-45S1
clinical_trial	NCT04123626	A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene (AURORA)	May 18, 2021	Recruiting	3P30CA013696-45S1
clinical_trial	NCT01878032	Color Vision as a Measure for Inherited Retinal Diseases	October 6, 2017	Completed	3P30CA013696-45S1
clinical_trial	NCT02755597	A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy (Bellini)	July 20, 2021	Suspended	3P30CA013696-45S1
clinical_trial	NCT02091063	ACY-1215 for Relapsed/Refractory Lymphoid Malignancies	February 10, 2020	Completed	3P30CA013696-45S1
clinical_trial	NCT01137006	An Open-Label, Dose-Escalation Study of IMC-20D7S In Participants With Malignant Melanoma	June 17, 2019	Completed	3P30CA013696-45S1
clinical_trial	NCT03364348	4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer	January 25, 2021	Active, not recruiting	3P30CA013696-45S1
clinical_trial	NCT01696877	A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer	March 28, 2019	Completed	3P30CA013696-45S1
clinical_trial	NCT04053062	LIGHT-PSMA-CART in Treating Patients With Castrate-Resistant Prostate Cancer	September 24, 2021	Recruiting	3P30CA013696-45S1
clinical_trial	NCT00999609	Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis	May 18, 2020	Active, not recruiting	3P30CA013696-45S1
clinical_trial	NCT02610582	Safety and Efficacy of rAAV.hCNGA3 Gene Therapy in Patients With CNGA3-linked Achromatopsia (Colourbridge)	April 1, 2021	Recruiting	3P30CA013696-45S1
clinical_trial	NCT03278873	Long-Term Follow-Up Gene Therapy Study for Achromatopsia CNGB3 and CNGA3	March 24, 2021	Recruiting	3P30CA013696-45S1
clinical_trial	NCT03758404	Gene Therapy for Achromatopsia (CNGA3) (CNGA3)	June 25, 2021	Completed	3P30CA013696-45S1
clinical_trial	NCT02935517	Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia	April 6, 2021	Recruiting	3P30CA013696-45S1
clinical_trial	NCT02599922	Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia	April 6, 2021	Recruiting	3P30CA013696-45S1
clinical_trial	NCT01461213	Gene Therapy for Blindness Caused by Choroideremia	November 17, 2017	Completed	3P30CA013696-45S1
clinical_trial	NCT02553135	Choroideremia Gene Therapy Clinical Trial	July 29, 2019	Completed	3P30CA013696-45S1
clinical_trial	NCT02671539	THOR - T&#252;bingen Choroideremia Gene Therapy Trial (THOR)	October 27, 2020	Completed	3P30CA013696-45S1
clinical_trial	NCT02065011	A Study to Determine the Long-Term Safety, Tolerability and Biological Activity of SAR421869 in Patients With Usher Syndrome Type 1B	October 13, 2021	Active, not recruiting	3P30CA013696-45S1
clinical_trial	NCT01505062	Study of SAR421869 in Participants With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B	March 18, 2020	Terminated	3P30CA013696-45S1
clinical_trial	NCT03116113	A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112 (XIRIUS)	May 18, 2021	Completed	3P30CA013696-45S1
clinical_trial	NCT03316560	Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations	July 15, 2021	Recruiting	3P30CA013696-45S1
clinical_trial	NCT03252847	Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) Retinitis Pigmentosa GTPase Regulator (RPGR)	March 13, 2020	Active, not recruiting	3P30CA013696-45S1
clinical_trial	NCT01482195	Trial of Subretinal Injection of (rAAV2-VMD2-hMERTK)	July 15, 2021	Completed	3P30CA013696-45S1
clinical_trial	NCT03374657	A First-in-human, Proof of Concept Study of CPK850 in Patients With RLBP1 Retinitis Pigmentosa	March 19, 2021	Recruiting	3P30CA013696-45S1
clinical_trial	NCT03328130	Safety and Efficacy Study in Patients With Retinitis Pigmentosa Due to Mutations in PDE6B Gene	March 18, 2021	Recruiting	3P30CA013696-45S1
clinical_trial	NCT01267422	Safety and Efficacy Study of rAAV2-ND4 Treatment of Leber Hereditary Optic Neuropathy (LHON) (rAAV2-ND4)	January 31, 2018	Completed	3P30CA013696-45S1
clinical_trial	NCT03153293	A Single Intravitreal Injection of rAAV2-ND4 for the Treatment of Leber's Hereditary Optic Neuropathy	September 17, 2020	Active, not recruiting	3P30CA013696-45S1
clinical_trial	NCT02161380	Safety Study of an Adeno-associated Virus Vector for Gene Therapy of Leber's Hereditary Optic Neuropathy (LHON)	July 6, 2021	Active, not recruiting	3P30CA013696-45S1
clinical_trial	NCT03293524	Efficacy &amp; Safety Study of Bilateral IVT Injection of GS010 in LHON Subjects Due to the ND4 Mutation for up to 1 Year (REFLECT)	February 8, 2021	Active, not recruiting	3P30CA013696-45S1
clinical_trial	NCT02317887	Study of RS1 Ocular Gene Transfer for X-linked Retinoschisis	May 3, 2021	Recruiting	3P30CA013696-45S1
clinical_trial	NCT02416622	Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS)	July 14, 2020	Active, not recruiting	3P30CA013696-45S1
clinical_trial	NCT04109924	TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study	July 23, 2021	Recruiting	3P30CA016056-43S5
clinical_trial	NCT00957424	Acceptability of Less Harmful Alternatives to Cigarettes	February 7, 2017	Completed	3P30CA016056-43S5
clinical_trial	NCT00849186	Sunitinib and Surgery in Treating Patients With Localized or Metastatic Kidney Cancer	February 6, 2015	Completed	3P30CA016056-43S5
clinical_trial	NCT00736164	Selenomethionine in Treating Patients Undergoing Surgery or Internal Radiation Therapy for Stage I or Stage II Prostate Cancer	February 6, 2012	Withdrawn	3P30CA016056-43S5
clinical_trial	NCT01892930	Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Kidney Cancer Undergoing Surgery	February 10, 2017	Completed	3P30CA016056-43S5
clinical_trial	NCT01892930	Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Kidney Cancer Undergoing Surgery	February 10, 2017	Completed	3P30CA016056-43S5
clinical_trial	NCT00690924	Calcitriol in Preventing Lung Cancer in Smokers and Former Smokers at High Risk of Lung Cancer	June 4, 2018	Completed	3P30CA016056-43S5
clinical_trial	NCT01769885	Tivozanib Before Surgery in Treating Patients With Localized Kidney Cancer	April 11, 2017	Withdrawn	3P30CA016056-43S5
clinical_trial	NCT00560495	Radiation Therapy and Ammonium Tetrathiomolybdate in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer	February 10, 2012	Withdrawn	3P30CA016056-43S5
clinical_trial	NCT01555268	Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia	February 15, 2017	Completed	3P30CA016056-43S5
clinical_trial	NCT00217516	Selenium in Treating Patients Who Are Undergoing Brachytherapy for Stage I or Stage II Prostate Cancer	February 9, 2012	Completed	3P30CA016056-43S5
clinical_trial	NCT02642913	Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients	March 5, 2021	Completed	3P30CA016056-43S5
clinical_trial	NCT03262662	EVarQuit: Extended Pre-quit Varenicline to Assist in Quitting Smoking (EVarQuit)	November 25, 2020	Recruiting	3P30CA016056-43S5
clinical_trial	NCT01847001	Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy	September 10, 2021	Completed	3P30CA016056-43S5
clinical_trial	NCT02013492	Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery	March 3, 2021	Active, not recruiting	3P30CA016056-43S5
clinical_trial	NCT03076372	A Study Evaluating MM-310 in Patients With Solid Tumors	February 27, 2018	Unknown	3P30CA016056-43S5
clinical_trial	NCT01835223	Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery	October 28, 2020	Completed	3P30CA016056-43S5
clinical_trial	NCT01835223	Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery	October 28, 2020	Completed	3P30CA016056-43S5
clinical_trial	NCT03970616	A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma (DEDUCTIVE)	September 10, 2021	Recruiting	3P30CA016056-43S5
clinical_trial	NCT03329950	A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies	September 10, 2021	Recruiting	3P30CA016056-43S5
clinical_trial	NCT03384836	Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery	October 12, 2021	Recruiting	3P30CA016056-43S5
clinical_trial	NCT03384836	Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery	October 12, 2021	Recruiting	3P30CA016056-43S5
clinical_trial	NCT00057733	Stress Management Training in Patients Undergoing Radiation Therapy for Cancer	May 30, 2013	Completed	3P30CA016056-43S5
clinical_trial	NCT03538223	Music Listening in Radiotherapy Treatment (MuLi_RT)	December 3, 2018	Unknown	3P30CA016056-43S5
clinical_trial	NCT03728205	Yoga for Solid Tumor	April 27, 2021	Withdrawn	3P30CA016056-43S5
clinical_trial	NCT03823144	Intravital Microscopy in Human Solid Tumors	March 25, 2021	Recruiting	3P30CA016056-43S5
clinical_trial	NCT03517852	Intravital Microscopy (IVM) in Patients With Peritoneal Carcinomatosis (PC)	January 29, 2021	Active, not recruiting	3P30CA016056-43S5
clinical_trial	NCT01886235	Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery	August 7, 2020	Completed	3P30CA016056-43S5
clinical_trial	NCT01829971	A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection	September 27, 2016	Terminated	3P30CA016056-43S5
clinical_trial	NCT01698294	Biomarkers in Post-Menopausal Women Receiving Flaxseed	July 23, 2020	Completed	3P30CA016056-43S5
clinical_trial	NCT01527136	Entolimod in Treating Patients With Locally Advanced or Metastatic Solid Tumors That Cannot Be Removed By Surgery	January 12, 2016	Completed	3P30CA016056-43S5
clinical_trial	NCT02752074	A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)	August 27, 2020	Completed	3P30CA016056-43S5
clinical_trial	NCT03561207	3D Prediction of Patient-Specific Response (3D-PREDICT)	October 7, 2021	Recruiting	3P30CA016056-43S5
clinical_trial	NCT00843726	Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer	June 15, 2021	Completed	3P30CA016056-43S5
clinical_trial	NCT02861300	CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer	May 6, 2021	Suspended	3P30CA177558-08S2
clinical_trial	NCT04250545	Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer	October 1, 2021	Recruiting	3P30CA177558-08S2
clinical_trial	NCT03047993	Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome	January 15, 2021	Recruiting	3P30CA177558-08S2
clinical_trial	NCT03528642	CB-839 With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma	October 11, 2021	Recruiting	3P30CA177558-08S2
clinical_trial	NCT03109661	N/A	N/A	N/A	3P30CA177558-08S2
clinical_trial	NCT03109561	Apolipoprotein E (ApoE) and Metabolism	July 23, 2020	Completed	3P30CA177558-08S2
clinical_trial	NCT00095927	Randomized Amifostine For SCCHN	January 4, 2017	Completed	3P30CA006516-55S9
clinical_trial	NCT00095901	Capecitabine For Nasopharyngeal Cancer	March 29, 2018	Completed	3P30CA006516-55S9
clinical_trial	NCT00084838	Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT	December 24, 2015	Completed	3P30CA006516-55S9
clinical_trial	NCT00069940	Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor	December 28, 2010	Completed	3P30CA006516-55S9
clinical_trial	NCT03029325	Molecular and Genetic Analysis of Lung Cancer	March 4, 2021	Recruiting	3P30CA006516-55S9
clinical_trial	NCT00429910	Natural History Study of Patients With Chronic Myelogenous Leukemia	January 2, 2017	Completed	3P30CA006516-55S9
clinical_trial	NCT00357500	Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer	October 1, 2014	Completed	3P30CA006516-55S9
clinical_trial	NCT00101075	Title XELOX FOR SALIVARY GLAND CANCERS	February 27, 2017	Terminated	3P30CA006516-55S9
clinical_trial	NCT00098865	Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma	October 7, 2014	Completed	3P30CA006516-55S9
clinical_trial	NCT00095875	Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial)	November 19, 2013	Completed	3P30CA006516-55S9
clinical_trial	NCT03974217	Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts	August 24, 2021	Recruiting	3P30CA006516-55S9
clinical_trial	NCT04276415	DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumor (GIST)	September 16, 2021	Active, not recruiting	3P30CA006516-55S9
clinical_trial	NCT04485130	DISulfiram for COvid-19 (DISCO) Trial (DISCO)	May 10, 2021	Recruiting	3P30CA006516-55S9
clinical_trial	NCT04594343	Clinical Study to Evaluate the Effects of Disulfiram in Patients With Moderate COVID-19	October 8, 2021	Completed	3P30CA006516-55S9
